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Preface
Neglected tropical diseases (NTDs) is a diverse group of communicable diseases
that prevail in tropical and subtropical conditions in 149 countries. NTDs affect
more than one billion people and cost developing economies billions of dollars
every year. According to the World Health Organization (WHO), NTDs mainly
affect populations living in poverty, without adequate sanitation, and in close
contact with infectious vectors, domestic animals, and livestock. Migration, as
well as climate change and variability, are key factors in NTD prevalence (11-13). 
Therefore, NTDs deserve more study.
Recently, viruses transmitted by vectors (arboviruses) that affect not only people
living in the tropics, but also travelers and migrating populations, have been caus-
ing epidemics. These viruses include Dengue, Chikungunya, Zika, Mayaro, and 
encephalitis viruses. These viruses emerge and reemerge in multiple regions of the
world, as occurred in the Americas recently (2013-2017) with Chikungunya and 
Zika.
Keeping these issues in mind, this book includes different aspects of research and 
clinical topics related to relevant NTDs, including their implications for public
health. This book has been organized in two sections: I. Vector-Borne Diseases; 
and, II. Zoonotic Diseases. Section I includes topics related to Dengue, Japanese
Encephalitis, Chikungunya, and vector control. Section II includes experiences on
Leprosy and Chagas Disease.
Commissioning of this book by IntechOpen was due, in part to my long commit-
ment to vector-borne, zoonotic, and neglected tropical diseases, being involved
as Co-Chair of the Working Group on Zoonoses of the International Society for
Chemotherapy (WGZ-ISC), as well in Colombia at the Committee on Tropical
Medicine, Zoonoses and Travel Medicine of the Colombian Association of
Infectious Diseases (Asociación Colombiana de Infectología, ACIN) and more
recently, as the Chair of the Colombian Collaborative Network of Research on
Zika (Red Colombiana de Colaboración en Zika) (RECOLZIKA), since January
2016.
I have been involved in NTDs for the last two decades, including Leishmaniasis,
Chagas Disease, and Dengue, and since 2014, Chikungunya and emerging arbo-
viruses, such as Zika and Mayaro. After moving from Venezuela to Colombia in
2011, I have been involved in NTD research in Risaralda, such as Leishmaniasis
(still prevalent in the area). Part of this work is a clear reflection of the work
mission at the Research Group Infection Public Health and Infection (classi-
fied A1 by Colciencias) of the Faculty of Health Sciences of the Universidad
Tecnológica de Pereira, directed by Dr. Guillermo Javier Lagos-Grisales, who
is not just a partner, colleague, and friend, but also an extreme believer in our
work in vector-borne and zoonotic diseases. I must also recognize the beginning
of a significant collaboration after a meeting in Cartagena in 2013, during the
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Colombian Congress of Infectious Diseases, where I met Dr. Wilmer Ernesto 
Villamil-Gómez, from Sincelejo, Sucre, Colombia, also part of the formerly known 
Committee of Zoonoses and Hemorrhagic Fevers of the Colombian Association of 
Infectious Diseases (Asociación Colombiana de Infectología, ACIN) (now called 
Committee of Zoonoses and Tropical Medicine), who became my most important 
collaborator on arboviruses, including Zika. In addition to this, since 2002 I have 
been involved in tropical medicine and travel medicine, participating in multiple 
studies on Chagas Disease, Leishmaniasis, and other tropical diseases. Currently 
in Colombia, we continue to study most of them, including in internally displaced 
populations. 
Following the same philosophy as my eight previous books with IntechOpen 
(Current Topics in Tropical Medicine, Current Topics in Public Health, Current 
Topics in Echinococcosis, Current Topics in Chikungunya, Current Topics in 
Malaria, Current Topics in Giardiasis, Current Topics in Zika, Current Topics in 
Tropical Emerging Infectious Diseases and Travel Medicine this book does not 
intend to be an exhaustive compilation. This first edition has included multiple 
different topics and a wide geographical participation from many countries from 
different regions of the world. Its online availability, as well the possibility to upload 
the complete book or their chapters to personal websites and institution reposito-
ries, allows it to reach a wide. Continuing on the series of “Current Topics” books, 
we are planning to develop other projects such as “Current Topics in Zoonoses” and 
“Current Topics in Virology”.
I would like to thank IntechOpen, and particularly to Andrea Koric (Commissioning 
Editor), for the opportunity to edit this interesting and important book, as well for 
her constant support.
I want to take the appropriate time and space to dedicate this book to my beloved 
family (Aurora, Alfonso José, Alejandro, and Andrea, the neurologist). Katterine, 
also I need to dedicate this book and further, to you. You arrived unexpectedly in 
my life to make it happier than ever. I love you with all my heart, my mind, and my 
soul.
Also, to my friends and my undergraduate and postgraduate students of health 
sciences in Colombia, Venezuela, and around Latin America. Thank you to 
my colleagues at the Working Group on Zoonoses, International Society for 
Chemotherapy, and the Committee on Zoonoses, Tropical Medicine and Travel 
Medicine (formerly Zoonoses and Haemorrhagic Fevers) of the ACIN and a large 
list of members of RECOLZIKA (www.RECOLZIKA.org). Special thanks again to 
my friend and colleague Dr. Guillermo J. Lagos-Grisales, MD, MPH. Members of 
our research group and incubator consist of young and enthusiastic medical stu-
dents and some veterinary medical students as well as young medical doctors, who 
are pursuing significant improvements in the understanding of the epidemiology of 
zoonotic, vector-borne, parasitic, and infectious diseases in our country with inter-
national projection. 2019 has been a great year, very productive for this recognized 
group, which was classified in 2017 by the national agency of science, Colciencias, 
in the highest rank “A1”, and then recognized again in 2019 with that rank, therefore 
positioning themselves as leaders in infectious diseases epidemiology research in 
the coffee-triangle region and in the country.
V
Finally, I hope our readers enjoy this publication as much as I did editing the chap-
ters of Current Topics in Neglected Tropical Diseases.
Alfonso J. Rodriguez-Morales, MD, MSc, DTM&H, FRSTMH(Lon),
FFTM RCPS(Glasg), FACE, PhD(c), Dr h c(HonDSc)
Professor,
Part-Time Faculty Instructor, Risk Factors (Epidemiology) (Coordinator), 
Department of Community Medicine, School of Medicine, 
Lecturer, Frontiers Research, Research IV, 
School of Veterinary Medicine & Zootechnics,
Director of Research, Faculty of Health Sciences, 
Universidad Tecnológica de Pereira, 
Pereira, Risaralda, Colombia
Chair, Colombian Network of Research in Zika (RECOLZIKA)
Co-Chair, Working Group on Zoonoses, 
International Society for Chemotherapy (ISC),
Vice President, Colombian Association of Infectious Diseases (ACIN),
Member of the Committee on Tropical Medicine, 
Zoonoses and Travel Medicine, ACIN,
President, ACIN Chapter Coffee Triangle Region,
President, Committee on Travel Medicine, 
Pan-American Association of Infectious Diseases, 
Senior Researcher, Colciencias (2019-2021)
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Chapter 1
Persistent Barriers to 
Implementing Efficacious 
Mosquito Control Activities in the 
Continental United States: Insights 
from Vector Control Experts
Imelda K. Moise, Leo C. Zulu, Douglas O. Fuller  
and John C. Beier
Abstract
Many barriers undermine vector surveillance and control efforts in the United 
States. Experts warn that such barriers, including funding, threaten the capacity 
of public-health surveillance systems to detect emerging mosquito-borne disease 
and respond appropriately, timely and effectively. This chapter explores the status, 
barriers, and corrective strategies to effective mosquito surveillance and control 
in the US based on experiences and insights of the 35 interviewed representatives 
of diverse mosquito-control programs selected from 18 U.S. states. Although our 
interest is in mosquito-borne diseases, we focus on the 2016 Zika outbreak. For the 
most part, this chapter will outline issues relating to mosquito control and surveil-
lance that have persistent among state, county and municipal programs as a result 
of insufficient and unreliable funding, inadequate trained personnel, poor facilities, 
and inadequate political support. At the community level, we will discuss issues 
that hinder mosquito control efforts including apathy and low public awareness, 
and provide examples of how mosquito control agencies have adapted to “readily” 
respond to changing vector-borne disease environments, demands and constrained 
funding.
Keywords: mosquito-borne diseases, Zika, barriers, mosquito control, United States
1. Introduction
The question of how ready United States (U.S.) public health officials are to 
prevent and control vector-borne disease transmission has received considerable 
attention since the first West Nile Virus (WNV) outbreak of 1999 in New York 
renewed by the recent Zika virus (ZIKV) outbreak. The first reported case of local 
ZIKV transmission through infected mosquitoes in the Continental United States 
was in Miami, Florida, in late July 2015. Although the global problem of mosquito-
borne diseases (MBDs) is “as old as the pyramids” [1], it is a critical time to revisit 
mosquito control because despite significant gains in reducing the risk and inci-
dence of some MBDs (particularly malaria); the world has seen a rise in the risk and 
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incidence of other MBDs. This is particularly true for viruses transmitted via Aedes 
mosquitoes, such as Chikungunya, Dengue and ZIKV [2–4]. At the same time, it is 
nearly impossible to eliminate the local risk of transmission of exotic arbovirus once 
introduced to an area. Therefore, responding to exotic emerging arbovirus poses 
new challenges for mosquito control programs [5], as characterized below:
“The unpredictable nature and severity of vector-borne disease outbreaks dem-
onstrates the urgent need for careful preparation and the incorporation of vector-
control emergency-management activities into overall public health preparedness 
efforts” [6].
Experts also worry that although prevention of MBDs is the best way forward 
and is substantially less costly than mosquito and disease control in response to a 
disease outbreak [7], MBD surveillance and control continued to be underfunded 
and to be the subject of budget cuts. In the 2011 U.S. fiscal year, a proposal was 
made to reduce funding for the Centers for Disease Control and Prevention 
(CDC)‘s MBD program by $26.7 million [8]. The 2016 Congressional resistance 
and seven-month delay before approving former President Obama’s request for 
emergency funding for ZIKV control [9] further illustrates such challenges. Such 
moves threaten the capacity of the existing public-health surveillance systems and 
response activities to deal with MBDs, such as the human WNV disease, Dengue 
and the ZIKV [10]. A national survey of the 50 state health departments reported 
a reduction in federal funding for mosquito surveillance of 61% between 2004 and 
2012. This reduction resulted in non-tracking of active human cases of WNV in 
22% of 56 jurisdictions (mosquito-control districts or territories), discontinued 
mosquito surveillance in 13%, reduced effort on mosquito trapping and testing 
in 70%, and reduction in WNV surveillance personnel by 38% [11, 12]. This does 
not bode well for the recent ZIKV outbreak in Florida and Texas, the serious birth 
defects it causes in babies, and the current lack limited planning to deal with it 
[13, 14]. Clinical tests for the ZIKV infection are of limited reliability and there is 
no vaccine to prevent ZIKV transmission directly from mosquitos or through the 
sexual transmission pathway. This makes surveillance and control of fundamental 
importance to prevent further ZIKV transmission and to prepare for dealing with 
other exotic arboviruses [15].
Maintaining sustainable systems for MBD surveillance can help define the 
nature and extent of the mosquito problem, provide a basis for evaluating the risk 
of transmission of MBDs, reduce the cost of responding to emerging vector-borne 
pathogens and ultimately gauge the efficacy of control activities [8]. While some 
research has been done on MBD control generically (though Hadler et al., [11, 12] 
as one exception), little has been done to explore variation in approaches, capacities 
and the quality of mosquito surveillance and control programs for emerging MBDs 
across the U.S., let alone from experiences and perceptions of mosquito-control 
Experts. Few studies have investigated the capacity to effectively surveil, prevent, 
and control arbovirus infections such as the ZIKV in the US.
In this chapter, inspired by the 2016 ZIKV outbreak in Florida, we use telephone 
interviews and qualitative research methods in understanding the diversity of 
current barriers and strategies to implementing efficacious mosquito surveillance 
and control in the Continental United States, particularly drawing on experiences 
and perspectives of active vector-control Experts. Insights from Experts can yield 
a range of locally relevant information that is difficult to obtain from traditional 
epidemiologic studies. Experts whose perspectives are included in this chapter 
include those working with state, county, municipal and other local mosquito-
control programs or districts. Furthermore, we also provide variation in the 
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perceived capacities of state and local mosquito-control programs with different 
funding structures and state locations across the six US regions, to respond quickly 
and adequately to emerging MBD threats within the context of Integrated Vector 
Management (Figure 1).
2. Integrated vector management
Integrated vector management involves the optimum use of a mix of methods 
and resources for the efficient, cost-effective, ecologically sound and sustainable 
vector management (surveillance and control) in order to control vector-borne  
diseases. Surveillance of the Aedes aegypti and Aedes albopictus mosquitos that 
transmit the Dengue, Chikungunya, and ZIKV viruses generally involves:
1. Determining absence or presence of the vectors in a particular area
2. Identifying the main types of breeding containers for targeted control
3. Detailed mapping of larval sites for the vectors if found in the area
4. Collecting mosquito-population data and identifying density hotspots (high 
risk)
5. Monitoring impact of control efforts, and
Figure 1. 
Challenges that must be addressed before effective vector surveillance and control can be implemented according 
to the perspectives of 35 interviewed representatives of diverse mosquito-control programs selected from 18 U.S. 
states.
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6. Collecting mosquito data on infection rates in ongoing outbreaks and deter-
mine thresholds of human infection [14].
Effective mosquito-control programs traditionally include (1) detecting and 
monitoring mosquito sources; (2) applying larvicides; (3) applying adulticide treat-
ments from the air (aerial spraying) or from the ground using handheld or more 
mechanized (e.g., from trucks) equipment; and (4) implementing outreach and 
public education. Further, the CDC recommends source reduction (e.g., container 
elimination) and larvicide treatments before the beginning of the mosquito season, 
and adulticide treatments, such as insecticide spraying, after detection of human 
arbovirus activity [14].
3.  Barriers and strategies to implementing sustainable mosquito control 
and surveillance systems
Statewide mosquito surveys are an essential tool to monitor the presence, 
diversity, intensity and spatial distribution of mosquito vectors in a state. Responses 
showed that half (9) of the surveyed states had ever conducted a statewide mos-
quito-vector survey, and many of the rest had outdated surveys. The oldest con-
ducted in 1940 (Arkansas) while only Arizona and Delaware had conducted one the 
previous year (2015). Only Delaware reported having conducting annual statewide 
mosquito surveys. In some rural states (e.g., Arkansas and North Dakota) mosquito 
control is the sole responsibility of local municipalities while in more urbanized 
states special mosquito control districts often complement local programs.
Responsibility and capacity for mosquito-vector surveillance and control varied 
across states. Knowledge about mosquitoes was greatest for mosquito species of 
concern to public health (e.g., Aedes aegypti, Aedes albopictus, and Culex species of 
mosquitoes). These species shaped the surveillance in most local programs. Asked 
if the ZIKV was an immediate public health concern in their state, respondents 
in sampled Southern States indicated that ZIKV was an enormous problem. Most 
respondents in surveyed Northern States indicated that locally transmitted ZIKV 
was not an immediate problem, mainly because the vectors are rare, absent, or 
another MBD (e.g., WNV) was more important:
ZIKV is not an issue in our state at all, as far as mosquito transmission because we 
do not have the mosquito Aedes aegypti. It has never been here and we certainly do 
not expect it to be here. Even the second vector, Aedes albopictus is extremely rare. 
WNV is much more serious here, (Mosquito Control Contractor).
Others, while focusing on WNV control, indicated that it was only a matter of 
time before ZIKV carrying Aedes aegypti or Aedes albopictus arrives in their states, as 
this Mid-western respondent stated:
We are going to have a response on it but we are going to continue to work on WNV 
because WNV kills people in Illinois, (Independent Mosquito Control Respondent).
3.1 Barriers to mosquito control
3.1.1 Inadequate and inconsistent funding
Mosquito-control efforts and their effectiveness vary greatly among control pro-
grams. The biggest factor perceived to determine effective mosquito surveillance and 
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control programs and activities was the funding structure. Almost all the indepen-
dent mosquito-control district respondents reported having dedicated, well-funded 
and stable mosquito control programs. The most common sources of funding for 
these self-funding or autonomous and semi-autonomous districts were local taxes 
(e.g., a small portion of property taxes and water bills) and revenues for contract 
work from private companies. On contrast, although respondents in dependent 
districts reported having a separate stable budget-line item for mosquito-control 
activities, their funding comes from county budgets and is therefore vulnerable to 
cuts where and when non-mosquito activities and programs have higher priority.
There was near consensus among Experts from state, county, municipal or other 
local programs that funding dedicated to mosquito-control activities was insuf-
ficient, unstable, and unpredictable. These programs were the most vulnerable to 
significant budget deficits and inconsistencies because they compete for funding 
with other departments and programs under tight municipal, county or County 
Boards of Commissioner budgets. Some interviewees felt that their agencies placed 
lower priority on mosquito-control activities. This forces them to be more reactive 
to outbreaks than proactive, an unlearnt lesson of the WNV outbreak with negative 
implications for program size, content, continuity and effectiveness in the context 
of the ZIKV outbreak:
…You have your director who is running the program but he has very little control 
over how money is spent. Therefore, when appropriated for mosquito control, but if 
another department is hurting in the budget arena, they can take some of mosquito 
control money, (County Mosquito Control Respondent).
We have known even before the days of ZIKV, realizing the importance of mosquito 
surveillance. Again, sometimes it takes a crisis to make people respond, (State Mosquito 
Control Respondent).
3.1.2 Institutional and logistical barriers
Institutional and logistical factors also impeded local vector surveillance and 
control programs, particularly state, municipal and county programs. Most Experts 
agreed that facilities and trained staff with requisite skills (e.g., in entomological 
skills) were insufficient. These shortages undermined essential activities such as 
effective specimen collection, vector identification, monitoring spatial mosquito 
distribution, MBD species present, number of cases in the locality, and the continu-
ity of these activities. In a minority of cases, the lack of expertise can be extreme:
…A lot of them, they do not have even the expertise where the person who is 
responsible for the mosquito control is their City Maintenance Worker or their City 
Water Commissioner. Sometimes it is even the City Auditor. In the small communi-
ties, it is sometimes the garbage man (State Mosquito Control Respondent).
Funding predictability and sustainability emerged as essential requirements 
to maintain programs and capacity to address emerging MBDs such as the ZIKV 
infection effectively. Respondents in cash-strapped programs generally attributes 
funding inconsistences to lack of or vacillating political will. There was consensus 
on the institutionally disruptive impacts of unreliable funding. These included 
laying off staff, scaling back surveillance and control activities such limiting 
mosquito-control activities to larviciding instead of the more targeted and effective 
adult mosquito-control applications, and suspending such activities altogether in 
some years. Respondent illustrates such impacts:
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adult mosquito-control applications, and suspending such activities altogether in 
some years. Respondent illustrates such impacts:
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Once we get money out there and start funding vector control, then all of a sudden, 
it stops, then people think that we do not care anymore or that it was not the threat 
that we thought it was originally. …long-term, level, stabilized funding from year 
to year is the only way to get a good vector control problem in to where we can actu-
ally mitigate the potential for disease transmission, (County Mosquito Control 
Respondent).
The importance of continuity is such that while most respondents were skepti-
cal that Congress would approve all or part of the federal emergency funding 
requested for ZIKV control by the Obama Administration in February 2016 in a 
timely manner, a small number paradoxically worried that some federal funding if 
provided would be unsustainable. They worried about building a technically and 
operationally costly surveillance and control program needed for arboviruses on a 
shaky foundation of federal funding that they considered particularly vulnerable to 
budget cuts:
We go through a few blank years with limited programs in place because we do not 
have funding to move forward with it. Then ZIKV hits and it becomes a national 
concern again and my biggest fear is the Federal Government will be nice enough 
to pass the budget and get money out but that funding isn’t sustainable, (County 
Mosquito Control Respondent).
I am afraid we’ll get a good program in place like the one we did with WNV and 
have surveillance and outreach and really get some abatement going, then all of a 
sudden the funding dries up and you’re stuck again with the need to do something 
without the capability of doing something, (State Mosquito Control Respondent).
Ultimately, funding unpredictability undercuts the ability to be proactive, a 
critical component of MBD control:
Once a disease has entered and gotten hold, it’s much more difficult to eliminate or 
control that disease, as opposed to being proactive, monitoring the situation and if 
a threat is identified, to establish some sort of game plan to be able to control the 
disease, (Independent Mosquito Control Respondent).
Some states have sought to balance quality surveillance and cost under tight bud-
gets. Thus, Arkansas traps for the presence/absence of mosquitoes along (both side) 
of county boundaries. This provides an even geographic spread for vector sampling 
within a limited area while providing the opportunity to share costs among border-
ing counties. Many programs focus surveillance on larvae because they know likely 
breeding sites, such as water containers for Aedes aegypti, and bias adult surveillance 
to areas that have had high Aedes aegypti densities in the past.
Another major institutional challenge was inadequate coordination across 
program service areas. As a mosquito control contractor noted, “there are always 
mosquitoes flying from outside of your control area,” and sometimes beyond their 
geographic range. Most respondents indicated that this cross-boundary mos-
quito mobility challenged their response since all surveyed programs (except in 
Arkansas) limited their activities within their county, township, or other jurisdic-
tional boundaries. Further, differences in resource availability, capacity, methods 
and priority of vector control across control jurisdictions results in fragmented 
mosquito surveillance and control and creates gaps in coverage, which undermine 
the ability of mosquito-control programs to mitigate the risk of MBD transmission 
across landscapes.
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3.1.3 Low public awareness and apathy on mosquito efforts
Most respondents decried apathy (lack of interest or concern), low public 
awareness of the need and nature of mosquito control, and low political will. 
This undermined community co-operation in mosquito surveillance and control, 
including limiting access to private property for trap placement, and participation 
in mosquito control at the household level (e.g., clearing containers). Further, 
many respondents cited resistance to chemical use for mosquito abatement among 
some community members based on environmental concerns, especially adverse 
non-target impacts, as well as on philosophical opposition to chemicals. They were 
particularly wary of such worldviews and attitudes because they can erode commu-
nity trust and co-operation, and undermine control efforts:
…we have many people who are philosophically opposed to what we do and they 
are misinformed, they expose themselves to all sorts of misinformation from various 
advocacy groups who are anti-pesticides, (Mosquito Control Contractor).
Many respondents indicated that they had come a long way in balancing public 
health and environmental concerns. This includes using the most environmentally 
friendly control chemicals. They also highlighted apathy and lack of knowledge 
among the public as a major barrier. Nearly all underscored public education as 
necessary to enhance mosquito control through individual behavior change and to 
gain community support for programs (including improved budgets and equip-
ment). Many admitted that previous public-education efforts had been inadequate, 
and often ineffective to effect positive behavioral change. Still, it was clear that 
Experts considered public education, community engagement, outreach, and media 
attention important strategies to overcome apathy and mitigate negative percep-
tions of mosquito control.
Enhanced and more effective public education emerged as an important strategy 
to address some of the some of the barriers. Respondents recognized the role of fed-
eral agencies (e.g., CDC) and states in public education and information dissemina-
tion, particularly during disease outbreaks. However, many preferred approaches 
that involved person-to-person contact, particularly door-to-door visits and school 
outreach, for their effectiveness in both getting cooperation and participation, and 
in passing on the message to others in the community. Some respondents indicated 
that neighborhood residents who actually experience mosquito management 
efforts were more likely to support vector and pest control programs. Outreach and 
integration of vector prevention and surveillance in schools is favored as a powerful 
tool to reach parents through school-going children while also preparing a future 
generation of informed leaders:
We actually have an educational outreach person who works in our biology depart-
ment and she goes to schools and works with the science teachers …educating kids 
on mosquitoes and all aspects of their breeding and how to control them, (State 
Mosquito Control Respondent).
3.2 Barriers to mosquito surveillance
3.2.1  Lack of standards on sampling and of evaluation of impacts of sub-optimal 
trap placement on MBD-risk assessment
Interviews revealed wide variation in mosquito-surveillance practices. 
Beyond virtual consensus that integrated vector management (IVM) is the ideal 
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on mosquitoes and all aspects of their breeding and how to control them, (State 
Mosquito Control Respondent).
3.2 Barriers to mosquito surveillance
3.2.1  Lack of standards on sampling and of evaluation of impacts of sub-optimal 
trap placement on MBD-risk assessment
Interviews revealed wide variation in mosquito-surveillance practices. 
Beyond virtual consensus that integrated vector management (IVM) is the ideal 
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approach, there were no agreed standards on practices, including accuracy criteria 
for estimates. There was wide variation in the type, number, sampling protocol, 
spacing and frequency of mosquito-trap placement across programs. Location of 
traps was based on diverse and sometimes subjective factors heavily dependent 
on local contingencies such as resource availability, local Expert knowledge, and 
convenience. Factors included the practical need to locate traps away from public 
view to prevent human disturbance and vandalism (deliberate destruction) and 
accessibility—many practitioners placed traps in public spaces (parks, natural 
areas) and on properties of willing residents. While laws on access to private 
property for mosquito abatement varied across states, respondents often negoti-
ated with individual residents for access and permission to place traps thereon. 
The type of mosquito trap used and the need to avoid vandalism or theft also 
mattered. Traps that require electricity, such as the New Jersey light traps, com-
monly used for Aedes aegypti and Aedes albopictus, are placed close to built-up 
areas with electricity supply. There was also a bias toward areas already known to 
have high mosquito densities. The following quotes illustrate some of the locally 
specific and sometimes-subjective factors that determined sampling particularly 
trap placements:
You want to place it somewhere where you are going to find mosquitos but it comes 
down to where I can hang it. We have our ideal of where we want to set it, and then 
it is rather where we can set it, (Independent Mosquito Control Respondent).
You try to cover the area the best you can, but, you know, just depends on what your 
limitations are. However, for an everyday surveillance, it would not be a good idea 
just to go to a specific neighborhood and put a bunch of traps out, (Dependent 
Mosquito Control Respondent).
We sometimes do not’ have control over where those traps are placed when there is a 
volunteer setting traps, (State Mosquito Control Respondent).
The problems of inadequate and unpredictable funding undermining mosquito 
control also afflict surveillance. Respondents noted that limited resources (funding, 
trained staff and others) often promote convenience sampling rather than optimal 
IVM practice. While some of the resulting inconsistencies are expected to vary due 
to local and regional variation in vector ecology and MBD transmission dynamics, 
they undermine cross-jurisdiction coordination and effective surveillance; many 
respondents noted the need for some standardization.
Reliability of mosquito-surveillance practices is important to guide sound 
decision-making on control interventions such as source reduction, larvicide 
treatment and adult reductions (e.g., adulticide). Some respondents admitted that 
their programs conducted little mosquito testing. A state mosquito-control Expert 
indicated that some programs conducted testing only when they note unusually 
high numbers of mosquitoes. While many small communities will use test results 
to trigger local vector control, “some of them don’t even look at the data.” Most 
Experts indicated that they used thresholds (e.g., mosquito larvae, pupal or adult 
density) derived from mosquito-surveillance data as triggers for fogging or spray-
ing. The thresholds, nevertheless, appeared not standardized and varied greatly by 
program and species, and some were vague:
There is a threshold set that if the mosquito traps show higher than that—or we 
will send people out and if they report that the landing rate count is at a certain 
number, we will send planes out, (Independent Mosquito Control Respondent).
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In response to Culex, our action thresholds are 50 females or more. As far as Aedes 
aegypti, and based on work that we did last year, we came up with a numerical 
threshold of 50 or more females per trap. …. if any of the Aedes aegypti test positive 
for our arboviruses, then we will go ahead and fog too, (County Mosquito Control 
Respondent).
Experts revealed common concerns that the current work environment was 
reactive rather than proactive and preventive. Many respondents decried the nar-
row focus on outbreaks of high profile MBDs—the so-called disease du jour or dis-
ease of the day, e.g., ZIKV, Dengue, and WNV—or on responding to extreme events 
such as hurricanes or flooding. Both tend to be geographically limited in scope. 
Many complained that this reactive approach undermined surveillance efforts and 
their capacity to detect, anticipate and respond to emerging MBDs instead of always 
playing catch-up:
Surveillance is important. Every couple of years, some mosquito disease captures 
the headlines. Today it is ZIKV; a couple years ago, it was Chikungunya and a 
couple years before that was West Nile Virus, which means a few years from now, 
something else will happen, (Mosquito Control Contractor).
3.2.2 Coordination across mosquito control jurisdictions
Conversations affirmed the general view that at the local scale of operation 
below the state level the better for surveillance and control because such districts 
were better able to respond to the high level of variability in vector ecology and 
social and institutional contexts. With better and stable funding, independent 
mosquito districts maximized local-scale advantages. Respondents nevertheless 
highlighted the need for enhanced cross-jurisdiction coordination and some level 
of standardization of best practices for consistent mosquito surveillance within and 
across jurisdictions. Some state agencies played this cross-jurisdiction coordination 
role functionally, administratively or in a regulatory capacity, drawing on broad 
federal guidelines provided by the CDC and the Environmental Protection Agency. 
For example, respondents in Florida indicated that the Florida’s Department of 
Agriculture and Consumer Services has Spot Teams that fill surveillance and control 
gaps by covering areas that have no funding or staff by using contractors or nearby 
programs, often on a cost-recovery basis in the case of disease control.
Florida also provides a commendable model for statewide coordination among 
mosquito-control Experts. A non-profit association, the Florida Mosquito Control 
Association (FMCA) was formed in1922 to promote the interests, exchange 
information and coordinate the activities members drawn from diverse mosquito-
control programs. Coordination includes standardization of practice, information 
exchange, and professional training and certification. A representative explained 
FMCA origins and significance:
…there was a need for exchange of information and coordination throughout the 
state. …to help coordinate and get information so that something that is found or 
discovered is shared with the rest of the State of Florida, (FMCA Representative).
3.2.3 Partnerships are important
Almost all program respondents reported formal and informal partnerships with 
other relevant agencies working at different scales—local, county, state, and federal. 
In addition to drawing overall guidance from the CDC, most respondents cited 
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below the state level the better for surveillance and control because such districts 
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social and institutional contexts. With better and stable funding, independent 
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across jurisdictions. Some state agencies played this cross-jurisdiction coordination 
role functionally, administratively or in a regulatory capacity, drawing on broad 
federal guidelines provided by the CDC and the Environmental Protection Agency. 
For example, respondents in Florida indicated that the Florida’s Department of 
Agriculture and Consumer Services has Spot Teams that fill surveillance and control 
gaps by covering areas that have no funding or staff by using contractors or nearby 
programs, often on a cost-recovery basis in the case of disease control.
Florida also provides a commendable model for statewide coordination among 
mosquito-control Experts. A non-profit association, the Florida Mosquito Control 
Association (FMCA) was formed in1922 to promote the interests, exchange 
information and coordinate the activities members drawn from diverse mosquito-
control programs. Coordination includes standardization of practice, information 
exchange, and professional training and certification. A representative explained 
FMCA origins and significance:
…there was a need for exchange of information and coordination throughout the 
state. …to help coordinate and get information so that something that is found or 
discovered is shared with the rest of the State of Florida, (FMCA Representative).
3.2.3 Partnerships are important
Almost all program respondents reported formal and informal partnerships with 
other relevant agencies working at different scales—local, county, state, and federal. 
In addition to drawing overall guidance from the CDC, most respondents cited 
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the Environmental Protection Agency (EPA) as a federal partner. Local partners 
included the Department of Environmental Quality (DEQ ), county health depart-
ments, Department of Agriculture and other government and county departments, 
universities, and other nearby mosquito-control districts, including local com-
munities. Several respondents, particularly from resource-constrained programs, 
indicated that such partnerships allowed their programs to reduce or externalize 
some operational costs. Some gained access to external resources through formal 
contracts, memoranda of understanding (e.g., California), grants, collaboration with 
other agencies, community volunteers, and local schools. Many programs often used 
these partnerships to fill skill gaps with external expertise. Some programs extended 
their available resources though cost savings, use of private contractors, and provi-
sion of incentives including grants. The quotes below illustrate such collaboration:
They recruit anywhere from eighty to a hundred…We try to have at least one in 
every county…These are New Jersey traps. The people who are doing this collection, 
they are volunteering. Every week they will take their… light trap and mail it (State 
Mosquito Surveillance Respondent).
We have a few contracts with county health departments to do mosquito con-
trol, usually surveillance. …. mostly, we work informally, (Mosquito Control 
Contractor).
3.3 Future prospects for mosquito surveillance and control
In addition to the barriers identifies to effective mosquito surveillance and 
control in the context of the ZIKV outbreak, the research also revealed promising 
measures that can be taken to improve the situation. On funding barriers, find-
ings affirmed the importance of increased funding. Given the nature of mosquito 
surveillance and control, and the consequent need for long-term investment, 
however, the predictability and sustenance of funding were even more important. 
The disruptive adverse impacts of reduced and inconsistent funding also illustrated 
in other studies, including stoppage of tracking of tracking of human cases of 
WNV, and reductions in mosquito trapping, testing and surveillance and personnel 
[10, 11], threaten effective surveillance, and early detection and prevention of MBD 
transmission, including for the ZIKV. This also includes inconsistent mosquito data 
from insufficient trap locations that undermine assessment of the risk of human 
exposure to the vector and MBDs [14, 16]. However, recent increases in funding 
for interventions and research offer new hope, so long as such funding is sustained 
particularly at municipal, county and state programs. Such funding includes  
$1.1 billion in emergency federal funding for ZIKV response (approved in 
September 2016), CDC funding of the establishment of four MBD s regional 
Centers of Excellence in the US (approved in December 2016), and state-level 
(Florida State funding of $25 million for the development of a ZIKV vaccine. Some 
gains can also be made in creative forms of financing and increases in efficiency in 
mosquito surveillance and control activities. Table 1 presents the identified barriers 
and strategies to implementing sustainable mosquito control and surveillance sys-
tems in the US. Emerging ideas included more dependence on local (tax) funding 
sources as independent control districts, mosquito sampling along county boundar-
ies to share and reduce costs (e.g., Kansas State), cross-jurisdiction collaboration 
and cost sharing, and the use of citizen science to enhance data collection.
In response to the challenge of lack of inconsistencies in mosquito surveillance 
techniques, the need for some degree of standardization in sampling protocols 
while accommodating vector spatial variability has also been noted in other studies. 
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To be sure, some variability is expected, particularly in mosquito-control approaches 
and practices (e.g., in scope, prioritization, technical methods, etc.) given their 
need to adapt to geographic variation in vector ecology, MBD transmission dynam-
ics, and socio-institutional conditions. However, for surveillance, Bowman et al., 
[22] also call for “standardized sampling protocols that adequately consider dengue 
spatial heterogeneity.” Research on mosquito-vector sampling and its impacts on 
the accuracy of human risk assessment remains relatively limited [17, 18]. Some 
common mosquito indices are sensitive to sampling differences [18] and others 
are poorly statistically correlated to the actual risk of disease [17], compounding 
negative impacts of such inconsistencies. Efforts by the CDC to provide generic 
guidelines in the USA [13] and the World Health Organization (WHO) to do the 
same globally [19], and other isolated studies offer a starting point for standardiza-
tion. One study in Cairns, Australia recommended a sampling intensity of one 
BG-Sentinel trap for an area of 150 by 150 m (two or three traps for three housing 
blocks) to monitor Aedes aegypti, given the limited spatial dispersal (as little as 
78–200 m in some studies) of this container-breeding species [18]. Modern spa-
tially explicit technologies, particularly remote sensing analysis and Geographic 
Information Systems (GIS), expand the sets of tools for mosquito surveillance at 
landscape scales. Thus, the Random sampling of trapping locations for Aedes aegypti 
Barriers
Inadequate and inconsistent funding 
(mainly for state, county and municipal 
programs).
Policies focused on sustaining funding statewide mosquito 
surveillance and control capabilities.
Developing partnerships for cost sharing and community 
training for participation in mosquito trapping, testing and 
prevention.
Lack of political will and support. Enhanced public education—raise awareness and concern, 
influence politicians.
Complex trans-boundary mosquito risks 
and limited cross-boundary coordination.
Enhanced collaborative arrangements and cooperation across 
mosquito districts, e.g., skill sharing, contracts, memoranda 
of understanding, voluntarism.
Limited capacity and specially trained 
personnel.
Hire skilled personnel and train existing ones on needed 
skills.
Use innovative technologies, e.g., smart traps.
Statewide or regional Experts for mosquito programs and 
activities.
Philosophical and environmental belief 
barriers to mosquito control.
IVM—innovative mix of synergistic methods, e.g., 
environmentally friendly insecticides and application 
technologies, biological control, habitat reduction.
More and effective public education and communication with 
stakeholders.
Legal abatement obstacles to timely 
response.
Promoting persuasive person-person community outreach to 
gain voluntary access.
Lack of standardization and inconsistent 
mosquito data from few trap locations and 
select locations
Develop standard surveillance methods for particular a 
subset of conditions, and quality control mechanisms.
New research on vector biology, control methods and 
responsiveness to MBDs.
Adequately funded and consistent surveillance for predicting 
and reducing human infection.
Table 1. 
Barriers and strategies to implementing sustainable mosquito control and surveillance systems.
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the Environmental Protection Agency (EPA) as a federal partner. Local partners 
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in urban areas based on Geographic Information Systems and satellite imagery has 
been shown to improve the accuracy of entomological indices compared to those 
derived through the common biased method of selecting locations or houses that 
are known to have high vector densities [20].
There are also promising technological advances in mosquito control, includ-
ing the introduction of biological control and low-cost, eco-friendly pesticides 
mosquito vectors and safeguard the environment and the public [19]. Recent 
(November 2016) FDA approval of field trials involving the release of genetically 
modified (GM) mosquitoes into the wild to control ZIKV and Zengue-carrying 
mosquitoes for in the Florida Keys, Florida, could increase the number of success-
ful cases of biological control using GMO mosquitoes beyond Brazil and China. 
Non-GM mosquitoes infected with naturally occurring Wolbachia bacteria also 
offer early promise as a biological pesticide and have been field-tested in at least 
three US states against Aedes albopictus, and in Clovis city, Fresco County, California 
(2016) against male Aedes aegypti mosquitoes [21]. Gene editing using the CRISPR-
Cas9 system facilitates the genetic engineering of mosquitoes to make them infertile 
or repel pathogens [22]. The use of organic or green-synthesized pesticides is also 
advancing the quest for inexpensive, nontoxic and eco-friendly methods for killing 
particular species of mosquitoes or their larvae and pupae. Examples include the 
use of green-synthesized pesticides, such as silver nanoparticles (AgNP) produced 
from seaweed (Hypnea musciformis) to kill the larvae and pupae of the vector Aedes 
aegypti alone [23] or in combination with mosquito-predator Asian bulldog tadpoles 
[24]. Other plants have also been tested, such as Zornia diphylla leaves against 
Anopheles subpictus, the dengue vector Aedes albopictus and the Japanese encephali-
tis vector Culex tritaeniorhynchus [25] (and the shoofly plant, Nicandra physalodes, 
as a botanical larvicidal extract to control Anopheles stephensi, Aedes aegypti (dengue 
vector), and Culex quinquefasciatus (filariasis vector) [26]. Although many of these 
technological advances are still some years before they can be approved for field 
application [19], more operational or implementation research is needed to further 
demonstrate their effectiveness in both mosquito control and cost under particu-
larly settings, in order to accelerate their approval and wider use.
Our findings show that the low hanging fruit in improved mosquito-vector 
surveillance and control lie in improving the institutional capacity of the relevant 
mosquito-control agencies at local, county, state, and federal scales, and build-
ing/strengthening creative partnerships among researchers, mosquito-control 
Experts and jurisdictions, local communities, schools, and the public at large. 
Benefits of partnerships fell into four categories: (1) sharing resources and reducing 
operational costs; (2) reducing apathy and enhancing individual responsibility in 
household mosquito-control efforts, particularly through person-to-person contact 
(including citizen science in mosquito trapping and other data collection); (3) 
strengthening community support to enhance political will and support for more 
and stable funding; and (4) more effective and sustainable mosquito control across 
service boundaries. In addition, more effective public education strategies were 
also crucial, including those involving human contact and the use of volunteers and 
students in data collection and other mosquito-surveillance tasks under the label of 
citizen science.
4. Conclusion
While some of the barriers identified in this study are consistent with those 
identified previously, for instance in regard to WNV outbreaks, their persistence 
is worrisome. These inadequate surveillance and insufficient, reactive funding 
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that prioritizes responses to the disease du jour, and vacillating political will First, 
funding barriers were acutely import for municipal, county and state mosquito 
programs. Independent and dependent taxing mosquito districts reported better 
funding and smoother operations. Second, continuity of funding emerged criti-
cal for effective IVM. Disruptions in funding interrupted critical surveillance or 
control efforts and institutional arrangements and partnerships that take time to 
build and are hard to replace and restart, threatening the capacity of programs to 
detect, prevent and control MBD outbreaks.
Another emerging challenge from Experts’ perspectives was relatively high 
variability in mosquito-surveillance methods and practices, insufficient standardiza-
tion and quality control. The lack of standardization can undermine the reliability 
of entomological indices of mosquito presence or abundance and thresholds derived 
from the disparate surveillance methods, and assessments of MBD transmission, 
and ensuing responses. In particular, disparities in practice on mosquito-vector 
sampling (method, size and representativeness) was a concern because its impacts 
on common mosquito indices and ultimately on the accuracy of human risk assess-
ment was understudied and often unknown. A degree of standardization is needed 
to enhance scientific rigor and consistency in mosquito surveillance over space and 
time. Modern spatially explicit technologies particularly remote sensing analysis 
and GIS offer promising tools for sampling standardization and surveillance across 
scales.
Findings also revealed instances of, and further need for, creativity and accom-
modation among mosquito-control Experts under resource-strained conditions and 
competing interests that can provide insights for further research and development 
of best practice for particular settings. Examples include cost-effective and meth-
odologically sound mosquito sampling and MBD risk assessments, adjusting the 
timing or spatial targeting of insecticide application to meet methodological and 
special-interest needs (e.g., to minimize harm to bees and maintain good relations 
with beekeepers); or skipping of particular houses whose owners do not want 
truck-fogging. Findings further revealed the need to determine the minimum set of 
surveillance services needed given the tight funding conditions of state, county and 
municipal programs.
Building effective partnerships among public, private and academic/research 
institutions, local communities and schools emerged as an important strategy 
among most mosquito-control Experts. An outstanding challenge was finding 
effective ways to address opposition to the use of pesticides in mosquito control 
among local communities. Creative and sustained methods to educate the public on 
the dangers and benefits of MBD and mosquitos are also needed.
Looking ahead, perspectives of Experts from this exploratory study reveal that 
increased and reliable funding is a priority to mitigate many of the barriers, ensure 
effective surveillance and early detection and prevention of MBD transmission at 
municipal, county or local, and state levels. Recent new funding for responding to 
the 2016/16 ZIKV outbreak and for research by the US Congress and the CDC at 
federal level, as well as at state level for at-risk states such as Florida, are promising 
developments. However, the long-term value lies in their ability to enhance the 
capacity, cost-effectiveness, and sustainability of programs at multiple scales.
Further introduction into integrated pest management approaches of biologi-
cal control and low-cost, eco-friendly pesticides hold considerable promise for 
the mosquitoes and MBD control in the near future while safeguarding the envi-
ronment and public health broadly. Examples include the release of genetically 
modified (GM) mosquitoes into the wild to control ZIKV and Dengue-carrying 
mosquitoes under FDA-approved field-testing in the Florida Keys, Florida, 
USA. Non-GM mosquitoes infected with naturally occurring Wolbachia bacteria 
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in urban areas based on Geographic Information Systems and satellite imagery has 
been shown to improve the accuracy of entomological indices compared to those 
derived through the common biased method of selecting locations or houses that 
are known to have high vector densities [20].
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modified (GM) mosquitoes into the wild to control ZIKV and Zengue-carrying 
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offer early promise as a biological pesticide and have been field-tested in at least 
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technological advances are still some years before they can be approved for field 
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demonstrate their effectiveness in both mosquito control and cost under particu-
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Our findings show that the low hanging fruit in improved mosquito-vector 
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ing/strengthening creative partnerships among researchers, mosquito-control 
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students in data collection and other mosquito-surveillance tasks under the label of 
citizen science.
4. Conclusion
While some of the barriers identified in this study are consistent with those 
identified previously, for instance in regard to WNV outbreaks, their persistence 
is worrisome. These inadequate surveillance and insufficient, reactive funding 
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also offer early promise as a biological pesticide (in at least three US states) against 
Aedes albopictus and Aedes aegypti. Research is also advancing on organic or green-
synthesized pesticides as inexpensive, nontoxic and eco-friendly methods for 
killing particular species of mosquitoes or their larvae and pupae.
While this study exploratory, qualitative study of is not meant to be statistically 
representative or generalizable to the entire U.S. of all settings, it offers a wide range 
of perspectives and insights from mosquito-control Experts on issues including 
the nature and range of barriers and opportunities for mosquito-vector control in 
Continental United States. More detailed empirical analysis in selected states, which 
have had recent outbreaks or are at high risk of ZIKV, such as Florida, Texas and 
Louisiana, is the next step in terms of research.
Acknowledgements
We thank all the 35 mosquito Experts who participated in the interviews and the 
research assistants who helped interview them. This publication was supported by 
Cooperative Agreement Number U01CK000510, funded by the Centers for Disease 
Control and Prevention. Its contents are solely the responsibility of the authors and 
do not necessarily represent the official views of the Centers for Disease Control 
and Prevention or the Department of Health and Human Services.
Conflict of interest
The authors declare no conflict of interest.
Abbreviations
AgNP silver nanoparticles
CDC Centers for Disease Control
DEQ Department of Environmental Quality
EPA Environmental Protection Agency
FDA Food and Drug Administration
FMCA Florida Mosquito Control Association
GIS geographic information system
GM genetically modified
GMO genetically modified organism
IVM integrated vector management
MBD mosquito-borne diseases
WHO World Health Organization
WNV West Nile virus
ZIKV Zika virus
17
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Persistent Barriers to Implementing Efficacious Mosquito Control Activities in the Continental…
DOI: http://dx.doi.org/10.5772/intechopen.76774
Author details
Imelda K. Moise1,3*, Leo C. Zulu2, Douglas O. Fuller1 and John C. Beier3
1 Department of Geography and Regional Studies, College of Arts and Sciences, 
University of Miami, USA
2 Department of Geography, Environment and Spatial Sciences, Michigan State 
University, USA
3 Department of Public Health Sciences, Miller School of Medicine, University of 
Miami, USA
*Address all correspondence to: moise@miami.edu
Current Topics in Neglected Tropical Diseases
16
also offer early promise as a biological pesticide (in at least three US states) against 
Aedes albopictus and Aedes aegypti. Research is also advancing on organic or green-
synthesized pesticides as inexpensive, nontoxic and eco-friendly methods for 
killing particular species of mosquitoes or their larvae and pupae.
While this study exploratory, qualitative study of is not meant to be statistically 
representative or generalizable to the entire U.S. of all settings, it offers a wide range 
of perspectives and insights from mosquito-control Experts on issues including 
the nature and range of barriers and opportunities for mosquito-vector control in 
Continental United States. More detailed empirical analysis in selected states, which 
have had recent outbreaks or are at high risk of ZIKV, such as Florida, Texas and 
Louisiana, is the next step in terms of research.
Acknowledgements
We thank all the 35 mosquito Experts who participated in the interviews and the 
research assistants who helped interview them. This publication was supported by 
Cooperative Agreement Number U01CK000510, funded by the Centers for Disease 
Control and Prevention. Its contents are solely the responsibility of the authors and 
do not necessarily represent the official views of the Centers for Disease Control 
and Prevention or the Department of Health and Human Services.
Conflict of interest
The authors declare no conflict of interest.
Abbreviations
AgNP silver nanoparticles
CDC Centers for Disease Control
DEQ Department of Environmental Quality
EPA Environmental Protection Agency
FDA Food and Drug Administration
FMCA Florida Mosquito Control Association
GIS geographic information system
GM genetically modified
GMO genetically modified organism
IVM integrated vector management
MBD mosquito-borne diseases
WHO World Health Organization
WNV West Nile virus
ZIKV Zika virus
17
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Persistent Barriers to Implementing Efficacious Mosquito Control Activities in the Continental…
DOI: http://dx.doi.org/10.5772/intechopen.76774
Author details
Imelda K. Moise1,3*, Leo C. Zulu2, Douglas O. Fuller1 and John C. Beier3
1 Department of Geography and Regional Studies, College of Arts and Sciences, 
University of Miami, USA
2 Department of Geography, Environment and Spatial Sciences, Michigan State 
University, USA
3 Department of Public Health Sciences, Miller School of Medicine, University of 
Miami, USA
*Address all correspondence to: moise@miami.edu
18
Current Topics in Neglected Tropical Diseases
[1] Hanem FK. Introductory chapter: 
Back to the future—Solutions for 
parasitic problems as old as the 
pyramids, natural remedies in the fight 
against parasites. In: Khater DH, editor. 
Natural Remedies in the Fight Against 
Parasites. Rijeka, Croatia: InTech; 2017
[2] Slutsker L, Kachur SP. It is time 
to rethink tactics in the fight against 
malaria. Malaria Journal. 2013;12:140. 
DOI: 10.1186/1475-2875-12-140
[3] Cauchemez S, Ledrans M, Poletto 
C, Quenel P, de Valk H, Colizza V, 
et al. Local and regional spread of 
chikungunya fever in the Americas. 
Euro Surveillance. 2014;19:20854
[4] Fauci AS, Morens DM. Zika virus in 
the Americas—Yet another arbovirus 
threat. New England Journal of 
Medicine. 2016;374:601-604
[5] Hemingway J. The role of vector 
control in stopping the transmission 
of malaria: Threats and opportunities. 
Philosophical Transactions of the Royal 
Society of London. Series B, Biological 
Sciences. 2014;369:20130431
[6] McKenna M. Disorganized mosquito 
control will make US vulnerable to Zika. 
Germination. 2016. Available from: 
http://phenomena.nationalgeographic.
com/2016/02/29/zika-mosquito-control/
[7] ASTHO. Public Health Confronts the 
Mosquito: Developing Sustainable State 
and Local Mosquito Control Programs. 
Washington, DC: ASTHO; 2005
[8] Vazquez-Prokopec GM, Chaves 
LF, Ritchie SA, Davis J, Kitron 
U. Unforeseen costs of cutting mosquito 
surveillance budgets. PLoS Neglected 
Tropical Diseases. 2010;4:e858
[9] STAT. Congress Approves $1.1 Billion 
in Zika Funding. 2016
[10] Couzin-Frankel J. Infectious 
diseases. Fears of lax surveillance 
if CDC program cut. Science. 
2010;328:1088
[11] Hadler JL, Patel D, Nasci RS, 
Petersen LR, Hughes JM, Bradley 
K, et al. Assessment of arbovirus 
surveillance 13 years after introduction 
of West Nile virus, United States. 
Emerging Infectious Diseases. 
2015;21:1159-1166
[12] Hadler JL, Patel D, Bradley K, 
Hughes JM, Blackmore C, Etkind 
P, et al. National capacity for 
surveillance, prevention, and control 
of West Nile virus and other arbovirus 
infections—United States, 2004 and 
2012. MMWR. Morbidity and Mortality 
Weekly Report. 2014;63:281-284
[13] Shanker D. Zika Is here, and 
America has no plan to fight it. 
Bloomberg. 2016
[14] CDC. Surveillance and Control of 
Aedes aegypti and Aedes albopictus in 
the United States. 2016. Available from: 
http://www.cdc.gov/chikungunya/
resources/vector-control.html
[15] Berkelman RL, Bryan RT, Osterholm 
MT, LeDuc JW, Hughes JM. Infectious 
disease surveillance: A crumbling 
foundation. Science. 1994;264:368-370
[16] Yoo E, Chen D, Russel C. West Nile 
Virus Mosquito Abundance Modeling 
Using Nonstationary Spatiotemporal 
Geostatistics. In: Chen D, Moulin B, 
Wu J, editors.  Analyzing and Modeling 
Spatial and Temporal Dynamics 
of Infectious Diseases. 2015. DOI: 
10.1002/9781118630013.ch14
[17] Bowman LR, Donegan S, 
McCall PJ. Is dengue vector control 
deficient in effectiveness or evidence? 
Systematic review and meta-analysis. 
References
19
Persistent Barriers to Implementing Efficacious Mosquito Control Activities in the Continental…
DOI: http://dx.doi.org/10.5772/intechopen.76774
PLoS Neglected Tropical Diseases. 
2016;10:e0004551
[18] Azil AH, Bruce D, Williams 
CR. Determining the spatial 
autocorrelation of dengue vector 
populations: Influences of mosquito 
sampling method, covariables, and 
vector control. Journal of Vector 
Ecology. 2014;39:153-163
[19] Fernandes JN, Moise IK, Maranto 
GL, Beier JC. Revamping mosquito-
borne disease control to tackle future 
threats. Trends in Parasitology. 2018: 
S1471-4922(18)30008-4 DOI: 10.1016/j.
pt.2018.01.005
[20] Troyo A, Fuller DO, Calderón-
Arguedas O, Beier JC. A geographical 
sampling method for surveys of 
mosquito larvae in an urban area using 
high-resolution satellite imagery. 
Journal of Vector Ecology. 2008;33:1-7
[21] Zhang S. A California city is fending 
off Zika by releasing 40,000 mosquitoes 
every week. Science. 2016
[22] Hammond A, Galizi R, Kyrou K, 
Simoni A, Siniscalchi C, Katsanos D, 
et al. A CRISPR-Cas9 gene drive system 
targeting female reproduction in the 
malaria mosquito vector Anopheles 
gambiae. Nature Biotechnology. 
2015;34:78
[23] Roni M, Murugan K, 
Panneerselvam C, Subramaniam J, 
Nicoletti M, Madhiyazhagan P, et al. 
Characterization and biotoxicity of 
Hypnea musciformis-synthesized silver 
nanoparticles as potential eco-friendly 
control tool against Aedes aegypti and 
Plutella xylostella. Ecotoxicology and 
Environmental Safety. 2015;121:31-38
[24] Murugan K, Priyanka V, Dinesh 
D, Madhiyazhagan P, Panneerselvam 
C, Subramaniam J, et al. Predation by 
Asian bullfrog tadpoles, Hoplobatrachus 
tigerinus, against the dengue 
vector, Aedes aegypti, in an aquatic 
environment treated with mosquitocidal 
nanoparticles. Parasitology Research. 
2015;114(10):3601
[25] Govindarajan M, Rajeswary M, 
Muthukumaran U, Hoti SL, Khater HF, 
Benelli G. Single-step biosynthesis and 
characterization of silver nanoparticles 
using Zornia diphylla leaves: A potent 
eco-friendly tool against malaria 
and arbovirus vectors. Journal of 
Photochemistry and Photobiology B: 
Biology. 2016;161:482-489
[26] Govindarajan M, Khater HF, 
Panneerselvam C, Benelli G. One-pot 
fabrication of silver nanocrystals 
using Nicandra physalodes: A novel 
route for mosquito vector control with 
moderate toxicity on non-target water 
bugs. Research in Veterinary Science. 
2016;107:95-101
18
Current Topics in Neglected Tropical Diseases
[1] Hanem FK. Introductory chapter: 
Back to the future—Solutions for 
parasitic problems as old as the 
pyramids, natural remedies in the fight 
against parasites. In: Khater DH, editor. 
Natural Remedies in the Fight Against 
Parasites. Rijeka, Croatia: InTech; 2017
[2] Slutsker L, Kachur SP. It is time 
to rethink tactics in the fight against 
malaria. Malaria Journal. 2013;12:140. 
DOI: 10.1186/1475-2875-12-140
[3] Cauchemez S, Ledrans M, Poletto 
C, Quenel P, de Valk H, Colizza V, 
et al. Local and regional spread of 
chikungunya fever in the Americas. 
Euro Surveillance. 2014;19:20854
[4] Fauci AS, Morens DM. Zika virus in 
the Americas—Yet another arbovirus 
threat. New England Journal of 
Medicine. 2016;374:601-604
[5] Hemingway J. The role of vector 
control in stopping the transmission 
of malaria: Threats and opportunities. 
Philosophical Transactions of the Royal 
Society of London. Series B, Biological 
Sciences. 2014;369:20130431
[6] McKenna M. Disorganized mosquito 
control will make US vulnerable to Zika. 
Germination. 2016. Available from: 
http://phenomena.nationalgeographic.
com/2016/02/29/zika-mosquito-control/
[7] ASTHO. Public Health Confronts the 
Mosquito: Developing Sustainable State 
and Local Mosquito Control Programs. 
Washington, DC: ASTHO; 2005
[8] Vazquez-Prokopec GM, Chaves 
LF, Ritchie SA, Davis J, Kitron 
U. Unforeseen costs of cutting mosquito 
surveillance budgets. PLoS Neglected 
Tropical Diseases. 2010;4:e858
[9] STAT. Congress Approves $1.1 Billion 
in Zika Funding. 2016
[10] Couzin-Frankel J. Infectious 
diseases. Fears of lax surveillance 
if CDC program cut. Science. 
2010;328:1088
[11] Hadler JL, Patel D, Nasci RS, 
Petersen LR, Hughes JM, Bradley 
K, et al. Assessment of arbovirus 
surveillance 13 years after introduction 
of West Nile virus, United States. 
Emerging Infectious Diseases. 
2015;21:1159-1166
[12] Hadler JL, Patel D, Bradley K, 
Hughes JM, Blackmore C, Etkind 
P, et al. National capacity for 
surveillance, prevention, and control 
of West Nile virus and other arbovirus 
infections—United States, 2004 and 
2012. MMWR. Morbidity and Mortality 
Weekly Report. 2014;63:281-284
[13] Shanker D. Zika Is here, and 
America has no plan to fight it. 
Bloomberg. 2016
[14] CDC. Surveillance and Control of 
Aedes aegypti and Aedes albopictus in 
the United States. 2016. Available from: 
http://www.cdc.gov/chikungunya/
resources/vector-control.html
[15] Berkelman RL, Bryan RT, Osterholm 
MT, LeDuc JW, Hughes JM. Infectious 
disease surveillance: A crumbling 
foundation. Science. 1994;264:368-370
[16] Yoo E, Chen D, Russel C. West Nile 
Virus Mosquito Abundance Modeling 
Using Nonstationary Spatiotemporal 
Geostatistics. In: Chen D, Moulin B, 
Wu J, editors.  Analyzing and Modeling 
Spatial and Temporal Dynamics 
of Infectious Diseases. 2015. DOI: 
10.1002/9781118630013.ch14
[17] Bowman LR, Donegan S, 
McCall PJ. Is dengue vector control 
deficient in effectiveness or evidence? 
Systematic review and meta-analysis. 
References
19
Persistent Barriers to Implementing Efficacious Mosquito Control Activities in the Continental…
DOI: http://dx.doi.org/10.5772/intechopen.76774
PLoS Neglected Tropical Diseases. 
2016;10:e0004551
[18] Azil AH, Bruce D, Williams 
CR. Determining the spatial 
autocorrelation of dengue vector 
populations: Influences of mosquito 
sampling method, covariables, and 
vector control. Journal of Vector 
Ecology. 2014;39:153-163
[19] Fernandes JN, Moise IK, Maranto 
GL, Beier JC. Revamping mosquito-
borne disease control to tackle future 
threats. Trends in Parasitology. 2018: 
S1471-4922(18)30008-4 DOI: 10.1016/j.
pt.2018.01.005
[20] Troyo A, Fuller DO, Calderón-
Arguedas O, Beier JC. A geographical 
sampling method for surveys of 
mosquito larvae in an urban area using 
high-resolution satellite imagery. 
Journal of Vector Ecology. 2008;33:1-7
[21] Zhang S. A California city is fending 
off Zika by releasing 40,000 mosquitoes 
every week. Science. 2016
[22] Hammond A, Galizi R, Kyrou K, 
Simoni A, Siniscalchi C, Katsanos D, 
et al. A CRISPR-Cas9 gene drive system 
targeting female reproduction in the 
malaria mosquito vector Anopheles 
gambiae. Nature Biotechnology. 
2015;34:78
[23] Roni M, Murugan K, 
Panneerselvam C, Subramaniam J, 
Nicoletti M, Madhiyazhagan P, et al. 
Characterization and biotoxicity of 
Hypnea musciformis-synthesized silver 
nanoparticles as potential eco-friendly 
control tool against Aedes aegypti and 
Plutella xylostella. Ecotoxicology and 
Environmental Safety. 2015;121:31-38
[24] Murugan K, Priyanka V, Dinesh 
D, Madhiyazhagan P, Panneerselvam 
C, Subramaniam J, et al. Predation by 
Asian bullfrog tadpoles, Hoplobatrachus 
tigerinus, against the dengue 
vector, Aedes aegypti, in an aquatic 
environment treated with mosquitocidal 
nanoparticles. Parasitology Research. 
2015;114(10):3601
[25] Govindarajan M, Rajeswary M, 
Muthukumaran U, Hoti SL, Khater HF, 
Benelli G. Single-step biosynthesis and 
characterization of silver nanoparticles 
using Zornia diphylla leaves: A potent 
eco-friendly tool against malaria 
and arbovirus vectors. Journal of 
Photochemistry and Photobiology B: 
Biology. 2016;161:482-489
[26] Govindarajan M, Khater HF, 
Panneerselvam C, Benelli G. One-pot 
fabrication of silver nanocrystals 
using Nicandra physalodes: A novel 
route for mosquito vector control with 
moderate toxicity on non-target water 




The Global Distribution and 
Burden of Dengue and Japanese 
Encephalitis Co-Infection in Acute 
Encephalitis Syndrome
Shailendra K. Saxena, Swatantra Kumar, Vimal K. Maurya 
and Madan L.B. Bhatt
Abstract
Dengue is widespread throughout the tropics globally in more than hundred coun-
tries and coincides with various climatic factors for co-infection with other flaviviral 
infections of the central nervous system (CNS). Dengue and Japanese encephalitis 
virus co-infection are highly prevalent, with diagnosis dilemma including significant 
mortality and morbidity in Southeast Asia. Both dengue and Japanese encephalitis 
transmissions intensify during the rainy season, during which the vector population 
increases. CNS involvement during dengue and Japanese encephalitis co-infection-
associated acute encephalitis syndrome (AES) is still poorly understood, and therefore, 
there is a desperate need to understand the etiology, therapeutics, clinical manage-
ment, and prevention of these tropically neglected diseases. AES can be differentiated 
from other etiologies of encephalopathy through considering its essential features: sud-
den onset of fever, cerebrospinal fluid (CSF) comprising inflammatory cells, magnetic 
resonance imaging (MRI)-based confirmation, and presence of pathogen or pathogen-
specific antibodies. Complementary and alternative medicine is progressively being 
used globally and can be effective for the overall management of this co-infection.
Keywords: dengue, Japanese encephalitis, co-infection, encephalitis,  
acute encephalitis syndrome (AES), differential diagnosis, treatment, management, 
prevention, complementary and alternative medicine
1. Introduction
Neglected tropical diseases (NTDs) are the diverse group of communicable 
diseases which exist in tropical and subtropical settings affecting more than one bil-
lion people worldwide [1]. Populations inhabiting places with poor sanitation are in 
close contact with infected vectors, and domestic animals are principally affected. 
Arthropod-borne or arboviruses such as dengue, Zika, and Chikungunya have been 
recently included in the list of NTDs by the World Health Organization [2].
Human infection of flavivirus may cause severe clinical manifestations and can 
be broadly subdivided into two groups as neurological diseases caused by Japanese 
encephalitis virus (JEV), West Nile virus, and Zika virus (ZIKV) and hemorrhagic 
and viscerotropic diseases caused by dengue virus (DENV), ZIKV, and yellow fever 
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1. Introduction
Neglected tropical diseases (NTDs) are the diverse group of communicable 
diseases which exist in tropical and subtropical settings affecting more than one bil-
lion people worldwide [1]. Populations inhabiting places with poor sanitation are in 
close contact with infected vectors, and domestic animals are principally affected. 
Arthropod-borne or arboviruses such as dengue, Zika, and Chikungunya have been 
recently included in the list of NTDs by the World Health Organization [2].
Human infection of flavivirus may cause severe clinical manifestations and can 
be broadly subdivided into two groups as neurological diseases caused by Japanese 
encephalitis virus (JEV), West Nile virus, and Zika virus (ZIKV) and hemorrhagic 
and viscerotropic diseases caused by dengue virus (DENV), ZIKV, and yellow fever 
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virus (YFV) [3]. More than half of the global population is now at the risk of getting 
flavivirus infections where the majority of areas are endemic for more than one flavi-
viruses which results in the phenomenon of co-infection [4]. The worldwide incident 
of dengue has extensively grown in few decades [5]. Majority of the dengue cases 
are asymptomatic, and therefore, it is hard to anticipate the accurate burden of the 
disease. The rise in number of cases from 2.2 million in the year 2010 to 3.34 million 
cases in 2016 suggests the sharp increase in the disease burden. The 2016 year is char-
acterized as the largest outbreak for dengue where 2.38 million cases were reported 
from the region of the Americas where 1.5 million cases were contributed by Brazil 
alone. Currently 3.9 billion in 128 countries people are at risk of DENV infection [6]. 
Unlike dengue, Japanese encephalitis (JE) is confined to Southeast Asia and Western 
Pacific regions. Approximately 68,000 clinical cases of JE are reported annually with 
13,000 to 24,000 deaths. Currently more than 3 billion in 24 countries are at risk of 
JEV infection [7]. The epidemiology of dengue and JE has been depicted in Figure 1.
DENV and JEV belongs to the Flaviviridae family, which consists of more than 
70 viruses, comprising of single-stranded positive-sense RNA genome protected by 
envelope protein [8]. Viruses from this family belong to the genus Flavivirus, which 
are transmitted by mosquitoes or ticks and are characterized as arthropod-borne 
infections. The transmission cycle of Flavivirus involves animals including human 
which are considered to be the dead-end hosts [9]. Hematophagous mosquitoes are 
the transmission vector for these diseases. Aedes albopictus and Aedes aegypti mos-
quitoes are known to transmit the dengue virus, whereas Culex tritaeniorhynchus 
is predominantly involve in the transmission of JEV [10]. These viruses have been 
shown to be transmitted via transplacental route as well [11].
Pathogen-associated acute encephalitis syndrome (PA-AES) may result from 
diverse pathogenic infections including DENV and JEV. PA-AES shows a wide range 
of symptoms including headache, vomiting and severe illness, reduced conscious-
ness, altered sensorium, convulsions, and tremors [12]. Flaviviruses share sub-
stantial sequence similarities to stimulate sero-cross-reactivity which results in the 
antibody-dependent enhancement (ADE) of infection with other flaviviruses [13]. 
Figure 1. 
Dengue and Japanese encephalitis epidemiology. The worldwide epidemiology of dengue and Japanese 
encephalitis has been depicted in this map. More than 100 countries are endemic for dengue where America, 
Western Pacific regions, and Southeast Asia are mostly affected. The Japanese encephalitis is confined to mostly 
in Southeast Asia and Western Pacific regions which include approximately 24 countries. The dengue-affected 
regions are highlighted in red color, JE-affected regions are highlighted in yellow color, and regions where both 
viruses are circulating have been highlighted in orange color.
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Outbreaks of DENV co-infection are predominantly associated with the JEV 
endemic area or areas of JE immunization [14]. Although DENV-induced encepha-
litis is rare, the co-infection may increase the severity of encephalitis. DENV 
infection causes dengue hemorrhagic fever (DHF), whereas JEV infection may 
result in neurological complications [15]. Intermittently, DENV has been reported 
to cause encephalitis, and JEV infection may cause extraneural hemorrhage [16, 17]. 
However, this may not be the case in co-infection with both the flaviviruses. 
Simultaneous detection of both the viruses is not unusual; nevertheless we need to 
be attentive in the diagnosis of the etiology of PA-AES.
2. Molecular mechanism of DENV and JEV co-infection
Co-infection with both viruses may occur in the single-cell types or different 
cells in the infected individuals. Simultaneous infection of target cells or different 
cell types by DENV and JEV defines the phenomenon of co-infection [18]. Both the 
viruses share common cell surface receptors expressed on target cell types such as 
DC-SIGN, mannose receptors, and CLEC5A [19]. On the other hand, virus can be 
internalized in the presence of non-neutralizing antibodies via Fcγ receptor-mediated 
endocytosis [20]. Clathrin-mediated endocytosis has been shown to be involved in the 
internalization of flaviviruses [21]. After internalization, the virus from the endocytic 
vesicles is delivered to the early endosomes [22]. Acidification of the endosomal 
Figure 2. 
DENV and JEV co-infection. The mechanism of co-infection has not been completely understood. 
Co-infection with DENV and JEV may occur in the single-cell types or different cells in the infected individuals. 
Co-infection results in the generation of antibodies against both viruses. However, detection of nucleic acids 
and antigens may confirm the phenomenon of co-infection (A). Upon infection, JEV is internalized by 
receptor-mediated endocytosis. The decrease in pH causes the fusion of viral and endosomal membrane which 
results in the release of viral RNA into the cytosol. The released viral genome is then translated prior to the 
commencement of replication. Virus maturation occurs at the Golgi complex and mature virus is released via 
the egress process. JEV infection in the hyperendemic area may result in false-positive diagnosis due to presence 
of pre-existing sero-cross-reactive antibody (B). Pre-existing sero-cross-reactive antibodies may bind to the 
viral particles upon infection which results in antibody-dependent enhancement of infection (C).
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compartments causes trimerization of the envelope protein that results in the fusion 
of endosomes to the viral membrane and release of nucleocapsid in the cytosol [23].
The released viral genome is then translated prior to the commencement of 
replication [24]. The backbone of flaviviral genome is invariable which are of ~10 kb 
that codes for three structural capsid (C), premembrane (prM), and envelope (E) 
and seven nonstructural proteins NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5. 
The viral genome encodes for 3400 amino acid long polyprotein which is arranged 
in the lumen endoplasmic reticulum where the replication takes place by the RNA-
dependent RNA polymerase [25]. Replicated copies of the genome interact with viral 
proteins to form nucleocapsid. Immature virions enter into the secretary pathway 
where furin-mediated cleavage of prM results in the maturation of virus [26]. 
Mature virus is then released from the infected cells via the egress process [27]. The 
conventional mechanism of pathogenesis and viral replication may not be followed in 
case of co-infection and may involve distinct process. In order to effectively control 
and treat the co-infection of DENV and JEV, we need to first understand the immu-
nopathogenesis of dual infection in various cell and animal models. The probable 
phenomenon of DENV and JEV co-infection has been demonstrated in Figure 2.
3. Diagnostic schemes for dengue and Japanese encephalitis co-infection
JEV is the most documented causative agent of acute encephalitis syndrome (AES) 
[28]. DENV has also been considered among the top three etiological agents causing 
Figure 3. 
Laboratory diagnostic algorithms during DENV and JEV co-infection. Suspected cases of DENV and 
JEV co-infection can be decided by the above laboratory diagnostic algorithms of co-infection. Detection of IgG 
antibodies against both viruses may be considered as the previous exposure of the viruses, whereas detection 
of IgM or NS1 antigen suggests the recent or current infectious conditions. However, this should be further 
validated based on the nucleic acid-based tests such as RT-PCR and isolation of virus which may define the 
co-infectious condition in addition to the clinical correlation. “Y” indicates positive, “N” indicates negative, and 
“?” indicates inconclusive test report.
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AES [29]. Broad spectrum of clinical features in the endemic areas of both viruses 
may dilute the encephalitis-like clinical presentation. Therefore, laboratory based 
diagnosis and discrimination of pathogenesis is crucial to understand. Detection of 
IgG antibodies against both viruses may be considered as the previous exposure of the 
viruses, whereas detection of IgM suggests the recent or current infectious condi-
tions. However, this should be further validated based on the nucleic acid-based tests 
where detection of DENV and JEV nucleic acids defines the co-infectious condition.
Nucleic acid-based detection by RT-PCR for other probable arboviral infections 
such as Zika and Chikungunya can also be included which may overlap with the 
clinical manifestations of dengue or JE [30]. Although the clinical manifestations 
presented in the individual cases of DENV and JEV infections are distinct, the co-
infection might be a complex situation to diagnose. Co-detection of serum anti-
bodies against both viruses may not be the evidence of co-infection. Surveillance 
programs conducted in the hyperendemic areas of flaviviruses have reported at 
least 9% of co-infections cases [31]. Moreover, the MRI findings of DENV-infected 
patients may show the characteristic features of encephalitis as in case of JEV 
where the basal ganglia, thalamus, and midbrain are predominantly affected 
[32]. Considering the sero-cross-reactivity among flaviviruses, the dependence 
of serum-based diagnosis may give false-positive results. However, simultaneous 
detection of nucleic acid or viral-specific antigens in blood or CSF samples may 
define the incident of co-infection. The laboratory diagnostic algorithms during 
DENV and JEV co-infection have been depicted in Figure 3.
4. Treatments regimes for dengue and Japanese encephalitis co-infection
Viral infections have always been a global threat to mankind due to scarcity of 
effective antiviral drugs. Flaviviral infections are not the exception since there is no 
specific treatment available for both DENV and JEV [33]. The overall treatment relies 
on the symptomatic relief of the patients. Due to the complex and unclear pathogen-
esis of dual infection, the potential candidate drugs may not effective. Therefore, we 
need to look for the complementary and alternative medicine (CAM) in alliance with 
conventional medicines as the choice of treatment during co-infection.
In case of DENV infection, various forms of CAM have been used such as 
Carica papaya leaf extracts is the most accepted one. Platelet-activating factor 
receptor (PTAFR) gene has been shown to be upregulated upon consumption of 
Carica papaya leaf extracts or its juices [34]. In case of sever dengue infection, 
maintenance of body fluids volume of the patients is critical [35]. However, this 
may or may not be effective in case of co-infections. Recently, andrographolide has 
been shown to exhibit anti-DENV activity [36]. Eupatorium perfoliatum which is a 
homeopathic medicine has been shown to exhibit anti-DENV activity [37]. Luteolin 
has been shown to be effective during JEV infection which also exhibits direct 
virucidal activity [38]. Similarly, belladonna has been shown to be effective in chick 
embryos infected with JEV [39]. Several of the CAM-based therapies have been 
shown to be effective in case of JEV infection, but these have to be validated in case 
of co-infection.
5.  Preventive strategies for dengue and Japanese encephalitis 
co-infection
To prevent the worldwide burden of DENV infection, the WHO has recently 
approved a tetravalent vaccine, Dengvaxia (CYD-TDV) in 20 countries. This has 
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been designed by using the yellow fever vaccine backbone expressing the prM and 
envelope protein of DENV 1–4 serotypes [40]. In case of JEV, a live attenuated 
vaccine based on SA 14–14-2 has been used in China, India, Sri Lanka, Republic 
of Korea, and Thailand. Due to higher sero-cross-reactivity, the one vaccine may 
induce the other infection due to the antibody-dependent enhancement [41]. 
Therefore, to design an effective vaccine for co-infection, there is a need to under-
stand the mechanism and probability of sero-cross-reactivity among the viruses. 
Apart from the vaccination, the personal preventive measures are always the 
paramount to prevent any vector-borne infections [42]. To prevent the mosquito 
biting, several protective measures include mosquito repellents, mosquito nets, and 
use of full sleeves cloths [43].
6. Conclusions
Genomic and proteomic sequence similarity among the flaviviruses causes 
the sero-cross-reactivity that leads to the phenomenon of antibody-dependent 
enhancement of infections. Incidence of DENV and JEV co-infection in the hyper-
endemic areas may be frequently reported. The diagnosis of co-infection should 
not rely on the presence of serum antibodies. However, simultaneous detection of 
nucleic acids or antigens may define the condition of co-infection. Clinical features 
may overlap in the patients infected with both viruses, and therefore we need to 
precisely distinguish the patients’ clinical reports. Development of effective antivi-
rals targeting both the viruses is the most imperative therapeutic strategy.
7. Future perspectives
Due to the similarity in the structural domains of the viral proteins, molecules 
may be designed to inhibit the action of viral proteins or enzymes. Similarly, 
vaccines may be designed to target the population living in the hyperendemic areas 
of flaviviruses. Peptide-based vaccines may be designed by using various immu-
noinformatics approaches by considering the consensus peptide sequences among 
the viruses. Apart from the vaccination, personal preventive measures are always 
recommended the best practice to reduce the chances of infections.
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Abstract
In recent years, large-scale outbreaks of chikungunya arbovirus (CHIKV), which 
is transmitted by the Aedes mosquito, have enabled the rapid propagation of the virus 
across the world. After acute infection phase with commonly fever, joint pain, head-
ache, or rash, chronic rheumatism (arthralgia or myalgia, anorexia, and concentration 
disorders) up to 40% of cases is observed. The chronic form is defined by symptoms 
persisting for more than 3 months, and up to years, after initial diagnosis. Chronic 
discomfort has been linked to one of the four genotypes described. These genotypes 
represent different geographic lineages (classification based on partial sequence of viral 
E1 glycoprotein): West African, East-Central-South-African (ECSA), ECSA-diverged 
or Indian Ocean Lineage (IOL), and Asian. The first marker detected in CHIK infection 
is the viral RNA, usually by reverse transcription-polymerase chain reaction (RT-PCR). 
This marker can be identified in samples within 8 days of symptom onset. The infection 
can also be diagnosed with serological testing to detect CHIKV-specific immunoglobu-
lin IgG and/or IgM. Sequencing studies can determine the infecting genotype.
Keywords: chikungunya, genotype, chronic
1. Introduction
Chikungunya virus (CHIKV) is an emerging mosquito-borne alphavirus that 
causes severe acute febrile infection, often debilitating polyarthralgias and arthri-
tis [1], and its symptoms are similar. The name chikungunya is derived from an 
African language makonde which means “that which bends up” or “stooped walk” 
because of the incapacitating arthralgia caused by the disease.
Chikungunya virus, the first reported case of which was in Tanzania in 1952 [2], 
is endemic in certain parts of West Africa, human serosurveys having identified 
antibodies to chikungunya virus in 35–50% of the population in some areas [3, 4].
1.1 Epidemiology, structure, and classification of chikungunya
Since 2004 CHIKV has spread into novel locations, with outbreaks having 
occurred in other parts of Africa as well as Asia, Europe, and the islands of the Indian 
Current Topics in Neglected Tropical Diseases
30
Journal of Virology. 2017;91(21):pii. 
e01055-17
[34] Sarala N, Paknikar S. Papaya extract 
to treat dengue: A novel therapeutic 
option? Annals of Medical and Health 
Sciences Research. 2014;4(3):320-324
[35] Hung NT. Fluid management 
for dengue in children. Paediatrics 
and International Child Health. 
2012;32(Suppl 1):39-42
[36] Panraksa P, Ramphan S, 
Khongwichit S, Smith DR. Activity of 
andrographolide against dengue virus. 
Antiviral Research. 2017;139:69-78
[37] Saxena SK, Haikerwal A, 
Gadugu S, Bhatt ML. Complementary 
and alternative medicine in alliance 
with conventional medicine for dengue 
therapeutics and prevention. Future 
Virology. 2017;12(8):399-402
[38] Fan W, Qian S, Qian P, Li X. 
Antiviral activity of luteolin against 
Japanese encephalitis virus. Virus 
Research. 2016;220:112-116
[39] Chakraborty U, Katoch S, Sinha M, 
Nayak D, Khurana A, Manchanda RK, 
et al. Changes in viral load in different 
organs of Japanese encephalitis virus-
infected chick embryo under the 
influence of belladonna 200C. Indian 
Journal of Research in Homoeopathy. 
2018;12(2):75
[40] Clapham H, Wills B. Implementing 
a dengue vaccination programme-who, 
where and how? Transactions of the 
Royal Society of Tropical Medicine and 
Hygiene. 2018;112(8):367-368
[41] Ginsburg AS, Meghani A, 
Halstead SB, Yaich M. Use of the live 
attenuated Japanese encephalitis vaccine 
SA 14-14-2 in children: A review of 
safety and tolerability studies. Human 
Vaccines & Immunotherapeutics. 
2017;13(10):2222-2231
[42] Demers J, Bewick S, 
Calabrese J, Fagan WF. Dynamic 
modelling of personal protection 
control strategies for vector-borne 
disease limits the role of diversity 
amplification. Journal of the Royal 
Society Interface. 2018;15(145):pii. 
20180166
[43] Tangena JA, Thammavong P, 
Chonephetsarath S, Logan JG, 
Brey PT, Lindsay SW. Field evaluation 
of personal protection methods 
against outdoor-biting mosquitoes 




Diagnosis and Molecular 
Characterization of Chikungunya 
Virus Infections
Marta E. Álvarez-Argüelles, Susana Rojo Alba,  
Mercedes Rodríguez Pérez, Jose Antonio Boga Riveiro  
and Santiago Melón García
Abstract
In recent years, large-scale outbreaks of chikungunya arbovirus (CHIKV), which 
is transmitted by the Aedes mosquito, have enabled the rapid propagation of the virus 
across the world. After acute infection phase with commonly fever, joint pain, head-
ache, or rash, chronic rheumatism (arthralgia or myalgia, anorexia, and concentration 
disorders) up to 40% of cases is observed. The chronic form is defined by symptoms 
persisting for more than 3 months, and up to years, after initial diagnosis. Chronic 
discomfort has been linked to one of the four genotypes described. These genotypes 
represent different geographic lineages (classification based on partial sequence of viral 
E1 glycoprotein): West African, East-Central-South-African (ECSA), ECSA-diverged 
or Indian Ocean Lineage (IOL), and Asian. The first marker detected in CHIK infection 
is the viral RNA, usually by reverse transcription-polymerase chain reaction (RT-PCR). 
This marker can be identified in samples within 8 days of symptom onset. The infection 
can also be diagnosed with serological testing to detect CHIKV-specific immunoglobu-
lin IgG and/or IgM. Sequencing studies can determine the infecting genotype.
Keywords: chikungunya, genotype, chronic
1. Introduction
Chikungunya virus (CHIKV) is an emerging mosquito-borne alphavirus that 
causes severe acute febrile infection, often debilitating polyarthralgias and arthri-
tis [1], and its symptoms are similar. The name chikungunya is derived from an 
African language makonde which means “that which bends up” or “stooped walk” 
because of the incapacitating arthralgia caused by the disease.
Chikungunya virus, the first reported case of which was in Tanzania in 1952 [2], 
is endemic in certain parts of West Africa, human serosurveys having identified 
antibodies to chikungunya virus in 35–50% of the population in some areas [3, 4].
1.1 Epidemiology, structure, and classification of chikungunya
Since 2004 CHIKV has spread into novel locations, with outbreaks having 
occurred in other parts of Africa as well as Asia, Europe, and the islands of the Indian 
Current Topics in Neglected Tropical Diseases
32
and Pacific Oceans, and more recently in the Americas, mostly during the tropical 
rainy season. The risk of CHIKV being imported into further new areas is ever pres-
ent because of the high attack rates, which affect between one-third to three-quarters 
of the population in areas where the virus is circulating, associated with the recur-
rence of epidemics, along with the high levels of viremia in infected humans and the 
worldwide distribution of the vectors, Aedes aegypti and Aedes albopictus [4]. Infected 
travelers can import chikungunya into new areas [1, 5–7], and in areas with A. aegypti 
and/or A. albopictus mosquitoes, local transmission can follow.
CHIKV multiple outbreaks have been identified as a cause of dengue-like illness 
with arthralgia in Africa and febrile hemorrhagic disease in Asia [2]. Although 
outbreaks of CHIKV were limited from the 1970s onward, in 2004–2005 the virus 
was detected in Kenya and the islands of the Indian Ocean in 2004–2005 [4, 8–10], 
and in the last decade, there have been massive outbreaks in new areas as well as in 
those where the virus is endemic [11]. What is more, local transmission of CHIKV 
has also been reported for the first time in parts of Europe, Asia [12], Australia [13], 
and America [9, 14, 15].
In the Americas, autochthonous CHIKV transmission was first reported in 
the Caribbean, on the island of St. Martin, in December 2013 [16], from which 
it is known to have spread to 45 countries or regions in Central/South/North 
America, where, according to the Pan American Health Organization, there had 
been 2 million suspected cases by 2014 [17]. It was detected in Central and South 
America in 2014, where there have since been multiple widescale outbreaks [13, 
17], and between June and November of that same year, cases were reported in 
people returning to Northwest Italy from the Caribbean and Central America, even 
though there had been no reported cases of CHIKF in either region for 3 years [18]. 
More recently, in 2016–2017, autochthonous CHIKV transmission was reported in 
India [19], Pakistan [20], and Italy [21]. It can be assumed that the combination of 
increased global travel and trade, the wide distribution of the mosquito vectors, and 
a lack of herd immunity have all contributed to the introduction and rapid spread of 
CHIKV in naïve populations.
Dengue and Zika viruses are transmitted by the same mosquito vectors as chi-
kungunya so all three viruses can co-circulate in a geographic region, and coinfec-
tions have been documented [22, 23]. This clearly has implications for diagnosis in 
the laboratory.
CHIKV belongs to the Togaviridae family, genus Alphavirus, within the Semliki 
Forest antigenic complex. Among the other members of this antigenic complex are 
the Mayaro, O’Nyong-nyong, and Ross River viruses, all of which are capable of 
causing disease in humans [24].
Chikungunya is a positive-sense single-stranded RNA virus with approximately 
12 kb. It is spherical in shape and has a diameter of about 70 nm. The viral particle 
comprises 240 copies of the capsid protein contained within a lipid bilayer envelope 
which has 80 trimer-shaped spikes formed by E1 and E2 glycoproteins protruding 
from it [25]. There are two open reading frames (ORFs) in the genome: the 5’ORF 
(genomic RNA) is responsible for encoding the nonstructural proteins nsP1, nsP2, 
nsP3, and nsP4, and the 3’ORF (subgenomic RNA) is responsible for encoding a 
polyprotein that is processed into the structural capsid and envelope proteins (E1 
and E2) and two peptides (E3 and 6 K) [26].
Several CHIKV genotypes which have been described are shown below: East-
Central-South-African (ECSA) isolates which comprise the East, Central and South 
African, and West Africa isolates (West Africa) and Asian isolates (Asian). The 
Indian Ocean Lineage (IOL) was identified in 2004 as a descendant of the ECSA 
lineage [27, 28].
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1.1.1 Chikungunya genotypes
CHIKV can be genetically classified into three major lineages: West African 
(WA); East, Central, and South African (ECSA); and Asian. Prior to 2004, these 
were rarely found outside the geographic limits implied by their names. The 
epidemics subsequent to 2004 were mainly due to isolates forming a distinct clade 
within the ECSA lineage [29], likely originating in eastern Kenya before spreading 
to cause large outbreaks affecting millions in islands of the Indian Ocean, India, and 
Asia [30], as well as numerous imported cases in previously nonendemic regions, 
including Europe and the Americas. More recently, since 2013, the Asian genotype 
has also caused significant outbreaks in the Caribbean and the Americas.
Additionally, the Indian Ocean (IOL) sublineage emerged within the ECSA 
clade, and the Asian/American sublineage emerged within the Asian clade [31, 32].
While differences in epidemiological and pathological characteristics among 
outbreaks involving different CHIKV lineages and sublineages have been suggested, 
few targeted investigations comparing lineage virulence levels have been reported.
The most important clades in terms of public health impact are the Asian lineage 
(including Asian/American) and the IOL sublineage, as well as some other ECSA 
lineage strains responsible for African outbreaks. They are responsible for multiple 
CHIKV outbreaks over the last 15 years involving millions of people [29, 32, 33], 
which continue to arise in Asia and Africa [34, 35].
CHIKV phylogenetic analysis, based on previous work speculating on the 
existence of distinct lineages [36], has established that the three principal currently 
circulating genotypes emerged from a common ancestor less than 500 years ago and 
that the ECSA and Asian genotypes separated within the past 150 years [29].
West African genotype is particularly well adapted to sylvatic mosquitoes or to a 
certain vector-host combination within the sylvatic cycle.
The Asian genotype that once circulated in India during the 1950s and 1960s 
formed a clade that was phylogenetically distinct from the Southeast Asian (SEA) 
strains that continue to circulate today. There is a remarkable spatial and temporal 
pattern in the evolution of the SEA lineage, spreading from Thailand to Indonesia 
and then to the Philippines and the South Pacific.
2.  Transmission, pathogenesis, clinical disease, and differential 
diagnosis
Chikungunya virus is transmitted to people, as mentioned above, primarily via 
mosquito bites (primarily during the day but also at night). Mosquitoes become 
infected when they feed on a person already infected with the virus and then spread 
the virus to other people via biting, after the virus reaches the mosquito salivary 
glands. Other less-frequent routes of transmission are through blood products, 
organ transplantation, and maternal-fetal.
Pregnant women infected with CHIKV are not at increased risk of atypical or 
severe disease, but maternal CHIKV infection has been associated with miscarriage 
in the first trimester [16, 37, 38]. However, when maternal infection occurs toward 
the end of pregnancy, only 12% of newborns are expected to be symptomatic, 
clinical manifestations—fever, poor feeding, tenderness, unexplained apnea, 
peripheral edema, thrombocytopenia, and rash—appearing 3–7 days after delivery 
[37, 39]. More severe symptoms have also been observed, such as encephalopathy 
and myocardial disease, and neurocognitive development was found to be poor in 
children with perinatal CHIKV infection [40].
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and Pacific Oceans, and more recently in the Americas, mostly during the tropical 
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and in the last decade, there have been massive outbreaks in new areas as well as in 
those where the virus is endemic [11]. What is more, local transmission of CHIKV 
has also been reported for the first time in parts of Europe, Asia [12], Australia [13], 
and America [9, 14, 15].
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lineage [27, 28].
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1.1.1 Chikungunya genotypes
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2.1 Clinical disease
The “natural” history of symptomatic CHIKV infection has been classified into 
three phases: acute, post-acute, and chronic.
Acute phase is considered the first 3 weeks of clinical manifestations. The 
incubation period is 3–7 days (range 1–14 days), and clinical manifestations begin 
abruptly, usually with high fever (>39°C), during 3–5 days (range 1–10 days), and 
malaise [41]. More than 85% of patients are symptomatic [1]. The duration of acute 
phase is usually 7–10 days.
Polyarthralgia, commonly bilateral and symmetric, begins 2–5 days after onset 
of fever and involves multiple joints: hands (50–76% of infected individuals), wrists 
(29–81%), ankles (41–68%), and axial skeleton (34–52%) [42, 43]. Pain may be 
intense and disabling, leading to immobilization.
Rash (maculopapular) has been reported in 40–75% of patients [43] and pruri-
tus in 25–50% of patients.
Serious complications are not common, except in patients older than 65 years 
and patients with underlying pathologies, where the infection and symptoms can 
contribute to the cause of death. These severe forms usually involve the central 
nervous system, respiratory system, and urinary system.
Most patients recover fully, but in some cases joint pain may persist, or the patient 
experiences relapses of signs and symptoms for several months or even years [26].
In the post-acute phase, only a small proportion of patients remain completely 
asymptomatic 2–3 weeks after the onset of disease [44]. Generally, most patients 
exhibit only transitory improvements in their clinical condition, and relapses occur 
after a brief “healing” period. Most studies have indicated that, on average, clinical 
manifestations persist in 50–90% of patients after the second or third week, and 
the percentage of patients with persistent polyarthralgia after the acute phase of 
CHIKV infection is more frequent in those older than 40 years and in women [45].
Clinical manifestations observed during the post-acute phase, which indicate 
the persistence of the initial inflammatory process, include arthritis/arthralgia, 
edematous polyarthritis of fingers and toes, morning pain and stiffness, and severe 
tenosynovitis [42].
A set of nonspecific clinical manifestations that are not always associated with 
CHIKV usually occurs, such as chronic fatigue, changes in skin color, alopecia, 
decompensated endocrine and metabolic diseases, as well as the decompensation of 
other preexisting chronic diseases, depression, and anxiety [44].
Chronic phase: It is estimated that the percentage of patients infected with chi-
kungunya virus who progress to chronic phase (more than 3 months) varies from 
40 to 80% [45–47], and they may endure clinical manifestations for a few months 
or even years [44]. Although no clear evidence exists to explain the pathogenesis 
of persistent symptoms following infection, two hypotheses have been proposed: 
(a) That viral and/or antigenic debris remains in the tissues of joints and muscles. 
Unfortunately, to date, the virus has not been isolated from such tissue. However, 
CHIKV proteins have been found in macrophages and muscle cell tissue of relaps-
ing CHIKV patients, supporting the notion that there may be low-grade replication 
of the virus or non-replicative viral debris present. (b) That infection triggers a 
persistent immune response. Studies are underway with mouse models to determine 
whether, and in what way, immunological mechanisms might be altered in patients 
with persistent symptoms [48, 49].
Chronic phase sufferers can be divided into three groups in terms of disease 
progression: those whose symptoms disappear either spontaneously or following 
treatment and who have no long-term complications, which accounts for the major-
ity of such cases; a group who experiences prolonged and persistence generalized 
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clinical symptoms, with or without joint problems; and another set of patients in 
whom the degenerative or inflammatory process is exacerbated and their condition 
becomes serious [44].
Twenty-five percent of CHIKV cases have been estimated to result in chronic 
inflammatory rheumatism, although this study did not address the issue of dif-
ferences between genotypes [50]. Other symptoms, such as chronic pain, mental 
health issues, and nonspecific manifestations, are also common in this phase 
[51–54], with arthralgia and arthritis with pain accompanied by articular edema 
or morning joint stiffness being the most frequent clinical manifestations [55]. 
Tenosynovitis is also frequent (with two or more tendons affected), and less com-
mon symptoms are fatigue and neuritis [44]. Clearly the daily life of patients with 
long-term chronic CHIKV symptoms is considerably impacted [54], and interest-
ingly there is some evidence that the incidence of chronic symptoms is greater 
in high-income than low-income countries, albeit that the confidence intervals 
overlapped [54]. These same authors did consider the relationship between virus 
genotype and self-reported chronic discomfort and found this symptom to be less 
prevalent in those infected by the ECSA group, followed by those carrying the Asian 
strain. The highest prevalence was linked to the ECSA-diverged/IOL genotypes, 
though there was overlap with the Asian strain.
There is no commercial vaccine against CHIKV, although development is under-
way [56–58] and there is no specific antiviral therapy for acute infection. Treatment 
in this phase consists of supportive care for as long as the infection is confirmed. 
It is, however, known that systemic glucocorticoids and other immunosuppressive 
medications should be avoided in patients during acute infection [44].
The management of persistent or relapse symptoms, particularly joint 
disease, depends upon the duration of the symptoms. Treatment with anti-
inflammatory drugs and analgesics is appropriate in the acute phase. On the 
other hand, for symptoms persisting for more than 3 months after infection, the 
use of disease-modifying antirheumatic drug (DMARD) therapy, such as metho-
trexate (MTX) and hydroxychloroquine [44], or, as an alternative, physiotherapy 
is indicated [59].
2.2 Differential diagnosis
Fever and polyarthralgia are key symptoms of CHIKV infection but are far from 
being reliable diagnostic markers since they have a sensitivity of only 84%, a posi-
tive predictive value (PPV) of 71%, and an 83% negative predictive value (NPV) 
[25]. Thus differential diagnosis of both the acute and the chronic manifestations 
of the disease can be complex and take time due to the nonspecific nature of the 
typical symptoms of arthralgia, high fever, and rash. The shared vectors, as well as 
symptoms, of CHIKV and the DENV, ZK, O’nyong-nyong, and Mayaro viruses, as 
well as the fact that the viruses all co-exist and are known to co-infect, mean that 
they must all be ruled out in the differential diagnosis.
Therefore, it is difficult to differentiate from those of other febrile illnesses or 
be misdiagnosed in areas where dengue occurs. Other infections that should be 
considered include malaria, yellow fever, leptospirosis, measles, mononucleosis, or 
African tick bite fever.
An additional diagnostic complication is the similarity of chronic arthralgia 
caused by chikungunya fever with other more common causes, and it has been dem-
onstrated that patients with underlying joint disease prior to CHIKV infection have 
worse prognosis and increased morbidity [60]. Differential serological diagnosis 
includes the exclusion of rheumatoid and systemic arthritis, lupus erythematosus 
Reiter arthritis, rheumatoid arthritis, and hepatitis C.
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clinical symptoms, with or without joint problems; and another set of patients in 
whom the degenerative or inflammatory process is exacerbated and their condition 
becomes serious [44].
Twenty-five percent of CHIKV cases have been estimated to result in chronic 
inflammatory rheumatism, although this study did not address the issue of dif-
ferences between genotypes [50]. Other symptoms, such as chronic pain, mental 
health issues, and nonspecific manifestations, are also common in this phase 
[51–54], with arthralgia and arthritis with pain accompanied by articular edema 
or morning joint stiffness being the most frequent clinical manifestations [55]. 
Tenosynovitis is also frequent (with two or more tendons affected), and less com-
mon symptoms are fatigue and neuritis [44]. Clearly the daily life of patients with 
long-term chronic CHIKV symptoms is considerably impacted [54], and interest-
ingly there is some evidence that the incidence of chronic symptoms is greater 
in high-income than low-income countries, albeit that the confidence intervals 
overlapped [54]. These same authors did consider the relationship between virus 
genotype and self-reported chronic discomfort and found this symptom to be less 
prevalent in those infected by the ECSA group, followed by those carrying the Asian 
strain. The highest prevalence was linked to the ECSA-diverged/IOL genotypes, 
though there was overlap with the Asian strain.
There is no commercial vaccine against CHIKV, although development is under-
way [56–58] and there is no specific antiviral therapy for acute infection. Treatment 
in this phase consists of supportive care for as long as the infection is confirmed. 
It is, however, known that systemic glucocorticoids and other immunosuppressive 
medications should be avoided in patients during acute infection [44].
The management of persistent or relapse symptoms, particularly joint 
disease, depends upon the duration of the symptoms. Treatment with anti-
inflammatory drugs and analgesics is appropriate in the acute phase. On the 
other hand, for symptoms persisting for more than 3 months after infection, the 
use of disease-modifying antirheumatic drug (DMARD) therapy, such as metho-
trexate (MTX) and hydroxychloroquine [44], or, as an alternative, physiotherapy 
is indicated [59].
2.2 Differential diagnosis
Fever and polyarthralgia are key symptoms of CHIKV infection but are far from 
being reliable diagnostic markers since they have a sensitivity of only 84%, a posi-
tive predictive value (PPV) of 71%, and an 83% negative predictive value (NPV) 
[25]. Thus differential diagnosis of both the acute and the chronic manifestations 
of the disease can be complex and take time due to the nonspecific nature of the 
typical symptoms of arthralgia, high fever, and rash. The shared vectors, as well as 
symptoms, of CHIKV and the DENV, ZK, O’nyong-nyong, and Mayaro viruses, as 
well as the fact that the viruses all co-exist and are known to co-infect, mean that 
they must all be ruled out in the differential diagnosis.
Therefore, it is difficult to differentiate from those of other febrile illnesses or 
be misdiagnosed in areas where dengue occurs. Other infections that should be 
considered include malaria, yellow fever, leptospirosis, measles, mononucleosis, or 
African tick bite fever.
An additional diagnostic complication is the similarity of chronic arthralgia 
caused by chikungunya fever with other more common causes, and it has been dem-
onstrated that patients with underlying joint disease prior to CHIKV infection have 
worse prognosis and increased morbidity [60]. Differential serological diagnosis 
includes the exclusion of rheumatoid and systemic arthritis, lupus erythematosus 
Reiter arthritis, rheumatoid arthritis, and hepatitis C.
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It is thus clear that differential diagnosis is essential to establish CHIKV infection 
and ensure the appropriate public health response as well as the optimal treatment 
regime for the patient. Employing a single PCR which targets all three infectious 
agents (CHIKV, DENV, ZV), available from US Centers for Disease Control and 
Prevention (CDC) and approved laboratories, would expediate diagnosis [61–64].
3. Diagnosis
Chikungunya virus infection should be suspected in patients with acute onset of 
fever and polyarthralgia and who meet the relevant epidemiologic exposure criteria 
(residence in or travel to an area where mosquito-borne transmission of chikungu-
nya virus infection has been reported).
The laboratory diagnosis of CHIKV infection can be achieved in the majority 
of cases by following two different strategies: the detection of viral RNA (virologi-
cal diagnosis) and the identification of the specific immune response (serological 
diagnosis). To this end, choosing the appropriate timing of specimen collection 
and of the use of the most suitable diagnostic methodologies is crucial for accurate 
diagnosis. The algorithm developed by the US Center for Disease Control and 
Prevention (CDC) to diagnose CHIKV infections is based on the characteristics of 
CHIKV infection and the timing of specimen collection (Figure 1).
CHIKV replicates rapidly to high titers in the host, and viral RNA gener-
ally can be detected by real-time RT-PCR in the first week after onset of clinical 
illness, while immunoglobulin M (IgM) antibodies are normally detectable in 
serum by days 5–7 after onset of illness [65]. Consequently, the kinetic replica-
tion and pathogenesis of CHIKV infection, including the duration of viremia and 
the response of the host immune response, should be considered when selecting 
the appropriate diagnostic tests [66]. Molecular assays (TaqMan real-time PCR, 
RT-LAMP assay, and reverse transcription PCR) are more sensitive in the early 
stage of chikungunya fever (2–5 days p.o.i.) when CHIKV-specific IgM is not 
yet detectable. In the later stages of chikungunya fever (>5 days p.o.i.), CHIKV-
specific IgM is a more reliable indicator.
Figure 1. 
Time course of chikungunya virus viremia and immune response. Source of CDC.
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In the CHIKV testing algorithm developed by the CDC arbovirus diagnostic 
laboratory, samples collected <6 days after onset of illness are first tested by viro-
logical methods (CHIKV real-time RT-PCR using two different set primers/probe 
that were developed to detect different genotypes (Figure 2)).
The CDC guidelines indicate that samples collected on or after day 6 of ill-
ness and samples with negative real-time RT-PCR results are tested by serological 
methods (the CHIKV IgM antibody-capture enzyme-linked immunosorbent assay 
(MAC-ELISA) or an indirect fluorescent antibody assay (IFA) and plaque reduction 
hemagglutination test as confirmation) [67–70].
3.1 Types of samples for chikungunya infection diagnosis
Samples for chikungunya diagnosis have to be collected as soon as possible. Two 
different types of sample are suitable for virological and/or serological diagnosis.
Viral diagnosis depends on the characteristics of CHIKV infection and the time 
elapsed since the viral infection, the type of patient (e.g., fetus, pregnant, etc.), and 
clinical manifestation of infection. Virological diagnosis can be made using samples 
of blood (whole blood, plasma, or serum), urine, blister fluid, cerebrospinal fluid, 
amniotic fluid, or tissues such as the placenta and brain, among others.
Samples must be collected in strictly aseptic conditions and in the right con-
tainer: sterile recipients for fluids and with transport viral medium for the others 
(blisters, biopsies, swabs, etc.).
Samples need to be sent to the laboratory quickly.
The best type of tube for serological diagnosis is serum separator. Heparin and 
EDTA are unsuitable for antibodies CHIK testing [71]. Serum used for serological 
test can be used for virological diagnosis, but plasma or whole blood (leukocytes) 
is preferable.
Figure 2. 
The Centers for Disease Control and Prevention diagnostic testing algorithm for detection of chikungunya virus 
infection. Source of CDC.
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tainer: sterile recipients for fluids and with transport viral medium for the others 
(blisters, biopsies, swabs, etc.).
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Figure 2. 
The Centers for Disease Control and Prevention diagnostic testing algorithm for detection of chikungunya virus 
infection. Source of CDC.
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3.2 Virological diagnosis
As was described above, for virological diagnosis it is important to know the 
pathogenesis and the infection kinetics. The RNA viruses are found in plasma or 
serum specimens between 2 and 6 days following onset of fever, which corresponds 
to the period of incubation [41]. Viral load can subsequently rapidly reach up to 
108/109 genome copies/ml of blood [1, 26, 37].
Complete virions as well as viral fragments (antigen or genome) are frequent in 
this phase, although replication later declines. In line with this kinetic replication, 
three methods can be used in the laboratory: viral isolation and antigen or genomic 
detection.
3.2.1 Viral isolation
Viral isolation is generally a research tool [71–73]. For viral culture it is essential 
to preserve the complete virion. Culture sensitivity for chikungunya virus is high 
only in early infection (during the viremic phase) but drops 5 days after onset of 
illness. As a result, virus isolation is rarely used in the diagnosis of CHIKV infection 
because low sensitivity occurs after only a few days post-infection, and it is time-
consuming and laborious procedure. However, it does allow for the identification 
of the viral strain and can be important for epidemiologic and research purposes. 
Samples where chikungunya virus is suspected should be handled under Biosafety 
Level (BSL) 3 conditions.
A wide variety of cells are used for in vitro CHIKV cultures in order to assess the 
full scope of the disease, including primary human skeletal muscle myoblasts [74], 
human blood monocytes [75], African green monkey kidney (Vero-E6) cells [76], 
and C6/36 (Aedes albopictus clone cells). Of particular interest, given the known 
tropism of chronic CHIKV for bone and synovial tissues, is the use of primary 
human fibroblast-like synoviocytes [77] and human osteoblasts.
Culture on HEL cells is more sensitive, and the presence of a cytopathic effect 
can be observed earlier than in Vero cells [78].
These cultures all need to be maintained under standard conditions.
3.2.2 Antigen detection
There are commercial immunochromatography antigen detection kits which 
detect CHIKV with high sensitivity in the early phase (up to 4–5 days after the onset 
of fever, when blood-enveloping proteins are still present). These tests also have 
high specificity since no cross-reactions with dengue virus are known to exist, and 
the method is straightforward and simple and does not require specially trained 
laboratory personnel [79].
However, a very important issue to consider is what genotype/s the tests 
are capable of detecting since not all detect all the known genotypes. Thus the 
geographical area from which the patient comes, meaning they are more likely 
to have one genotype or another, needs to be taken into account for accurate 
diagnosis (e.g., Okabayashi’s immunochromatography only detects the Asian 
genotype) [80].
These methods are therefore, generally, sensitivity compromised.
3.2.3 Genomic detection (RT-PCR)
The diagnosis of CHIKV infection in the acute phase of infection is typically 
performed by the detection of viral RNA in plasma or serum (or other sample 
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types) by RT-PCR. The viral RNA can be detected by various molecular methods, 
such as nested and real-time PCRs [37].
Conventional and real-time PCRs have been used to amplify nsP1, nsP2, or even 
envelope protein genes (E3, E2, or E1) [81, 82].
Molecular diagnostic tests used for the detection of CHIKV include reverse tran-
scription (RT) and amplification (PCR) assay of fragments in the nsP1, nsP2, nsP3, 
nsP4, or E1 regions of the CHIKV genome, in general by real-time [65, 82–86]. 
Labeled probes or SYBR Green is used for real-time quantification of the amplified 
PCR products [87, 88]. In these assays, the limits of detection range between 0.5 and 
1.5 log10 RNA copies/reaction. Although the detection of positive-strand RNA is 
commonly used for diagnostic purposes, assays to detect negative-strand CHIKV 
RNA have also been developed. These include strand-specific quantitative RT-PCRs 
for nsP1 [89] and nsP3 [90], which use a tagged-primer system to improve PCR 
specificity and accuracy. In comparison to the detection of positive-strand RNA, the 
detection limit for negative-strand RNA assays is slightly decreased, 3 log10 RNA 
copies [91].
While there is an ever-present possibility of CHIKV spreading further in 
developed countries in the Americas and Europe, CHIKV still predominantly 
occurs in resource-limited countries. Loop-mediated isothermal amplification 
(LAMP) amplifies nucleic acid under isothermal conditions without the use of 
a thermal cycler and is a fast, specific, and cost-effective technique [92]; LAMP 
represents a cheaper alternative amplification method, albeit with lower sensi-
tivity than real-time RT-PCR. Monitoring by turbidity as well as observation of 
color change after adding SYBR Green has also been described for the detection 
of CHIKV [85, 92]. Visualization is made with the naked eye, meaning no sophis-
ticated equipment is required, and thus LAMP is especially useful in developing 
countries or in field studies.
Another method, microfluidic lab-on-chip integrating multiplex molecular 
amplification and DNA microarray hybridization, has been developed for the 
simultaneous detection of 26 globally important tropical pathogens such as 
CHIKV, Dengue virus (DENV), and other arboviruses [93]. Such diagnostic capac-
ity provides an effective and rapid means to establish the presence of specific 
potential pathogens.
The CDC protocol for chikungunya infection diagnosis uses two RT-PCRs. The 
nucleotide sequences of the two sets of primers and probes used are listed in Table 1  
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because low sensitivity occurs after only a few days post-infection, and it is time-
consuming and laborious procedure. However, it does allow for the identification 
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Culture on HEL cells is more sensitive, and the presence of a cytopathic effect 
can be observed earlier than in Vero cells [78].
These cultures all need to be maintained under standard conditions.
3.2.2 Antigen detection
There are commercial immunochromatography antigen detection kits which 
detect CHIKV with high sensitivity in the early phase (up to 4–5 days after the onset 
of fever, when blood-enveloping proteins are still present). These tests also have 
high specificity since no cross-reactions with dengue virus are known to exist, and 
the method is straightforward and simple and does not require specially trained 
laboratory personnel [79].
However, a very important issue to consider is what genotype/s the tests 
are capable of detecting since not all detect all the known genotypes. Thus the 
geographical area from which the patient comes, meaning they are more likely 
to have one genotype or another, needs to be taken into account for accurate 
diagnosis (e.g., Okabayashi’s immunochromatography only detects the Asian 
genotype) [80].
These methods are therefore, generally, sensitivity compromised.
3.2.3 Genomic detection (RT-PCR)
The diagnosis of CHIKV infection in the acute phase of infection is typically 
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types) by RT-PCR. The viral RNA can be detected by various molecular methods, 
such as nested and real-time PCRs [37].
Conventional and real-time PCRs have been used to amplify nsP1, nsP2, or even 
envelope protein genes (E3, E2, or E1) [81, 82].
Molecular diagnostic tests used for the detection of CHIKV include reverse tran-
scription (RT) and amplification (PCR) assay of fragments in the nsP1, nsP2, nsP3, 
nsP4, or E1 regions of the CHIKV genome, in general by real-time [65, 82–86]. 
Labeled probes or SYBR Green is used for real-time quantification of the amplified 
PCR products [87, 88]. In these assays, the limits of detection range between 0.5 and 
1.5 log10 RNA copies/reaction. Although the detection of positive-strand RNA is 
commonly used for diagnostic purposes, assays to detect negative-strand CHIKV 
RNA have also been developed. These include strand-specific quantitative RT-PCRs 
for nsP1 [89] and nsP3 [90], which use a tagged-primer system to improve PCR 
specificity and accuracy. In comparison to the detection of positive-strand RNA, the 
detection limit for negative-strand RNA assays is slightly decreased, 3 log10 RNA 
copies [91].
While there is an ever-present possibility of CHIKV spreading further in 
developed countries in the Americas and Europe, CHIKV still predominantly 
occurs in resource-limited countries. Loop-mediated isothermal amplification 
(LAMP) amplifies nucleic acid under isothermal conditions without the use of 
a thermal cycler and is a fast, specific, and cost-effective technique [92]; LAMP 
represents a cheaper alternative amplification method, albeit with lower sensi-
tivity than real-time RT-PCR. Monitoring by turbidity as well as observation of 
color change after adding SYBR Green has also been described for the detection 
of CHIKV [85, 92]. Visualization is made with the naked eye, meaning no sophis-
ticated equipment is required, and thus LAMP is especially useful in developing 
countries or in field studies.
Another method, microfluidic lab-on-chip integrating multiplex molecular 
amplification and DNA microarray hybridization, has been developed for the 
simultaneous detection of 26 globally important tropical pathogens such as 
CHIKV, Dengue virus (DENV), and other arboviruses [93]. Such diagnostic capac-
ity provides an effective and rapid means to establish the presence of specific 
potential pathogens.
The CDC protocol for chikungunya infection diagnosis uses two RT-PCRs. The 
nucleotide sequences of the two sets of primers and probes used are listed in Table 1  
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capable of detecting both Asian and ECSA genotypes [95]. The 856 primer/probe 
set targets the Asian genotype, which has a slightly higher sensitivity than the 3855 
set, which is prevalent in the Caribbean. This elevated sensitivity makes it a valu-
able tool for confirming diagnosis in samples where CHIKV RNA levels are reduced. 
These characteristics should be taken into account for testing protocols (i.e., which 
sets to use and in what order).
In our experience “in-house” real-time PCR is a useful tool in the chikungunya 
diagnosis. As such, proprietary primers and probe have been designed (Table 2) 
for CHIKV. In addition, for the syndromic diagnosis of imported viral diseases, our 
in-house RT-PCR can also detect other arboviruses such as Zika, dengue, yellow 
fever, and West Nile (Table 2) with sensitivities/specificities comparable to, or even 
superior to, commercially available techniques [63].
Genomic analysis is also used to classify and characterize viruses usually by 
Sanger sequencing method.
The sequencing of envelope E1 (viral structural glycoprotein) is often used for 
phylogenetic analysis. The three principal strains of CHIKV (ECSA, West African, 
and Asian) have been typed by nucleotide sequencing of a portion of the E1 region 
using RT-PCR [96].
Using sequencing studies to examine genomic evolution, it has been deter-
mined that global chikungunya outbreaks since 2005 have occurred as a result 
of a mutation of the ECSA lineage: an alanine-to-valine substitution in the E1 
envelope glycoprotein at position 226 (A226V), which enabled the virus to 
acquire a new mosquito vector, A. albopictus, commonly known as the Asian tiger 
mosquito, conferring increased virus adaptation and replication ability in Aedes 
albopictus.
There are also specific regions that showed nucleotide variability and novel 
mutations making them suitable for phylogenetic analysis in nsP2 and E2 CHIKV 
regions [97].
Virus Name Sequence (5′- 3′) Amplicon size
DEN.ZIK-TR-S AAGGACTAGAGGTTAGAGGAGACCC
Dengue DEN-TR-A GAGACAGCAGGATCTCTGGTCT 83 bp
DEN-FAM AACAGCATATTGACGCTGG
DEN.ZIK-TR-S AAGGACTAGAGGTTAGAGGAGACCC
Zika ZIK-TR-A3 GGCCAGCGTGGTGGAA 96 bp
ZIK-FAM AAACAGCATATTGACG
CHK-TR-S CGGCGACCATTTGTGATCA
Chikungunya CHK-TR-A TTCGTATTCCGTTGCGTTCTG 127 bp
CHK-FAM CCGGCATCCTTGCTA
WN.FA-TR-S GGCTGGGGCAAYGGCT
Yellow fever FA-TR-A CCTCAAACAAACTCATGGATTTG 91 bp
WN-FA-FAM CATGCGCCAAATT
WN.FA-TR-S GGCTGGGGCAAYGGCT
West Nile WN-TR-A CAAGATGGTTCTTCCTATTGCCT 96 bp
WN-FA-FAM CATGCGCCAAATT
Table 2. 
Primers and probes used to detect DENV, CHIKV, ZIKV, YFV, and WNV.
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3.3 Serological diagnosis
A variety of serological methods (hemagglutination inhibition, ELISA, 
complement fixation, and neutralization of viral infectivity using reference serum 
samples) can be used to characterize the alphavirus species [15, 98]. A fourfold 
increase in levels of CHIK virus IgG antibody in serum samples taken during the 
acute and the recovery phase is required to serodiagnosis. However, it is often 
problematic to collect paired samples, and so the existence of CHIKV-specific IgM 
antibodies in acute-phase samples is used instead. Also, patient serum coupled 
with neutralization by reference serum can be taken as definitive proof of the 
presence of CHIKV.
Several serological assays have been developed, the large majority of which 
demonstrate high reliability and specificity. The most common first-line sero-
logical techniques used for CHIKV diagnosis are the enzyme-linked immunosor-
bent assay (ELISA) and indirect immunofluorescence (IFA) assays, and the most 
suitable sample type is serum, generally using 1/100 dilutions. Commercially 
available ELISA tests, for example, have been shown to demonstrate high sen-
sitivity (ranging from 82 to 88%) and specificity in samples from recovering 
patients [99, 100].
The presence of IgM antibodies indicates recent CHIKV infection [41], gener-
ally occurring in samples taken 2 weeks prior to patients becoming symptomatic. 
Detection of specific IgG antibodies, on the other hand, indicates previous CHIKV 
infection, which can be recent or as long ago as several months or years, given the 
persistence of anti-CHIKV IgG antibodies [1].
3.3.1 Enzyme-linked immunosorbent assay
CHIKV-specific IgM and IgG can be detected in serum using enzyme-linked 
immunosorbent assay immunocapture. The first antibodies detected in patients 
with chikungunya fever is CHIKV-specific IgM, which commonly appears 3–8 days 
after the onset of infection and may persist for several months to 2 years. After 
4–10 days since onset of infection, the IgG antibodies become detectable in serum 
and may persist for years (Figure 1) [1] and be potentially lifelong. The chances of 
cross-reactivity between IgG and other viruses of the Semliki antigenic serocom-
plex are less now than in the past due to improvements in test design and procedure, 
but IgG seroconversion (greater than fourfold increase) is still recommended for 
reliable diagnosis. Furthermore, the existence of closely related alphaviruses in the 
area where the patient was infected necessitates the use of plaque reduction neutral-
ization testing to confirm CHIKV infection [101].
ELISA is a rapid and sensitive method largely used for the detection of anti-
CHIKV antibodies. The most common tests used for the diagnosis of CHIKV 
infection are IgM antibody-capture ELISA (MAC- ELISA) and indirect ELISA 
(i-ELISA) for the detection of type M (IgM) and type G (IgG) immunoglobulin, 
respectively [102]. A list of different commercially available ELISA tests is shown 
in Table 3.
Enzyme-linked immunosorbent assays can be used to confirm the presence of 
anti-CHIKV antibodies, with IgM antibody levels highest 3–5 weeks post-infection 
and persisting for up to 2 months.
ELISA is not, however, without its disadvantages: false-positives because of 
cross-reactivity with other alphaviruses (Ross River virus, Barmah Forest virus, 
and Sindbis virus [103]) and its sensitivity being much reduced (4–20%) in serum 
samples taken during the acute phase [104].
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3.3 Serological diagnosis
A variety of serological methods (hemagglutination inhibition, ELISA, 
complement fixation, and neutralization of viral infectivity using reference serum 
samples) can be used to characterize the alphavirus species [15, 98]. A fourfold 
increase in levels of CHIK virus IgG antibody in serum samples taken during the 
acute and the recovery phase is required to serodiagnosis. However, it is often 
problematic to collect paired samples, and so the existence of CHIKV-specific IgM 
antibodies in acute-phase samples is used instead. Also, patient serum coupled 
with neutralization by reference serum can be taken as definitive proof of the 
presence of CHIKV.
Several serological assays have been developed, the large majority of which 
demonstrate high reliability and specificity. The most common first-line sero-
logical techniques used for CHIKV diagnosis are the enzyme-linked immunosor-
bent assay (ELISA) and indirect immunofluorescence (IFA) assays, and the most 
suitable sample type is serum, generally using 1/100 dilutions. Commercially 
available ELISA tests, for example, have been shown to demonstrate high sen-
sitivity (ranging from 82 to 88%) and specificity in samples from recovering 
patients [99, 100].
The presence of IgM antibodies indicates recent CHIKV infection [41], gener-
ally occurring in samples taken 2 weeks prior to patients becoming symptomatic. 
Detection of specific IgG antibodies, on the other hand, indicates previous CHIKV 
infection, which can be recent or as long ago as several months or years, given the 
persistence of anti-CHIKV IgG antibodies [1].
3.3.1 Enzyme-linked immunosorbent assay
CHIKV-specific IgM and IgG can be detected in serum using enzyme-linked 
immunosorbent assay immunocapture. The first antibodies detected in patients 
with chikungunya fever is CHIKV-specific IgM, which commonly appears 3–8 days 
after the onset of infection and may persist for several months to 2 years. After 
4–10 days since onset of infection, the IgG antibodies become detectable in serum 
and may persist for years (Figure 1) [1] and be potentially lifelong. The chances of 
cross-reactivity between IgG and other viruses of the Semliki antigenic serocom-
plex are less now than in the past due to improvements in test design and procedure, 
but IgG seroconversion (greater than fourfold increase) is still recommended for 
reliable diagnosis. Furthermore, the existence of closely related alphaviruses in the 
area where the patient was infected necessitates the use of plaque reduction neutral-
ization testing to confirm CHIKV infection [101].
ELISA is a rapid and sensitive method largely used for the detection of anti-
CHIKV antibodies. The most common tests used for the diagnosis of CHIKV 
infection are IgM antibody-capture ELISA (MAC- ELISA) and indirect ELISA 
(i-ELISA) for the detection of type M (IgM) and type G (IgG) immunoglobulin, 
respectively [102]. A list of different commercially available ELISA tests is shown 
in Table 3.
Enzyme-linked immunosorbent assays can be used to confirm the presence of 
anti-CHIKV antibodies, with IgM antibody levels highest 3–5 weeks post-infection 
and persisting for up to 2 months.
ELISA is not, however, without its disadvantages: false-positives because of 
cross-reactivity with other alphaviruses (Ross River virus, Barmah Forest virus, 
and Sindbis virus [103]) and its sensitivity being much reduced (4–20%) in serum 
samples taken during the acute phase [104].
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For these reasons, commercially available rapid diagnostic kits often do not 
provide as reliable results as RT-PCR because they all tend to detect host-derived 
anti-CHIKV IgM antibodies. Furthermore, since IgM antibodies are produced later 
in the course of infection than the antigen, this is a less sensitive test and as such can 
delay diagnosis and reduce the effectiveness of disease management [105].
3.3.2 Indirect immunofluorescence
IFA is an accurate and reliable technique widely used for the detection of specific 
anti-CHIK antibodies. IFA reveals the presence of type-specific antibodies against 
CHIKV by detecting the presence of virus antigens in infected cells.
The specificity of commercial IFA tests has been found to range from 75 to 100% 
in serum collected 5–6 days after infection [106]. That said IFA has some shortcom-
ings in that it is laborious and the personnel carrying out the procedure need to be 
specially trained. In addition interpretation of the microscope examination results 
can be rather subjective, and there is no standardization between labs.
3.3.3 Antibody neutralization assay
The neutralization assay is generally used following ELISA or IFA results to con-
firm CHIKV. Neutralization involves the interaction of viral antigens and specific 
antibodies to block infection. The neutralization test requires the mixing of virus 
and serum, and the resulting mixture is then inoculated into cell culture. Inhibition 
of the virus can then be tested, using a variety of methods, after a number of days 
[107]. The microneutralization assay (MNA) evaluates the neutralizing antibodies. 
Although both methods have high specificity and sensitivity, there are disadvan-
tages, namely, they are labor-intensive since only a small number of samples can 
be processed in each run and a Biosafety Level 3 laboratory (BSL-3) is required 
because live virus is being used.
The drawbacks to antibody testing include cross-reactivity with other alpha 
viruses and the problem of it not being able to distinguish between recent past 
and acute infection, as well as the fact that its sensitivity varies between clinical 
settings.
Company IgM IgG Test
Euroimmun + + ELISA
Novatec + / IgM-capture ELISA
Novatec / + ELISA
IBL + / IgM-capture ELISA
IBL / + IgG-capture ELISA
Abcam + + ELISA
DRG + / IgM-capture ELISA
DRG / + ELISA
GenWay + / IgM-capture ELISA
GenWay / + ELISA
Standard diagnostic + + ELISA
Euroimmun + + IFA
Table 3. 
Commercial diagnostic test available for serological diagnosis of CHIKV infection.
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3.4 Diagnosis in other patients
Diagnosis is clearly always important for appropriate patient management, but it 
becomes crucial in several specific circumstances.
3.4.1 Transplantation or transfusion
CHIKV, like other arboviruses, can be transmitted by blood transfusion or 
through organ transplant from infected donors who were asymptomatic at the time 
of donation. Transmission via organ transplantation could also occur since chi-
kungunya viremia (which may exceed 109 RNA copies/ml plasma) is likely prior to 
onset of symptoms [86, 108, 109].
In a case series of Rosso et al., 80% of the patients presented high viral load 
(>106 copies/ml), and none of the solid organ transplant patients with CHIKV 
infection developed graft rejection or died [110].
In these patients, blood and/or tissues are essential in the diagnosis.
3.4.2 Maternal-fetal transmission
Vertical transmission of CHIKV is a possibility and can affect the fetus, both 
congenital and perinatal infection having been demonstrated.
Congenital and perinatal CHIKV infections were reported following delivery to 
mothers with documented viremia accompanied by symptoms of CHIKF [16, 111, 112].
Vertical transmission rate of CHIKV has been estimated to range from 27.7 to 
48.29%, and the same paper found transmission to be increased in mothers experi-
encing viremia at the time of birth. Neonatal symptoms were found to begin within 
3–9 days postpartum, although there is no evidence of any link between birth 
method and incidence of congenital disease [113].
No link between CHIKV exposure in the first trimester of gestation and 
higher miscarriage risk or congenital malformation has been found to date 
[114, 115]. However, infection in the second or third trimester has been linked 
with increased fetal mortality, although the mechanism of this is unclear [111, 
116]. Furthermore, a change in the evolution of neonates vertically infected 
with CHIKV has been seen following the spread of the virus to Indian Oceanic 
regions and Latin America in terms of the previously minor, self-limiting symp-
toms having been replaced by multiple severe manifestations and sometimes 
death [117].
Of particular note is the serious outbreak of CHIKV in 2006 in the Reunion 
Islands where complications were reported, including seizures and abnormal 
MRI scans [118, 119] as well as cardiac defects in almost 50% of patients [119]. 
In infants, these conditions can lead to death in the first year of life if swift and 
targeted medical intervention is not carried out [120, 121]. All patients in this 
outbreak who exhibited symptoms of neuroinvasive disease were infected with 
the A226V variant strain [122].
Virus infection in fetuses can be documented by positive RT-PCR in the amniotic 
fluid, and placenta, and in the cases of miscarriage, the involvement of CHIKV can 
be investigated in the brain or other fetal tissues [40].
3.4.3 Children
The first descriptions of CHIKF in children were made in the 1960s during out-
breaks in India and South Asia [123–127]. In these younger patients, the infection 
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For these reasons, commercially available rapid diagnostic kits often do not 
provide as reliable results as RT-PCR because they all tend to detect host-derived 
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Company IgM IgG Test
Euroimmun + + ELISA
Novatec + / IgM-capture ELISA
Novatec / + ELISA
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IBL / + IgG-capture ELISA
Abcam + + ELISA
DRG + / IgM-capture ELISA
DRG / + ELISA
GenWay + / IgM-capture ELISA
GenWay / + ELISA
Standard diagnostic + + ELISA
Euroimmun + + IFA
Table 3. 
Commercial diagnostic test available for serological diagnosis of CHIKV infection.
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3.4 Diagnosis in other patients
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death [117].
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MRI scans [118, 119] as well as cardiac defects in almost 50% of patients [119]. 
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outbreak who exhibited symptoms of neuroinvasive disease were infected with 
the A226V variant strain [122].
Virus infection in fetuses can be documented by positive RT-PCR in the amniotic 
fluid, and placenta, and in the cases of miscarriage, the involvement of CHIKV can 
be investigated in the brain or other fetal tissues [40].
3.4.3 Children
The first descriptions of CHIKF in children were made in the 1960s during out-
breaks in India and South Asia [123–127]. In these younger patients, the infection 
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presented as a febrile illness, with rash and joint pain or dengue-like illness, 
hemorrhagic fever, or CSF infection. Asian lineage infection of children resulted 
in a lower frequency of arthralgia than in those infected by the African lineages, 
although hemorrhagic fever was more frequent in children testing positive for the 
former [117].
Lately, in the regions surrounding the Indian Ocean and the expansion of 
CHIKV into the Western Hemisphere, CHIKV-WH infections in children and 
neonates are reported more frequently and with more severe syndromes and 
sequelae [117].
4. Summary
In recent years, large-scale outbreaks of the chikungunya arbovirus 
(CHIKV) have permitted rapid propagation of the virus across the globe. 
CHIKV is transmitted by the Aedes mosquito, and the acute infection phase 
typically results in fever, joint pain, headache or rash, and chronic rheumatism 
(arthralgia or myalgia, anorexia, and concentration disorders) in up to 40% of 
cases.
The chronic form is defined by symptoms which persist for more than 3 months, 
and up to years, after initial diagnosis. The negative impact of CHIKV infection 
on the patient’s health-related quality of life is quite severe and is not limited to 
the acute disease, and the repercussions may last for several months after clinical 
recovery. The highest prevalence of chronic discomfort was linked to one of the 
four genotypes described. These genotypes represent different geographic lineages 
(classification based on partial sequence of viral E1 glycoprotein): West African, 
East-Central-South-African (ECSA), ECSA-diverged or Indian Ocean Lineage, and 
Asian lineage.
The first marker detected in CHIK infection is the viral RNA, usually by 
RT-PCR. This marker can be present in samples taken within 8 days of onset of the 
illness. After this initial acute phase, the infection can also be diagnosed by serologi-
cal detection of CHIKV-IgG and/or IgM-specific immunoglobulin, and sequencing 
studies can determine the infecting genotype.
The correct diagnosis of chikungunya infection enables the disease pro-
gression to be better predicted and patients’ treatment to be more effectively 
managed.
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Chapter 4
Clinical Features and Management 
of Chronic Chikungunya Arthritis
Joshua Britton Bilsborrow, José Kennedy Amaral  
and Robert T. Schoen
Abstract
Chikungunya virus is a single-stranded RNA alphavirus transmitted to humans by 
Aedes species mosquitos, causing an acute illness known as chikungunya fever with 
maculopapular rash, headache, polyarthritis/arthralgias, and gastrointestinal symp-
toms. Up to half of affected patients develop a chronic disabling arthritis following 
resolution of the acute infection, which can last for months or even years. The patho-
physiology of chronic chikungunya arthritis remains controversial; it may result from 
a dysregulated immune response or be caused by persistent viral infection. Treatment 
for patients with chronic chikungunya arthritis remains investigational. Limited data 
suggests that immunosuppressive therapies such as methotrexate and TNF alpha 
inhibitors may be beneficial, though randomized clinical trials are needed.
Keywords: chikungunya, alphavirus, arthritis, disability, DMARDs
1. Introduction
Chikungunya virus (CHIKV) is a small, single-stranded RNA alphavirus 
transmitted to humans by Aedes species mosquitoes, including Aedes aegypti and 
Aedes albopictus. CHIKV was initially isolated in Tanzania in 1952–1953 [1]. The 
word “chikungunya” means “that which bends up” or “to become contorted” in the 
Makonde language, referring to the prostrated appearance of affected patients [2].
Prior to its isolation, chikungunya (CHIK) was often misdiagnosed as dengue 
[3]. During the twentieth century, chikungunya fever (CHIKF) epidemics occurred 
sporadically and were limited to Africa and Asia, but in the twenty-first century 
CHIK has become a global disease. There was a major outbreak in coastal Kenya in 
2004, which subsequently spread to Réunion in 2005 and throughout the Indian 
Ocean region [4]. Cases among travelers returning from endemic regions were 
reported in Italy in 2007 [5].
CHIKV reached the Western Hemisphere in 2013 with an outbreak on the island 
of Saint Martin. Since then, the virus has spread throughout the region with more 
than 2 million cases documented in the Americas by the end of 2016, though the 
actual number is likely much higher [3]. In the United States, cases involving travel-
ers to endemic regions have been documented in 49 states, and locally-acquired 
cases have occurred in Florida and Texas [6].
Factors contributing to the spread of CHIK include increasing urbanization, 
overstrained health care infrastructures in developing countries, ease of interna-
tional travel, and climate change with expansion of mosquito vectors [7].
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Abstract
Chikungunya virus is a single-stranded RNA alphavirus transmitted to humans by 
Aedes species mosquitos, causing an acute illness known as chikungunya fever with 
maculopapular rash, headache, polyarthritis/arthralgias, and gastrointestinal symp-
toms. Up to half of affected patients develop a chronic disabling arthritis following 
resolution of the acute infection, which can last for months or even years. The patho-
physiology of chronic chikungunya arthritis remains controversial; it may result from 
a dysregulated immune response or be caused by persistent viral infection. Treatment 
for patients with chronic chikungunya arthritis remains investigational. Limited data 
suggests that immunosuppressive therapies such as methotrexate and TNF alpha 
inhibitors may be beneficial, though randomized clinical trials are needed.
Keywords: chikungunya, alphavirus, arthritis, disability, DMARDs
1. Introduction
Chikungunya virus (CHIKV) is a small, single-stranded RNA alphavirus 
transmitted to humans by Aedes species mosquitoes, including Aedes aegypti and 
Aedes albopictus. CHIKV was initially isolated in Tanzania in 1952–1953 [1]. The 
word “chikungunya” means “that which bends up” or “to become contorted” in the 
Makonde language, referring to the prostrated appearance of affected patients [2].
Prior to its isolation, chikungunya (CHIK) was often misdiagnosed as dengue 
[3]. During the twentieth century, chikungunya fever (CHIKF) epidemics occurred 
sporadically and were limited to Africa and Asia, but in the twenty-first century 
CHIK has become a global disease. There was a major outbreak in coastal Kenya in 
2004, which subsequently spread to Réunion in 2005 and throughout the Indian 
Ocean region [4]. Cases among travelers returning from endemic regions were 
reported in Italy in 2007 [5].
CHIKV reached the Western Hemisphere in 2013 with an outbreak on the island 
of Saint Martin. Since then, the virus has spread throughout the region with more 
than 2 million cases documented in the Americas by the end of 2016, though the 
actual number is likely much higher [3]. In the United States, cases involving travel-
ers to endemic regions have been documented in 49 states, and locally-acquired 
cases have occurred in Florida and Texas [6].
Factors contributing to the spread of CHIK include increasing urbanization, 
overstrained health care infrastructures in developing countries, ease of interna-
tional travel, and climate change with expansion of mosquito vectors [7].
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There are three known genotypes of CHIKV: Asia, East/Central/South Africa, 
and West Africa. The 2004–2005 pandemic that originated in Kenya and subse-
quently spread throughout the Indian Ocean region involved the East/Central/
South Africa genotype. The pandemic that emerged in the Americas in 2013 origi-
nally involved the Asia genotype, although more recently the East/Central/South 
Africa lineage has been reported in the Western Hemisphere [8, 9].
2. Clinical manifestations
2.1 Acute chikungunya fever
CHIKV infection results from transmission by the mosquito vector. Following an 
incubation period of 5–7 days, patients develop an acute febrile illness, chikungunya 
fever (CHIKF), characterized by high fevers, maculopapular rash, headaches, poly-
arthritis/arthralgias, myalgias, nausea, vomiting, and diarrhea [1]. Joint pain is often 
severe, and most often involves the metacarpal-phalangeal and interphalangeal joints 
of the hands, the wrists, the ankles, and the metatarsal-phalangeal joints of the feet. 
Less commonly involved but described joints include the shoulders, elbows, hips, 
knees, and inter-vertebral joints [10]. Acute CHIKF causes significant physical disabil-
ity. For example, during the 2005 Comoros epidemic, an estimated 80% of affected 
patients were hospitalized or bed-bound due to severity of their symptoms [11].
More severely affected patients can develop neurological disease including 
meningoencephalitis, myelitis, radiculitis, and/or peripheral neuropathy, including 
reports of Guillain-Barré syndrome [12]. Rare ophthalmological manifestations 
reported include keratitis, episcleritis, optic neuritis, uveitis, and retinal detach-
ment [13]. Uncommon but serious cardiac manifestations include arrhythmias, 
vasculopathy, myocarditis, and/or dilated cardiomyopathy [14, 15]. Patients with 
acute infection can have laboratory abnormalities including thrombocytopenia and 
leukopenia (lymphopenia is more common than neutropenia) [4].
Maternal-to-child transmission has also been reported, with up to 50% of neo-
nates acquiring infection during childbirth if born within 5 days of maternal infec-
tion. Musculoskeletal manifestations are less prominent in newborns, with CHIKF 
being more notable for fevers, rash, cytopenias, hepatitis, and/or encephalitis [16].
Acute CHIKF typically resolves in 10–14 days, and has an overall reported case 
fatality rate of <1% based on epidemics in the Indian Ocean region and the Americas. 
However, the case fatality rate is higher among newborns, the elderly, and patients 
with underlying cardiovascular and pulmonary conditions [7, 17, 18]. Economopoulou 
and colleagues studied the case fatality rate among atypical cases of CHIKF in 
Réunion (defined as patients presenting with symptoms other than fevers and arthral-
gias); 65/610 patients from this group died for a case fatality rate of 10.6% [19].
During the widespread Indian Ocean region pandemic, a point mutation 
(A226V) in the E1 surface glycoprotein of CHIKV may have allowed better adapta-
tion in Aedes albopictus, which had previously been a minor vector [20]. Along with 
low background immunity among populations residing in regions not historically 
affected, this may account for the rapid spread and high rates of infectivity seen for 
CHIKV in the twenty-first century.
2.2 Chronic chikungunya arthritis
Arthritis/arthralgia is a principal feature of CHIKF. Many patients recover 
within several weeks, but up to 50% develop chronic joint pain and swelling. When 
rheumatic disease persists for more than 12 weeks, we refer to these symptoms as 
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chronic chikungunya arthritis (CCA). Arthritic manifestations can last for weeks, 
months, or even years [21]. Rodriguez-Morales and colleagues retrospectively 
studied 283 patients from the 2015 epidemic in Risaralda Department, Colombia. 
At 26 weeks post-infection, 53.7% of the patients reported chronic musculoskeletal 
symptoms, including 49.5% with morning stiffness, 40.6% with joint swelling, and 
16.6% with joint erythema [22]. Another large observational study from Kerala, 
India found that 57% of patients had chronic polyarthralgias, 22% chronic polyar-
thritis, and 19.5% chronic tenosynovitis 15 months after CHIKF [23].
The classical pattern of arthritis involves the small-to-medium sized joints in a 
peripheral and symmetric distribution [24]. This pattern can resemble rheumatoid 
arthritis (RA). Joint pain with/without synovitis can persist following acute CHIKF, 
or joint symptoms may remit and then recur at a later time [21].
A prospective Mexican cohort study showed that greater severity of acute 
infection predicted development of chronic arthritis, as measured by the disease 
activity index 28 (DAS28), World Health Organization Disablement Assessment 
Schedule II (WHODAS-II), and serum IL-6 level [25]. Other risk factors for 
chronic disease include patient age >45 years and high viral load (>109 per ml) 
during acute infection [26].
During acute CHIK infection, serum cytokines IL-1Ra, IL-1β, IL-6, IL-7, IL-8, 
IL-12, IL-15, and IFN-α increase, while RANTES (CCL5) decreases [27, 28]. With 
the transition to CCA, elevated levels of IL-6, GM-CSF, and IL-17 become predomi-
nant [28]. The IL-17 signature in particular may drive chronic joint inflammation, 
stimulating the upregulation of other pro-inflammatory cytokines, including IL-1, 
IL-6, and TNF-α, matrix metalloproteinases, and RANK-RANKL leading to osteo-
clastogenesis and bone erosions [29]. Alphavirus infection of osteoblasts has been 
shown to perturb the RANKL-osteoprotegerin ratio, contributing to bone loss. This 
imbalance may also provide a mechanism for joint erosions in chronic disease [30].
CHIKV primarily infects human epithelial and endothelial cells, fibroblasts, 
and macrophages. Replication has not been observed in lymphocytes, monocytes, 
or monocyte-derived dendritic cells [31]. Viral tropism to the highly-vascularized 
synovial tissues of the joints may be responsible for the prominence of arthritis 
following acute infection. Whether CHIKV persists in synovial tissue during the 
chronic phase remains unclear, however, and there is ongoing debate about whether 
CCA arises secondary to immunological dysregulation or is due to persistent alpha-
virus infection of the synovial tissue.
Hoarau and colleagues demonstrated the presence of CHIKV RNA and viral 
proteins within perivascular synovial macrophages from one patient with CCA 
18 months following acute infection [32]. This finding has not been replicated in 
other patients with chronic joint disease, however. Viral RNA has been isolated from 
knee synovial tissue of patients infected with a related alphavirus, Ross River virus 
[33]. In non-human primates, CHIKV can be recovered from muscle, synovial, 
lymphoid, and hepatic tissues following resolution of acute infection. Macrophages 
have also been identified as viral reservoirs [34].
In a cohort from the Réunion epidemic, 16 CCA patients were evaluated for 
persistence of viral infection. Synovial fluid (10 patients) and biopsied tissue 
(6 patients) was evaluated with reverse transcriptase polymerase chain reaction 
(RT-PCR) for CHIKV. All samples were negative, suggesting active viral replication 
is not the cause of chronic articular disease [35].
These findings were replicated in a Colombian cohort with CCA, evaluated during 
the 2014–2015 epidemic. In all patients, synovial fluid was aspirated from inflamed 
joints. CHIKV DNA was not recovered by RT-PCR, viral proteins were not detected 
by mass spectrometry, and viral cultures were also negative for all patients. The 
authors concluded that CCA is probably a post-infectious autoimmune process [36]. 
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joints. CHIKV DNA was not recovered by RT-PCR, viral proteins were not detected 
by mass spectrometry, and viral cultures were also negative for all patients. The 
authors concluded that CCA is probably a post-infectious autoimmune process [36]. 
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Evidence for molecular mimicry between host tissues and CHIKV E1 glycoprotein 
has been postulated [37]. However, the specific mechanisms by which CHIK infection 
might lead to immunological dysregulation and autoimmunity are unknown.
2.3 Diagnosis of chronic chikungunya arthritis
The diagnosis of CHIK depends on epidemiologic information, characteristic 
clinical features, the time course of the infection, and laboratory confirmation. 
Many patients live in or have had recent travel to an area with endemic transmis-
sion of Aedes mosquitos. Laboratory testing depends on the time course of infec-
tion. During acute disease, CHIK viremia lasts for 5–7 days. At this time, RT-PCR 
of serum can be diagnostic. Anti-CHIKV IgM antibodies appear at 3–8 days and 
remain positive for 1–3 months. Anti-CHIKV IgG antibodies are detectable at 
4–10 days and remain positive for months to years [1].
CCA patients present with chronic debilitating joint symptoms ranging from 
morning stiffness and arthralgias to frank inflammatory synovitis. A classical 
pattern of small-and-medium joint peripheral involvement has been described, but 
mono- and oligoarthritis can also occur (Figure 1). In some patients, CCA presents 
clinically as an RA “mimic,” but most patients have negative tests for rheumatoid 
factor and anti-cyclic citrullinated peptide antibodies [38]. Patients with CCA 
often meet diagnostic and/or clinical criteria for RA or spondyloarthritis [39]. The 
distinguishing clinical feature is a previous history of acute CHIKF, with laboratory 
confirmation of serum positivity for IgM and/or IgG anti-CHIK antibodies.
Radiographic imaging of involved joints may be normal, especially early in the 
disease, with progression to bone erosions in some patients over time. Magnetic 
resonance imaging has greater sensitivity for the detection of inflammatory 
changes, and can show synovial thickening, bone marrow edema, effusions, and/or 
tenosynovitis [38].
Figure 1. 
Patient with chronic chikungunya arthritis (CCA). A 50-year-old woman with CCA and synovitis of the right 
third PIP and left second PIP joints. She had acute CHIKF 3 years prior and subsequently developed CCA of 
the hand joints. Image courtesy of José Kennedy Amaral, M.D., Pernambuco, Brazil.
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3. Treatment of chronic chikungunya arthritis
Guidelines for the management of CCA emphasize symptomatic pain control 
with acetaminophen/paracetamol, codeine, and/or neuropathic medications such as 
gabapentin. Adjunctive treatment includes physical therapy, thermotherapy, and/or 
cryotherapy [16]. These approaches can relieve pain and improve function, but are 
not disease-modifying.
3.1 Corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs)
In an uncontrolled case series during the 2005–2006 Indian Ocean pandemic, 
short-term corticosteroid treatment improved arthritis and tenosynovitis, and 
reduced disability in patients with CCA [40]. Corticosteroid treatment led to 
greater pain relief and patient satisfaction compared to paracetamol, NSAIDs, 
medicinal herbs, and physical exercise [41].
Padmakumar and colleagues performed a randomized-controlled trial evaluat-
ing the efficacy of single and combination NSAID and corticosteroid treatment 
regimens for CCA. Functional and pain assessments improved with corticosteroids 
(prednisolone 10 mg daily) in addition to the NSAID aceclofenac 200 mg daily, 
compared to those who received aceclofenac alone. The addition of hydroxychloro-
quine (HCQ ) did not provide added benefit [42].
Despite positive results, long-term use of corticosteroids is not advised 
due to well-known risks of infection, cataracts, glaucoma, hyperglycemia and 
diabetes mellitus, and osteopenia/osteoporosis associated with chronic cortico-
steroid use.
3.2 Chloroquine and hydroxychloroquine
An open-label pilot study of chloroquine (CQ ) treatment for CCA in South 
Africa showed improvement in patient and physician disease activity assessments, 
though this trial was not blinded [43]. Brito and colleagues recommended HCQ 
at a dose of 6 mg/kg daily as first-line treatment for CCA, as part of a regimen 
potentially escalating to triple therapy with sulfasalazine (SSZ) and methotrexate 
(MTX) [44].
However, a randomized-controlled trial comparing short-term treatment with 
CQ to placebo for acute CHIK arthritis found no differences between-group in the 
duration of arthralgias or viremia, but increased rates of chronic arthralgias in the 
treated group [45]. Chopra and colleagues performed a comparative effectiveness 
trial between CQ 250 mg daily and meloxicam 7.5 mg daily in patients with CCA 
and found no difference in efficacy [46].
In the open-label randomized trial by Ravindran and Alias, combination therapy 
(MTX 15 mg weekly, SSZ 1000 mg daily, and HCQ 400 mg daily) was superior to 
HCQ monotherapy [47]. The trial did not include a placebo group, precluding the 
possibility of determining the efficacy of HCQ.
Overall, most current evidence suggests that antimalarials such as CQ and HCQ 
are not effective for the treatment of CCA.
3.3 Sulfasalazine
The Ravindran and Alias trial included SSZ 1000 mg daily in combination with 
HCQ and MTX as part of triple therapy, compared to HCQ [47]. While combination 
therapy was more efficacious, the contribution of SSZ separate from MTX could 
not be established.
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Ganu and Ganu evaluated a cohort of 16 patients with persistent arthritis 
following acute CHIKF, comparing treatment with SSZ and MTX to SSZ alone. 
Improvement was noted in 71.4% of patients receiving combination therapy com-
pared to 12.5% of patients receiving SSZ monotherapy [48]. A significant limita-
tion of this trial was the lack of a control group; it remains questionable whether 
SSZ was any more effective than a placebo response. In addition, a majority of the 
patients had anti-cyclic citrullinated peptide antibodies, suggesting they had RA 
rather than CCA.
Overall, there is very limited data suggesting efficacy of SSZ monotherapy for 
the treatment of CCA, but it may be efficacious in combination with other medica-
tions such as MTX.
3.4 Methotrexate
Pandya treated 149 Indian patients with CCA with MTX 15–20 mg weekly in 
combination with HCQ. At 16 weeks, ACR20 responses were achieved in 48.9%, 
ACR50 in 18.8%, and ACR70 in 4.0%. Clinical response was less robust as measured 
by DAS28-ESR, with just 1/149 patients achieving clinical remission (DAS28-ESR 
<2.6) and only 4/149 with a good clinical response (DAS28-ESR <3.2) [49]. One 
important limitation of the study was that the diagnosis of CCA was made entirely 
on clinical grounds, without serological confirmation of anti-CHIKV antibodies. 
As such, the patient population may have been heterogeneous, including non-CHIK 
inflammatory arthritis syndromes.
In the trial by Ravindran and Alias, the combination therapy regimen including 
MTX 15 mg weekly (along with SSZ 1000 mg daily and HCQ 400 mg daily) was 
superior to HCQ alone (DAS28-ESR <3.2 at 24 weeks, 84% versus 14% respec-
tively). Both groups also received prednisolone 7.5 mg daily, but this was tapered 
off by 6 weeks [47]. In another trial by Ganu and Ganu, patients with an inadequate 
treatment response to combination SSZ and HCQ were escalated to treatment with 
MTX 15–20 mg weekly versus placebo. The MTX group achieved a superior clinical 
response versus SSZ/HCQ (71.4% versus 12.5%) [48].
Javelle and colleagues reported on treatment of a Réunion cohort with CCA 
following the 2005-2006 epidemic. Among patients treated with MTX 7.5–25 mg 
weekly, 54/72 (75%) achieved a good clinical response [39].
Bouquillard and Combe treated patients with acute CHIKF who were sub-
sequently diagnosed with RA. Among 19 patients treated with MTX, 13 had a 
good clinical response (68.4%). Among these patients, 54.1% were positive for 
rheumatoid factor, and 28.6% had anti-cyclic citrullinated peptide antibodies [50]. 
As such, many of the patients were diagnosed with seronegative RA, which can 
closely mimic the signs and symptoms of CCA, and which might respond to similar 
treatments.
Amaral and colleagues treated 48 patients with CCA with open-label MTX 
initiated at 7.5 mg weekly, with dose escalations for refractory symptoms at 4 weeks. 
The final mean MTX dose was 9.2 ± 3.2 mg per week. MTX therapy was combined 
with prednisone at a mean daily dose of 6.1 ± 2.2 mg for nine patients (18%). 
Two patients received HCQ (400 mg daily) with MTX, and one also received SSZ 
(1000 mg daily). At the first visit, the mean value for pain by visual analog scale 
was 7.7 ± 2.0. The mean values for pain at 4 and 8 weeks, compared to baseline, 
decreased to 3.0 and 2.6 respectively [24].
Overall, MTX has shown promise in the treatment of CCA, though previous tri-
als have either combined MTX with HCQ and SSZ, or have been unblinded. Further 
randomized trials are needed to evaluate MTX monotherapy.
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3.5 Biologics
No human trials have yet been conducted to evaluate the efficacy of biologic 
therapy with monoclonal antibodies for the treatment of CCA.
Ross River virus (RRV) is an alphavirus phylogenetically related to CHIKV. In 
RRV infected mice, treatment with the TNF-α inhibitor etanercept resulted in 
decreased weight gain, increased viral titers, and increased inflammatory cell 
recruitment and tissue damage [51]. This study suggests that etanercept treatment 
of human patients with acute CHIKF might be detrimental, though treatment of 
patients with CCA could have a different outcome.
Bouquillard and Combe treated patients with acute CHIKF followed by the 
diagnosis of RA (not categorized as CCA) with TNF-α inhibitors. These patients 
had been refractory to initial therapy with MTX. 6/6 patients had a good clinical 
response (four with etanercept, two with adalimumab) [50]. The majority of the 
patients had been diagnosed with seronegative RA, which was not distinguished 
from CCA.
Treatment of CHIKV acutely-infected mice with the anti-CTLA-4 monoclonal 
antibody abatacept showed decreased T cell infiltration of joint tissues without 
affecting viral replication [52]. There is currently no data for its use in humans, nor 
for its use in treating CCA.
3.6 Novel agents
Pentosan polysulfate is a novel glycosaminoglycan-like molecule developed for 
the treatment of alphavirus infections. Treatment of CHIKV-infected mice with 
pentosan polysulfate reduced cartilage thinning and immunological infiltration 
of joints [53]. Intra-articular levels of the pro-inflammatory cytokines IL-6, IL-9, 
CCL2, and G-CSF were decreased, and levels of the anti-inflammatory IL-10 were 
increased through unclear mechanisms [30]. While developed for the treatment of 
acute CHIK infection, it remains unclear if pentosan polysulfate could be used for 
the treatment of CCA, in particular to prevent joint erosions.
Fingolimod is a sphingosine 1-phosphate receptor agonist developed for the 
treatment of multiple sclerosis. In CHIKV-infected mice, fingolimod treatment 
decreased the migration of CD4+ T cells into joints without affecting viral replica-
tion [54]. While the utility of fingolimod for treatment of CCA remains unknown, 
decreasing T cell migration into joints might be beneficial.
4. Conclusions
CCA is an emerging chronic and disabling rheumatological syndrome which 
can persist for weeks, months, or years after acute CHIKF. With the global spread 
of CHIKV in past decades, increasing numbers of patients from developing coun-
tries in particular have acquired or are at risk for this chronic disabling rheumatic 
syndrome.
The pathophysiology of the disease remains uncertain, though the weight of 
evidence suggests that the syndrome is caused by a post-viral autoimmune process, 
which follows viral clearance.
There is limited clinical trial evidence for the use of disease modifying therapeu-
tics for patients with CCA. Most previous trials have been open-label or of limited 
quality. Empiric treatment courses with corticosteroids, NSAIDs, antimalarials, and 
SSZ can be considered. However, given similarities between CCA and RA, it is our 
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SSZ can be considered. However, given similarities between CCA and RA, it is our 
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opinion that management with MTX should be further evaluated. Over time, new 
treatments including biologics and novel agents (pentosan polysulfate, fingolimod) 
may also emerge as treatment options.
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Chagas disease, or American trypanosomiasis, is a parasitic disease of the 
Americas. In nature, Trypanosoma cruzi is transmitted through various species 
of triatomine bugs. However, non-vectorial transmission can also occur, such as 
transmission through blood products or by transplanting infected organs, by verti-
cal transmission, and lately by oral route. Currently, Chagas disease affects approxi-
mately 6–7 million people worldwide, and the process of urbanization in Latin 
America and migratory movements from endemic countries have led to Chagas dis-
ease being diagnosed in areas where the infection is not endemic. There are several 
methods for diagnosing Chagas disease. Some of these are mostly used for research 
purposes, while others are used in routine diagnostic laboratories. According to the 
World Health Organization (WHO), chronic Chagas disease diagnosis is based on 
two serological techniques. To establish a definitive diagnosis, the results must be 
concordant. In the case of discordances, the WHO proposes repeating serology in a 
new sample, and if results remain inconclusive, a confirmatory test should be per-
formed. This chapter shows aspects of the diagnosis of Chagas disease, which varies 
in its sensitivity and specificity, and its use depends on the geographical location, 
the available resources, and the purpose of the diagnosis.
Keywords: chagas disease, T. cruzi, diagnosis, serology, antigens
1. Introduction
The infection caused by the protozoan parasite Trypanosoma cruzi leads to 
Chagas disease, with an estimated 6–7 million infected people and nearly 60 million 
at risk of infection [1, 2]. Chagas disease ranks among the world’s most neglected 
diseases and is considered to be the parasitic infection with the greatest socioeco-
nomic impact in Latin America, being responsible for an estimated US$ 1.2 billion 
in lost productivity annually [3]. It is a disease that a century after its discovery 
still requires appropriate control measures, effective treatment, and especially 
an accurate diagnosis. This disease is endemic to most countries in Latin America 
[4], but it has now become more important in other regions. The increasing pres-
ence of Chagas in non-endemic areas, as well as the resurgence of the disease in 
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endemic countries, has been a major focus of attention in recent years [5] and, over 
the last 40 years, has become a global health concern due to the huge migration 
flows from Latin America to Europe, United States, Canada, and Japan. In Europe, 
most migrants from Chagas disease-endemic areas are concentrated in Spain, Italy, 
France, United Kingdom, and Switzerland (Figure 1) [6]. The flagellate protozoa  
T. cruzi is usually transmitted through infected feces and/or urine excreted by 
triatomines (Hemiptera: Reduviidae) during blood feeding. However, this is a 
nonlinear phenomenon, as mammals can be exposed to infection multiple times 
through distinct routes [7]; the main routes of transmission of the parasite are 
through the insect vector, blood transfusion, transplants of organs, congenital via, 
orally and it is now reported that the infection is capable of being transmitted sexu-
ally (Figure 2). In addition, the fact that Chagas disease can be transmitted sexu-
ally, along with the migration problems of individuals affected with Chagas disease 
to countries that were previously not endemic, and travel to endemic countries, has 
direct implications for public health for the spread of this disease [8], the transmis-
sion through vector only occurs in endemic areas for this disease. In non-endemic 
countries, the main routes of transmission are blood and congenital transmission 
[9–11]. T. cruzi has a high genetic diversity, which is why it has been classified into 
discrete typing units (DTU): TCI-TcVI, in addition, of a genotype associated with 
bats (TcBat); this classification was made based on different characteristics such as 
geographical distribution and clinical manifestations of the disease, among others. 
As TcI is the most widely distributed DTU and with a wide genetic diversity, it has 
been divided into domestic and sylvatic genotypes (TcIDom and TcISyl) [12].
The disease presents two phases. In the acute phase, ranging from the time of 
infection until about 6 weeks after this, patients present a high parasitemia and 
may show nonspecific symptoms, such as fever and headache. During the chronic 
phase, which can last up to 30 years, approximately 30% of patients develop cardiac 
complications such as arrhythmias and cardiomyopathy, and 10% of patients may 
present intestinal complications, especially constipation, or neurological complica-
tions. However, the chronic phase is characterized by the absence of symptoms 
in most patients (Figure 3) [1, 13]. The latter, coupled with the fact that patients 
can be found in non-endemic areas where the disease is unknown, represents an 
added difficulty for the diagnosis of infection [14]. The effectiveness of methods 
for diagnosing infectious diseases depends on their sensitivity and specificity for 
the unambiguous detection of the presence of the pathogen or the specific host 
Figure 1. 
Distribution of Chagas Disease (WHO: Estimated data 2010).
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response in response to infection. New technologies based on molecular biol-
ogy have enabled the identification of biomarkers exclusive of infectious agents, 
molecules involved in interactions with their hosts, and of the host molecules which 
mediate response to infection [15]. Infectious diseases remain a major public health 
problem worldwide. In this scenario, the immunodiagnostic method has been and 
will remain an essential tool to demonstrate the presence of infection in patients, 
for disease prognosis, for monitoring clinical studies, and, also, as tools to monitor 
the success of strategies for control and epidemiological monitoring [16]. Finally, 
Figure 2. 
Main routes of transmission of the Trypanosoma cruzi.
Figure 3. 
Chagas disease has two stages or clinical phases: an acute phase and a chronic phase. People (from 70 to 80% 
of those infected) are asymptomatic throughout their lives, but from 20 to 30% of those affected, this disease 
progresses to chronic symptoms.
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this chapter was conceived to the current need for an accurate diagnosis for Chagas 
disease, since the correct diagnosis is a priority not only to identify the people who 
should receive the appropriate treatment but also to reduce and prevent the risk of 
transmission through a blood transfusion or an organ transplant.
2. Why the need for an accurate diagnosis for Chagas disease
One of the limitations for the prevention and control of neglected tropical dis-
eases is that the sociocultural aspects associated with diseases are ignored. Cases of 
Chagas disease in endemic areas occur in specific contexts marked by sociocultural, 
political, and economic circumstances. In addition, in the case of Chagas disease, 
the absence of symptoms in most cases, the lack of ability to detect and/or identify 
the disease, the lack of information on services and immigration policies, affect. 
It is very important to be able to obtain prevention and control measures for the 
disease, even in non-endemic countries [17]. Understanding this behavior can allow 
to guide health policies to combat these types of diseases, where indigenous groups 
and children are considered especially vulnerable groups.
2.1 The current status of the diagnosis of Chagas disease
Diagnostic methods for T. cruzi can be included in three main groups: parasitologi-
cal, serological, and molecular (Figure 4). Parasitological methods aim to visualize the 
presence of parasites, and their sensitivity varies depending on the stage of infection 
[18]. For diagnosis of the disease in the phase where the parasitemia is very low, immu-
nological methods (serological) are based primarily on the search for G antibodies 
(IgG) anti-T. cruzi in the blood of patients and their colorimetric reaction visible in the 
case that the blood of the patients contains the antibodies. [19]. The most commonly 
used methods are ELISA test (sensitivity = 94–100%, specificity = 96–100%), indirect 
hemagglutination (HAI, sensitivity = 88–99%, specificity = 96–100%), and indirect 
immunofluorescence (IFI, sensitivity = 98%, specificity = 98%). Despite being highly 
sensitive and specific, serological tests can have some cross-reactivity.
Figure 4. 
Diagnostic methods for T. cruzi.
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Another technique based on the search for anti-T. cruzi antibodies is the 
Western blot, which has been used in the diagnosis of Chagas disease using mainly 
 excretion-secretion antigens and in some cases recombinant proteins. In the 
reported works, the Western blot has been used mainly to confirm the serologi-
cal results obtained when other serological techniques are discordant or when 
there are cases of cross-reaction with Leishmania, and it has been observed that 
the technique possesses a high sensitivity and specificity. Although this test is not 
used routinely, and it is not considered as a substitute for conventional serological 
tests, it may be useful as an additional diagnostic test or for field studies [20–22]. 
Detection of parasite DNA using molecular diagnostic tools could be an alternative 
or complement to current diagnostic methods, but its implementation in endemic 
regions remains limited, due to lack of standardization, complexity, lack of clinical 
evidence, and the cost of implementation [23].
The application of molecular biological techniques has allowed the production of 
specific antigens in large quantities for use in immunologic techniques, including 
recombinant antigens and synthetic peptides [24]. Molecular biology methods are 
characterized by a high specificity and sensitivity, particularly during the acute 
phase, and hybridization techniques have been used for the detection of specific 
DNA fragments of the parasite genome by polymerase chain reaction (PCR) [25–27]. 
One of the major limitations of the PCR technique in the diagnosis of Chagas disease 
is its low sensitivity in the chronic phase due to the very low level of circulating 
parasites, since these are confined to tissues [28, 29]. However, it is important to note 
that the sensitivity of PCR is also influenced by the method of DNA extraction and 
the volume of blood that is used for DNA extraction [30]. Parasite detection from 
organ biopsies is indeed more successful during chronic infection when parasites 
sequester within organs; however, this technique is impractical because biopsies are 
not easily collected [31, 32]. Some authors proposed that circulating parasite anti-
gens could be used as highly specific biomarkers of infection by T. cruzi as observed 
in mouse models [33]. Serum proteins have also been proposed as markers of 
Chagasic patients [34]. However, diagnosis remains mostly focused on the identifica-
tion of antibodies against the parasite (Table 1) [35]. The nature of the antigens used 
in anti-T. cruzi assays is critical for the specificity of the assay, particularly in the case 
of individuals infected with related protozoan parasites such as Leishmania, as 
epitopes may cross-react with crude T. cruzi antigens [36]. Various types of serologic 
tests are currently used to establish the diagnosis of Chagas disease (Table 2), based 
on total parasite extracts and/or recombinant antigens [37, 38]. These serological 
assays for detecting antibodies to T. cruzi are generally classified as screening or 
confirmatory assays (Table 2). First-line screening assays provide the presumptive 
identification of antibody-reactive specimens, and supplemental assays are used to 
confirm whether samples found reactive with a particular screening assay do indeed 
contain antibodies specific to T. cruzi. When a single screening assay is used for 
testing in a population with a very low prevalence of Chagas disease, the probability 
that an individual is infected when a reactive test result is obtained (i.e., the positive 
predictive value) is very low, since the majority of individuals with reactive results 
are not infected. This problem occurs even when an assay with high specificity is 
used. Accuracy can be improved if a second supplemental assay is used to retest all 
those specimens found reactive by the first assay. Those found non-reactive by the 
assay are considered negative for antibodies to T. cruzi. Serum/plasma samples with 
low antibody titer are frequently found in individuals from endemic regions. In 
general, those samples are difficult to confirm and give a definitive final status.  
The clinical significance of these samples and associated potential risk of transmis-
sion by an individual presenting with low antibody titer is also little understood. 
These could represent individuals spontaneous cure or treated by current 
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Figure 4. 
Diagnostic methods for T. cruzi.
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Another technique based on the search for anti-T. cruzi antibodies is the 
Western blot, which has been used in the diagnosis of Chagas disease using mainly 
 excretion-secretion antigens and in some cases recombinant proteins. In the 
reported works, the Western blot has been used mainly to confirm the serologi-
cal results obtained when other serological techniques are discordant or when 
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evidence, and the cost of implementation [23].
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parasites, since these are confined to tissues [28, 29]. However, it is important to note 
that the sensitivity of PCR is also influenced by the method of DNA extraction and 
the volume of blood that is used for DNA extraction [30]. Parasite detection from 
organ biopsies is indeed more successful during chronic infection when parasites 
sequester within organs; however, this technique is impractical because biopsies are 
not easily collected [31, 32]. Some authors proposed that circulating parasite anti-
gens could be used as highly specific biomarkers of infection by T. cruzi as observed 
in mouse models [33]. Serum proteins have also been proposed as markers of 
Chagasic patients [34]. However, diagnosis remains mostly focused on the identifica-
tion of antibodies against the parasite (Table 1) [35]. The nature of the antigens used 
in anti-T. cruzi assays is critical for the specificity of the assay, particularly in the case 
of individuals infected with related protozoan parasites such as Leishmania, as 
epitopes may cross-react with crude T. cruzi antigens [36]. Various types of serologic 
tests are currently used to establish the diagnosis of Chagas disease (Table 2), based 
on total parasite extracts and/or recombinant antigens [37, 38]. These serological 
assays for detecting antibodies to T. cruzi are generally classified as screening or 
confirmatory assays (Table 2). First-line screening assays provide the presumptive 
identification of antibody-reactive specimens, and supplemental assays are used to 
confirm whether samples found reactive with a particular screening assay do indeed 
contain antibodies specific to T. cruzi. When a single screening assay is used for 
testing in a population with a very low prevalence of Chagas disease, the probability 
that an individual is infected when a reactive test result is obtained (i.e., the positive 
predictive value) is very low, since the majority of individuals with reactive results 
are not infected. This problem occurs even when an assay with high specificity is 
used. Accuracy can be improved if a second supplemental assay is used to retest all 
those specimens found reactive by the first assay. Those found non-reactive by the 
assay are considered negative for antibodies to T. cruzi. Serum/plasma samples with 
low antibody titer are frequently found in individuals from endemic regions. In 
general, those samples are difficult to confirm and give a definitive final status.  
The clinical significance of these samples and associated potential risk of transmis-
sion by an individual presenting with low antibody titer is also little understood. 
These could represent individuals spontaneous cure or treated by current 
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antiparasitic medication [39] or have cross-reactivity with other agents such as 
Leishmania [40]. To date, and according to the WHO, an individual is diagnosed as 
infected with T. cruzi in the chronic phase of the disease when the results of two 
serological tests are positive, due to the different immunogenicity of different strains 
of the parasite, different immune responses between patients, and the existence of 
cross-reactions with other trypanosomatids coexisting in endemic areas when using 
crude parasite antigens [16, 38]. When inconclusive or discordant results appear, a 
third technique [38] or additional samples are required [41]. However, during the 
diagnosis of the disease, we must take into account certain conditions and/or 
variables that are not directly dependent on the design and development of the test; 
as in the case of the host response, this depends partly on the strain of parasite and 
secondly on the genetic background of the host [42]. Moreover, the existence of the 
“immunological memory” in models where there was a parasitological cure suggests 
that parasite antigens may persist in some organs, which could be inducing the 
production of antibodies, regardless of the presence of live parasite [43, 44]. In 
patients treated during the chronic phase, the objective is to analyze a tendency for 
negativization of the serological tests, which requires to monitor patients for many 
years following treatment. This has brought controversies regarding the criterion of 
a serologic cure [45, 46]. Some researchers believe that a reduction in antibody titers 
after a prolonged time can be considered as a criterion of cure, in contrast to others 
who recommend total negativization of serological tests [47]. In areas where Chagas 
disease is endemic, the choice among ELISA, IIF, or IHA for serological testing is 
based on availability [31, 32, 38, 48]. However, these techniques may be unspecific as 
they can cross-react with other parasites [49]. Because of this cross-reaction, the use 
of antigen secretion/excretion of parasite in diagnostic tests has been proposed. It 
has been shown that proteins from trypomastigotes are better antigens to detect 
antibodies against the parasite; however, most antigens used for immunological tests 
are total protein extracts derived from epimastigotes, because of the ease of 
Diagnostic methods in the acute phase
Direct methods without concentration
Direct methods of concentration
• Microhematocrit
• Strout test





Other parasitological and molecular biology methods*
• Xenodiagnostic
• In vitro culture
• PCR
*Can be used in any phase, with low parasitemia, and is not detected by other methods.
Table 1. 
Diagnoses for chagas disease.
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Test Antigen Manufacturer Country
Immunoenzymatic assay
AccuDiag™ Chagas ELISA Kit NI Diagnostic Automation/
Cortez Diagnostics, Inc.
USA
ImmunoComb® II Chagas Ab Kit RA Alere Inc. Germany
Anti-Chagas IgG ELISA Kit NI Abcam United 
Kingdom
Abbott ESA Chagas Purified antigens Abbott Laboratories USA
Abbott PRISM Chagas Purified antigens Abbott Laboratories USA
T. cruzi Ab (Chagas) Bioars Argentina
EIAgen Trypanosoma cruzi Ab Total extract Adaltis Italy




Chagas ELISA IgG + IgM RA Vircell Spain
Pathozyme Chagas RA Omega Diagnostics 
Limited
Scotland
Chagas Rec ELISA RA Human Diagnostics 
Worldwide
Germany
Chagas ELISA Total extract Ebram Produtos 
Laboratoriais Ltda
Brazil
Chagatek ELISA Purified antigens Laboratório Lemos SRL Argentina





Premier Chagas IgG ELISA test Purified antigens Meridian Diagnostics USA




Bio-Manguinhos EIA Total extract/RP Bio-Manguinhos Brazil
IVD ELISA NI IVD Research Inc. USA
DRG®Trypanosoma cruzi IgG NI DRG International Inc. USA
Chagas IgG ELISA RA Gull Laboratories Inc./
Meridian Bioscience Inc.
USA
Cellabs T. cruzi IgG CELISA NI Cellabs Pty Ltd. Australia
BIOELISACRUZI Total extract Biolab-Mérieux Brazil
Dia Kit Bio-Chagas RA Gador SA Argentina
BIOZIMA Chagas kit Purified antigens Laboratório Lemos SRL Argentina
Abbott Chagas Anticorpos EIA RA Abbott Laboratories USA
Cruzi TEST ELISA NI GenCell Biosystems Ireland
Chagas test IICS, ELISA Total extract (Y 
strain)
IICS Univ de Asunción Paraguay
HBK 401 Hemobio Chagas Total extract Embrabio Brazil
Chagatest ELISA Total extract/RP Wiener lab Argentina
Bioelisa Chagas Synthetic 
peptides
Biokit Spain
Chagas Hemagen Purified antigens Hemagen Diagnósticos USA
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Test Antigen Manufacturer Country
BioMérieux Total extract/RP BioMérieux France
BLK Total extract BLK diagnostics Spain
Siemens IMMULITE Chagas IgG RA Siemens Healthcare USA
Anti-Chagas Symbiosis NI Symbiosys Brazil
ORTHO T. cruzi ELISA Test System Total extract Jhonson and Jhonson USA
Certest (Strain Tulahuen 
and Mn)
Abbott Laboratories Spain
ImmunoComb II Chagas Ab RA/peptides Orgenics Israel
Elecsys Chagas assay Recombinant 
antigens
Roche Diagnostic




ELISA Chagas III Total extract Grupo Bios Chile
Imuno-ELISA Chagas Recombinant 
antigens
Wama Diagnóstica Brazil
T. cruzi Ab, DIAPRO Recombinant 
antigens
Diagnostic BioProbes Italy
Trypanosoma cruzi IgG ELISA Kit Total extract MyBiosource USA





Chagas (Trypanosoma cruzi) IgG 
ELISA
NI GenWay Biotech, Inc. USA
Chagas (Trypanosoma cruzi) IgG 
ELISA
NI IBL International GmbH Germany




OnSite Chagas Ab Rapid test RA CTK Biotech USA
Chagas AB Rapid RA Standard Diagnostics Korea
WL Check Chagas RA Wiener Lab Argentina
Chagas Instantest Antigens attached 
to colloidal gold
Silanes Mexico
Prueba rápida Chagas Antigens attached 
to colloidal gold
Amunet Labarotarios Mexico




Chagas-certum Antigens attached 
to colloidal gold
Certum® Diagnostics Mexico




Chagas Stat-Pak assay RA Chembio Diagnostic 
Systems
USA
PATH-Lemos rapid test RA Laboratório Lemos SRL Argentina
Immu-Sure Chagas (T. cruzi) Millennium Biotech USA
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Test Antigen Manufacturer Country
SD Chagas Ab Rapid RA Standard Diagnostic Korea
ICT Operon Purified antigens Operon Spain
Hemagglutination assays
Chagas HAI Imunoserum Sheep red 




Laboratório Lemos SRL Argentina









Chagas HAI Bird red 
blood cells are 
sensitized by 
binding purified
T. cruzi (Y strain)
Ebram Brazil
Imuno-HAI Chagas Bird red 
blood cells are 
sensitized by 
binding purified
T. cruzi (Y strain)
WAMA Brazil
Chagas Hemagen HA Human red 























Chagas IFA NI Vircell Spain
Inmunofluor Chagas kit Epimastigotes Biocientífica S.A Argentina
Kit Trypanosomiasis IFI Epimastigotes Tryniti-Mardx 
(Inverness Medical)
USA
Inmunofluor Chagas IFI Parasites NI Biocientífica S.A. 
(Inverness Medical)
Argentina
MarDx IFA MarDx Diagnostics, Inc. USA
IFA Kit Trypanosomiasis Innogenetics Ibérica Spain
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obtaining them, at lower cost and the presence of common antigens with trypomas-
tigotes [50]. Nevertheless, these tests also show cases of false negatives and cross-
reactivity [51–56]. Due to the complexity of the interaction of T. cruzi with its host, a 
single recombinant antigen has not reached the efficacy shown by the total extracts 
of the parasite. Thus, the antigenic composition of the tests based on recombinant 
antigens includes a combination of several epitopes [57]. Flow cytometry has mainly 
been used for differential diagnosis between Chagas disease and leishmaniasis owing 
to cross-reactivity. Even with optimized serological assays that use parasite-specific 
recombinant antigens, inconclusive test results continue to be a problem [58]. 
However, this technique is utilized for monitoring treatments rather than for diagno-
sis [59]. In the past decade, several technologies have emerged as diagnostic tools 
capable of improving diagnosis by using several antigens. The diagnostic process 
becomes faster and less expensive, and the hands-on time in laboratories decreases 
substantially since these platforms can be fully automated. A multiplex assay 
platform was evaluated to detect T. cruzi infection using the recombinant antigens 
CRA, FRA, CRA-FRA fusion and parasite lysate; these antigens presented different 
Test Antigen Manufacturer Country
Chemiluminescent immunoassay
Architect Chagas assay (prototype) 
immunoparticles
RA Abbott Laboratories Spain
CHAGAS VIRCLIA NI Vircell Spain
PCR assays






NA Eiken Chemical 
Company
China
RealCycler CHAG NA Progenie Molecular Spain
TCRUZIDNA.CE NA Diagnostic Bioprobes Srl Italy
RealStar® Chagas PCR Kit RUO NA altona Diagnostics 
GmbH
Germany
VIASURE Trypanosoma cruzi Real 
Time PCR Detection Kit







University of Iowa USA








Multiplex Immunoassay Multi-cruzi 
(prototype)
Protein array NA NA
RA, recombinant antigen; NI, not indicated; NA, not applicable.
Table 2. 
List of commercial diagnostic tests for the serological detection of T. cruzi (Chagas disease).
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sensitivity and specificity by themselves; however, when mixed they increased its 
sensitivity and specificity, suggesting that they could be an alternative to single-test 
detection for Chagas disease [60]. Moreover, the immunochromatography represents 
a promising method which can be performed with whole blood, and it has many 
advantages over most existing diagnostic methods, requires little time, and does not 
require trained personnel; its main advantage is that it can be used in field work [61], 
but there are cases of discordance [62]. However, despite that, there are reports 
where it manifests that it no longer needed investing so much in research and 
development for the diagnosis of Chagas disease, because that rapid tests on the 
market are sufficiently valid both in America and in Europe and Asia-Pacific [63]; 
however, this is not entirely true, since several studies have shown discordance 
between the various commercial techniques. As mentioned, the diagnosis of Chagas 
disease is based mainly on serological tests because parasitemia is generally low or 
cannot be detected during the chronic phase of the infection. Finally, low reaction 
samples may not be detectable by all serological assays; besides, the presence of the 
so-called “serosilent” infections [64], in which parasitemia is detectable in seronega-
tive individuals, represents a potential risk to acquire the parasite.
2.2 The world of diagnosis for Chagas disease: a discordant paradise
The accurate diagnosis of T. cruzi infection is pivotal to the clinical manage-
ment of Chagas disease. T. cruzi has a complex life cycle, and its ability to infect 
any nucleated cell complicates diagnosis [65]. Additionally, the absence of a “gold 
standard” test that reliably and consistently detects the presence of a T. cruzi infec-
tion makes the evaluation of current methods difficult [28, 66]. Serodiscordance in 
Chagas disease remains a challenge since individuals with inconclusive results are 
clinically complicated to manage [67]; this problem usually arises in the diagnosis 
during the chronic phase. Performing two or more serological testing does not guar-
antee that the result shall be univocal. It is called serodiscordance when in the same 
patient two tests give different results (frequent situation during treatment, in preg-
nant patients or patient in acute cases), because the main criterion for “cure” has 
been the conversion to negative serology on all tests performed. However, this result 
is often not observed until 8–10 years posttreatment and then only in approximately 
15% of treated adult subjects [68]. Experts recommend that the IFI which has a 
sensitivity of 95% and a specificity of 100% is used. However, it is often not the 
most advisable since reading can be subjective, depending on the experience of the 
technician. Another situation that often occurs in reading spectrophotometric tests, 
such as ELISA, is that the values of optical density (OD) are very close to the cutoff 
value (±10%), in which case the result should not be considered positive or negative 
but rather indeterminate. Alternatives have been proposed as IFI, antigens’ parasite 
excretion-secretion (TESA) used in ELISA or immunoblot assays or by radioimmu-
noassay (RIPA), or various recombinant antigens used in immunoblot [14]. To date 
no test alone can establish the diagnosis or confirmation of infection by T. cruzi nor 
rule out the problem of cross-reactivity; the combination of tests usually generates 
discrepant results, often in a limited number of cases. Some commercial tests have 
very limited ability to detect T. cruzi infection in populations of particular study; 
internal tests based on crude parasite antigens showed a higher sensitivity but were 
still unable to detect all cases of T. cruzi infection [69], for example, the University 
of Sao Paulo conducted tests to detect T. cruzi antibodies using the three methods 
IH, IIF, and ELISA; 4000 serum samples were analyzed, of which only 1901 (48%) 
were positive for all three tests, 718 (18%) were negative, and 1381 (35%) had a 
questionable or inconclusive results. The discrepancies were attributable to the 
type of parasite antigen; IIF detects a specific antibody that reacts with a parasite 
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ment of Chagas disease. T. cruzi has a complex life cycle, and its ability to infect 
any nucleated cell complicates diagnosis [65]. Additionally, the absence of a “gold 
standard” test that reliably and consistently detects the presence of a T. cruzi infec-
tion makes the evaluation of current methods difficult [28, 66]. Serodiscordance in 
Chagas disease remains a challenge since individuals with inconclusive results are 
clinically complicated to manage [67]; this problem usually arises in the diagnosis 
during the chronic phase. Performing two or more serological testing does not guar-
antee that the result shall be univocal. It is called serodiscordance when in the same 
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most advisable since reading can be subjective, depending on the experience of the 
technician. Another situation that often occurs in reading spectrophotometric tests, 
such as ELISA, is that the values of optical density (OD) are very close to the cutoff 
value (±10%), in which case the result should not be considered positive or negative 
but rather indeterminate. Alternatives have been proposed as IFI, antigens’ parasite 
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noassay (RIPA), or various recombinant antigens used in immunoblot [14]. To date 
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rule out the problem of cross-reactivity; the combination of tests usually generates 
discrepant results, often in a limited number of cases. Some commercial tests have 
very limited ability to detect T. cruzi infection in populations of particular study; 
internal tests based on crude parasite antigens showed a higher sensitivity but were 
still unable to detect all cases of T. cruzi infection [69], for example, the University 
of Sao Paulo conducted tests to detect T. cruzi antibodies using the three methods 
IH, IIF, and ELISA; 4000 serum samples were analyzed, of which only 1901 (48%) 
were positive for all three tests, 718 (18%) were negative, and 1381 (35%) had a 
questionable or inconclusive results. The discrepancies were attributable to the 
type of parasite antigen; IIF detects a specific antibody that reacts with a parasite 
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membrane antigen, whereas HI detects an antibody that reacts with a subcellular 
antigen. Each of these serological reactions operates in different specificity systems 
[70]. Another study in Spain was found to have a higher sensitivity (97–100%), 
and for serological screening of T. cruzi infection, a combination of tests is needed 
[71]. Finally, in a study conducted in a rural community in Veracruz, Mexico, using 
a combination of five ELISA tests based on different antigenic preparations (two 
in-house enzyme-linked immunosorbent assay based on crude extract, Chagatest 
ELISA recombinant v3.0, Chagatek ELISA, and NovaLisa Chagas), a very high level 
of discordance (32%) was also found among the ELISA tests used, with very poor 
agreement among them. This showed that the commercial tests had a very limited 
ability to detect T. cruzi infection, and the in-house tests based on crude parasite 
antigens showed a greater sensitivity but were still unable to detect all cases of T. 
cruzi infection, even when based on a local parasite strain [69].
To date, T. cruzi diagnostic present problems of sensitivity, making the diagnosis 
confusing and often requiring additional testing [40, 70, 71]. In congenital cases, it 
has been observed that discordance between the samples analyzed also occurs, and 
discordant results were confirmed by a third diagnostic test [72]. Although numer-
ous assays are available for diagnosing Chagas disease, no single test is considered 
the reference standard to confirm the diagnosis of infection by the parasite [73–76]. 
Serology is a useful tool in the diagnosis of Chagas disease, but in certain cir-
cumstances, none of the techniques described above serves as a marker of cure or 
progression of infection. Some authors mention that the Western blot is suitable for 
confirmation of infection by T. cruzi, so it is strongly recommended for confirma-
tion and discrimination of discordant cases [22, 77], because this technique has 
a sensitivity of 86.6% [20, 78], 99% [79], and 100% [80, 81] and a specificity of 
100%, making it more effective than techniques such as ELISA, HAI, and IIF. The 
adequate choice of T. cruzi strains as antigen source for the diagnosis of Chagas dis-
ease is still controversial due to differences in terms of accuracy reported between 
different diagnostic tests. The results of this study showed that the sensitivity index 
did not vary, with percentages of 100% for all strains in both tests. However, the 
specificity index for the ELISA tests showed differences between 92 and 98% but 
was reduced to 78–89% when the Leishmania-positive sera were included [82].
2.3 Looking for the correct diagnosis
After more than a century of the discovery of Chagas disease, there is no con-
sensus on the choice of a reference technique. Studies in South America reported a 
high efficiency of commercial kits manufactured in this region [40, 83]. However, 
work carried out in Central America shows that the use of antigens prepared from 
T. cruzi strains that are isolated in these areas increases the sensitivity of antibody 
detection assays [69, 84, 85]. This could be due to the predominance of the lineage 
TcI in the region [86] and the wide expansion of genotypes TcII–TcVI reported in 
the Southern Cone countries [87]; but lately, the presence of additional DTUs  
has been demonstrated in countries such as Mexico and the United States  
[88, 89]. The development of new diagnostics is partially limited by the availability 
of well-characterized antigens, in addition to the great variability among strains 
and DTUs in terms of virulence, infectivity, tissue tropism, progression of disease, 
drug susceptibility, and geographical distribution [31, 90–92]. However, there is 
as yet no clear association between genetic variants of the parasite and these life 
history or epidemiological characteristics. Several recombinant antigens that have 
serologic utility have been identified. However, the most effective antigens have 
been those with immunodominant, repeating B-cell epitopes [93]. The use of 
recombinant antigens and/or synthetic peptides has been proposed [94] to improve 
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specificity and sensitivity, which is essential if false-positive or false-negative 
results are to be avoided. Peptide analysis is a technique widely used for mapping of 
linear epitopes in proteins from pathogens [95, 96].
The recent availability of peptide microarrays allows rapid and inexpensive 
serological diagnosis with high performance [97, 98]. The availability of complete 
pathogen genomes has renewed interest in the development of diagnostics for 
infectious diseases. Synthetic peptide microarrays provide a rapid, high-throughput 
platform for immunological testing of potential B-cell epitopes. Therefore, compu-
tational approaches for prediction and/or prioritization of diagnostically relevant 
peptides are required [99]. Currently, high-density peptide chips for the discovery 
of linear B-cell epitopes’ specific pathogens from clinical samples provide the basis 
for the detection of biomarkers and proteome-scale studies of the immune response 
against pathogens [100].
The challenge for this process is to identify, by bioinformatics within a given 
proteome, peptides that could be good targets for a B-cell response. A number of 
algorithms have been developed for computational prediction of B-cell epitopes 
[101]. Computational prediction of B-cell epitopes is still an active research field, and 
a number of state-of-the-art predictors show improved performance [102–105]. As 
a consequence, predicting diagnostic epitopes in the context of a particular disease 
or infection is a complex problem, where many additional limitations are not taken 
into account, such as the mechanism of invasion of infectious agents, the expres-
sion pattern of parasite proteins. All these additional variables affect the outcome 
of the immune response and may explain the observed variability in responses [99]. 
In recent years, microarray technology has been of great interest, offering valuable 
opportunities to study the function of genes and the development of diagnostics. The 
main advantage of a microarray assay is to determine different analytes simultane-
ously, and it is more sensitive and faster than the conventional ELISA system. Peptide 
microarrays combined with a bioinformatics peptide selection strategy constitute a 
powerful and cost-effective platform for serodiagnostic biomarker screening of infec-
tious diseases just as Chagas disease [100]. The development of efficient methods 
for the detection of microspots with high sensitivity and specificity will enable new 
applications in future studies applied to protein microarrays [106, 107].
New-generation tests with potentially improved accuracy have been developed 
recently. The use of a large mixture of recombinant antigens and the incorporation 
of different detection systems, such as chemiluminescence, increase the sensitivity 
and specificity of the techniques. Other advantages of new-generation tests are 
automation, rapidity, and high performance, such as the Architect Chagas or Bio-
Flash Chagas (Biokit, Lliçà d’Amunt, Spain), which have improved the diagnosis of 
Chagas disease with innovative new tools (large mixture of recombinant antigens 
and chemiluminescence as detection system). Previous studies have also proposed 
a chemiluminescent ELISA (CL-ELISA) with purified trypomastigote glycoproteins 
for the detection of lytic protective antibodies against T. cruzi in human serum  
[35, 108–110]. Detection systems, such as chemiluminescence, increase light ampli-
fication and signal duration in comparison with traditional ELISAs, which may be 
a point in favor of these new methodologies, leading to higher accuracy in the diag-
nosis of Chagas disease. Further studies with other new-generation techniques with 
similar characteristics (recombinant antigens and chemiluminescence) are neces-
sary [35]. The use of a single technique would reduce diagnosis costs and therefore 
allow the application of screening and control programs in countries where such 
systems have not yet been implemented. Previous studies on the cost-effectiveness 
of Chagas disease management have been undertaken, but the costs of different 
diagnostic methods have not been compared [111–114]. Thus, several groups have 
implemented the usage of PCR to the identification of the genetic material from the 
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ously, and it is more sensitive and faster than the conventional ELISA system. Peptide 
microarrays combined with a bioinformatics peptide selection strategy constitute a 
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of different detection systems, such as chemiluminescence, increase the sensitivity 
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automation, rapidity, and high performance, such as the Architect Chagas or Bio-
Flash Chagas (Biokit, Lliçà d’Amunt, Spain), which have improved the diagnosis of 
Chagas disease with innovative new tools (large mixture of recombinant antigens 
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a chemiluminescent ELISA (CL-ELISA) with purified trypomastigote glycoproteins 
for the detection of lytic protective antibodies against T. cruzi in human serum  
[35, 108–110]. Detection systems, such as chemiluminescence, increase light ampli-
fication and signal duration in comparison with traditional ELISAs, which may be 
a point in favor of these new methodologies, leading to higher accuracy in the diag-
nosis of Chagas disease. Further studies with other new-generation techniques with 
similar characteristics (recombinant antigens and chemiluminescence) are neces-
sary [35]. The use of a single technique would reduce diagnosis costs and therefore 
allow the application of screening and control programs in countries where such 
systems have not yet been implemented. Previous studies on the cost-effectiveness 
of Chagas disease management have been undertaken, but the costs of different 
diagnostic methods have not been compared [111–114]. Thus, several groups have 
implemented the usage of PCR to the identification of the genetic material from the 
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parasite, in blood and serum samples as well as tissue samples. Several types of the 
PCR techniques are available to detect T. cruzi DNA in serum and blood samples; 
among them we find conventional PCR, hot-start PCR, and nested PCR. Several 
tools that use probes to verify the presence/absence of specific DNA are also used; 
such as: Southern Blot or PCR and hybridization and real-time PCR. An important 
advantage that the use of PCR offers as a diagnosis tool is that it allows the char-
acterization of the circulating strains in an endemic area for Chagas disease [115]. 
Finally, there is a need to develop new non-serological non-PCR-based assays to 
address the limitations of the current methods available for T. cruzi detection. For 
this purpose, assays that detect biomarkers of Chagas disease need to be developed. 
Biomarker discovery studies reported for Chagas disease lead to the identification 
of characteristics of host origin, such as host proteins or immune markers, which 
were elevated in Chagas disease [116, 117]. However, one cannot exclude the pos-
sibility that these host markers could also be modulated in conditions unrelated to  
T. cruzi infection, and thus these biomarkers have limited specificity [118]. In order 
to overcome the issues of specificity, the detection of pathogen-specific factors 
would be ideal biomarkers of T. cruzi infection [33].
3. Conclusions
Chagas disease causes 12,000 deaths each year, and it is estimated that between 
7 and 8 million people suffer. This is one of the major public health problems in 
Latin America. In recent decades, cases have also been detected in North America, 
Europe, and Asia-Pacific, mainly as a result of migration. An ideal serological test 
should be easy to perform in a single step, be fast, and be cheap, require no special 
equipment or refrigeration of reagents, and have 100% sensitivity and specific-
ity; unfortunately, no such test exists for Chagas disease. The lack of a reference 
standard serological assay for the diagnosis of T. cruzi infection has prompted the 
development of new tests, which require further evaluation, so that the develop-
ment of diagnostic methods for detecting T. cruzi infections, after more than a 
hundred years of its discovery, remains a challenge which depends mainly on the 
availability of specific high-affinity antigens. The diagnosis of Chagas disease has 
limitations, mainly due to the great complexity of the factors that involve it, as well 
as to the low sensitivity of the parasitological techniques and the low specificity of 
the immunological tests. Finally, the application of immunomics, which combines 
serology with proteomics, would help to discover genes and molecules related to 
the susceptibility and immunity of T. cruzi infection, allowing the creation of an 
adequate diagnosis for the disease, elucidating new therapeutic targets, and, why 
not, allowing the creation of a vaccine against Chagas disease.
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Epidemiology of Leprosy in 
Vietnam and the Effectiveness of 
Multidrug Therapy (MDT) in the 
Management of the Disease
Tran Hau Khang, Ngo Minh Thao and Le Huu Doanh
Abstract
Leprosy is a chronic infection caused by the acid-fast, rod-shaped bacillus 
Mycobacterium leprae. Leprosy can be considered connected diseases that primar-
ily affect the superficial tissues, especially the skin and peripheral nerves. The 
social and psychological effects of leprosy, as well as its highly visible debilities 
and sequelae, have resulted in a historical stigma associated with leprosy. Vietnam 
has seen a highly significant decrease in the prevalence rate (PR) of leprosy since 
1983. From 1983 onwards, with the introduction of multidrug therapy (MDT), the 
prevalence of the disease has dropped to less than one case per 10,000 individu-
als from 1995. After over two decades, a total of 109 cases were registered with a 
prevalence rate of 0.01 per 10,000 population in 2017. It is clear that over the past 
35 years, the profile of leprosy in Vietnam has been changed significantly followed 
by the treatment with MDT. Leprosy has become a rare disease in Vietnam. This 
chapter presents the trend in the epidemiology of leprosy in Vietnam from 1983 
to 2018 and also mentions the effectiveness of multidrug therapy (MDT) in the 
management of this disease. Based on individual records and annual reports, the 
prevalence of registered cases, the number of new cases detected yearly, their sex, 
age, classification (MB, multibacillary; PB, paucibacillary) and disability status are 
carefully presented.
Keywords: leprosy, multidrug therapy, relapse, prevalence, incidence, disability
1. Introduction
Vietnam, officially the Socialist Republic of Vietnam, is the easternmost country 
on the Indochina Peninsula which is a part of the Western Pacific Region. With 
another four countries, including China, Malaysia, Papua New Guinea and the 
Philippines, Vietnam contributed to 86% of the total prevalence, according to the 
WHO’s report in 2010 [1]. While the lack of knowledge about leprosy in the lower 
socio-economic group is an important cause why most of patients with untreated 
leprosy end up with severe deformities and disfigurements, there has been a degree 
of stagnation and new approaches in leprosy control. Therefore, in 1991, the global 
leprosy control network was established. The WHO set the goal of elimination of 
leprosy as a public health problem in which the prevalence rate needs to be below 
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1. Introduction
Vietnam, officially the Socialist Republic of Vietnam, is the easternmost country 
on the Indochina Peninsula which is a part of the Western Pacific Region. With 
another four countries, including China, Malaysia, Papua New Guinea and the 
Philippines, Vietnam contributed to 86% of the total prevalence, according to the 
WHO’s report in 2010 [1]. While the lack of knowledge about leprosy in the lower 
socio-economic group is an important cause why most of patients with untreated 
leprosy end up with severe deformities and disfigurements, there has been a degree 
of stagnation and new approaches in leprosy control. Therefore, in 1991, the global 
leprosy control network was established. The WHO set the goal of elimination of 
leprosy as a public health problem in which the prevalence rate needs to be below 
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one case per 10,000 people [2]. Vietnam has achieved the national target in 1995 and 
succeeded in maintaining the elimination threshold, reaching that sub-nation at the 
end of the year 2000 [3]. However, based on the annual data collected from 2000 
onwards, several new case detections have been reported [3, 4]. This requires con-
tinuing the implementation of the main principles of leprosy control in the nation, 
with a special focus on the five fields, such as timely detection of new cases, contact 
investigation, multidrug therapy (MDT) treatment, the treatment compliance and 
prevention of disabilities and also rehabilitation. The strategic directions are inte-
gration, early diagnosis and treatment which help to strengthen and sustain leprosy 
activities, quality patient care and reduction of the leprosy burden of physical, social 
and economic consequences. The introduction of MDT for the treatment of leprosy 
in 1983 was one of the important landmarks in combating the disease. In the past, 
many clinical trials of MDT have been implemented with high effectiveness and 
well toleration. The addition of ofloxacin to multidrug regimens has been developed 
to reduce the required duration of MDT possible. Moderate to marked clinical and 
bacterial improvement with minimal adverse effects has been observed [5, 6].
2. Network of leprosy control programme
Vietnam’s National Leprosy Control Programme was established in 1982 [7]. The 
present national framework for leprosy control is characterized by the integrated 
delivery of basic leprosy services, which are provided at the peripheral level. The 
leprosy control system is a part of the healthcare system which follows the adminis-
trative system (Figure 1). The National Hospital of Dermatology and Venereology 
(NHDV) is the leading institute responsible to the Ministry of Health (MOH) for 
skin diseases, sexually transmitted infections (STIs) and leprosy control in the 
Figure 1. 
Leprosy control system according to healthcare and administrative system.
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whole country [4]. There are the supported systems, namely, Dermato-Venereology 
Clinic, vertically under NHDV in each province, covering these fields at provincial 
level. Dermato-venereological activities including leprology work are continu-
ously separated into the leprosy programmes at district level. At the district’s social 
diseases unit in endemic zones, several practitioners are specially trained to work 
exclusively in leprosy field, whereas in less endemic district, they are in charge of 
some contagious diseases, including leprosy, tuberculosis, malaria, HIV/AIDS, 
etc. In each commune that includes 2–5 villages with 1000–3000 people, leprosy 
and other social diseases are managed by one or two health workers. They are the 
specialized units with leprosy expertise at intermediate levels that provide the 
necessary technical guidance. Their main work is to refer suspect cases for diagnosis 
confirmation, to treat and to follow up confirmed cases. Antileprosy drugs are 
stored at any levels, from central to local. The leprosy programme plays a para-
mount importance to facilitate early case detection and reduce the disease burden 
further in all endemic areas because they encourage voluntary or self-reporting 
and help increase the capabilities of the peripheral general healthcare staff through 
training.
3. Epidemiology of leprosy
3.1 Before 1975
There is no exact data of this period because dermato-venereology profession 
network was just established in 1975, but the estimated prevalence rate of leprosy 
was 6–7/10,000 population in 1975 [4]. Most of patients are being congregated in 
places such as leprosy villages/colonies despite no segregation law.
3.2 From 1976 to 2018
The National Leprosy Control Programme (NLCP) was formed in 1982, and 
MDT was implemented 1 year later, in 1983 [7].
3.2.1 The trend in prevalence rate of leprosy
According to the annual data reported from 1983 to 2018, there was a decreasing 
trend in both prevalence rate and the annual newly detected cases (Figure 2). As a 
result of the long-term efforts, Vietnam, which was one of the first 15 countries in 
the region, had reached the goal of elimination at the national level in 1995 with the 
prevalence rate of 0.7 per 10,000 population [2]. At the end of the year 2000, the 
subnational target has been reported. In 2000, only 28 provinces reached Vietnam’s 
3 elimination criteria [3, 4]. But from 2001 to 2015, all the rest 36 provinces com-
pleted the WHO’s elimination goal at the provincial level in the country (Vietnam’s 
4 elimination criteria) [7], and relatively high case detection rate was found in some 
area, particularly in the central highland and some southern provinces.
They were varied from 38,652 prevalent cases in 1983, corresponding a rate of 
6.78 per 10,000 people, to 18,418 cases, corresponding of 2.71 in 1991 (see Table 1). 
During this period, the registered prevalence number was very high due to several 
main factors, such as retreated with MDT in patients previously treated with 
dapsone and managing the national leprosy by using 24-month regimen without 
ofloxacin. However, since 1992 onwards, the number of registered prevalence cases 
reduced dramatically (Figure 2). Starting from 9245 cases in 1992, it decreased 
to 96 in 2018 and the rate dropped continuously from 1.36 to 0.01 per 10,000 
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etc. In each commune that includes 2–5 villages with 1000–3000 people, leprosy 
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places such as leprosy villages/colonies despite no segregation law.
3.2 From 1976 to 2018
The National Leprosy Control Programme (NLCP) was formed in 1982, and 
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result of the long-term efforts, Vietnam, which was one of the first 15 countries in 
the region, had reached the goal of elimination at the national level in 1995 with the 
prevalence rate of 0.7 per 10,000 population [2]. At the end of the year 2000, the 
subnational target has been reported. In 2000, only 28 provinces reached Vietnam’s 
3 elimination criteria [3, 4]. But from 2001 to 2015, all the rest 36 provinces com-
pleted the WHO’s elimination goal at the provincial level in the country (Vietnam’s 
4 elimination criteria) [7], and relatively high case detection rate was found in some 
area, particularly in the central highland and some southern provinces.
They were varied from 38,652 prevalent cases in 1983, corresponding a rate of 
6.78 per 10,000 people, to 18,418 cases, corresponding of 2.71 in 1991 (see Table 1). 
During this period, the registered prevalence number was very high due to several 
main factors, such as retreated with MDT in patients previously treated with 
dapsone and managing the national leprosy by using 24-month regimen without 
ofloxacin. However, since 1992 onwards, the number of registered prevalence cases 
reduced dramatically (Figure 2). Starting from 9245 cases in 1992, it decreased 
to 96 in 2018 and the rate dropped continuously from 1.36 to 0.01 per 10,000 
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population in the same period (Table 1). The main reasons were considered, such 
as disseminating MDT therapy in the whole country and introducing patients to 
12-month regimen for shortening the required duration of MDT possible in 1998.
Analysis of a total data from 1983 to 2018 revealed that the prevalence rate has 
dropped significantly from 6.78 per 10,000 in 1983 to 0.01 per 10,000 in 2018 
(Table 1). It is clear that over the past 35 years, the prevalence rate of leprosy has 
changed dramatically by around 99.9%. With this prevalence rate, it was believed 
that the transmission of M. leprae would be reduced and leprosy would naturally 
disappear. The post-elimination challenges in the future are sustaining high-quality 
leprosy programmes and reaching the target of district level. Although leprosy has 
become a rare disease in Vietnam, all activities of the NLCP are sustained from the 
national to grassroot levels. At the present, Vietnam has several provinces which 
achieved the goal of elimination at the district level.
3.2.2 Trend in case detection
The new cases include patients who are newly diagnosed during the calendar 
year. Due to the development of the leprosy network and acceleration of activi-
ties of health education, the number of new cases detected yearly was remarkably 
increased from 1991 to 1997 (Figure 2). A total of more than 32 special projects, 
namely, SAPEL, LEC and mini-LEC, were conducted in this period, during 
1991–1997 [3]. The results, not only the new case detections but also the remaining 
undetected cases, especially in the high plateau areas and some places in southern 
provinces, were found out. During 1993–1998 the number of new cases detected 
annually increased. From 1999 up to now, the annual detection rate has declined 
(Figure 2). Only 77 cases were detected in 2018 with a rate of 0.1 per 100,000 
inhabitants and a decrease from 1795 cases in 1999, corresponding to a rate of 2.35 
per 100,000 population (Table 1). Compared with other countries in the region, 
Vietnam has significantly declined in the incidence cases. Between 2013 and 2014, 
while India alone accounted for 58.85% of the global Leprosy burden, with a total 
of 127,000 new cases detected, that number in Vietnam was only 521 new cases 
[8], <243.7 times. Because case detection is highly influenced by the intensity of 
Figure 2. 
Prevalence rate (PR) and detection rate (DR) of leprosy (1983–2018) (detection rate (DR), proportion of new 
cases per 100,000 population; prevalence rate (PR), proportion of leprosy cases per 10,000 population).
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Year Prevalence Cases detected
n Per 10,000 n Per 100,000
1983 38,652 6.78 2021 3.74
1984 36,226 6.14 2103 3.77
1985 32,483 5.36 2062 3.59
1986 29,219 4.79 2292 3.88
1987 27,401 4.42 2183 3.61
1988 24,570 3.90 1847 2.98
1989 23,612 3.69 2073 3.26
1990 24,081 3.65 1995 3.47
1991 18,418 2.71 2500 3.69
1992 9245 1.36 3142 4.53
1993 7090 1.01 3185 4.38
1994 7104 1.00 3173 4.29
1995 5277 0.70 2591 3.45
1996 4827 0.68 2883 3.83
1997 4665 0.61 2808 3.65
1998 3482 0.44 2162 2.74
1999 2087 0.27 1795 2.35
2000 1718 0.23 1477 1.94
2001 1532 0.2 1336 1.73
2002 1269 0.16 1158 1.44
2003 1204 0.15 949 1.18
2004 828 0.1 858 1.04
2005 642 0.1 746 0.9
2006 572 0.1 666 0.75
2007 510 0.1 552 0.66
2008 540 0.1 530 0.62
2009 350 0.04 413 0.48
2010 318 0.04 359 0.41
2011 322 0.04 374 0.43
2012 265 0.03 296 0.34
2013 260 0.02 294 0.29
2014 187 0.02 227 0.2
2015 178 0.02 168 0.19
2016 138 0.02 153 0.15
2017 109 0.01 112 0.12
2018 96 0.01 77 0.1
Table 1. 
Prevalence and case detection in Vietnam (1983–2018).
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1987 27,401 4.42 2183 3.61
1988 24,570 3.90 1847 2.98
1989 23,612 3.69 2073 3.26
1990 24,081 3.65 1995 3.47
1991 18,418 2.71 2500 3.69
1992 9245 1.36 3142 4.53
1993 7090 1.01 3185 4.38
1994 7104 1.00 3173 4.29
1995 5277 0.70 2591 3.45
1996 4827 0.68 2883 3.83
1997 4665 0.61 2808 3.65
1998 3482 0.44 2162 2.74
1999 2087 0.27 1795 2.35
2000 1718 0.23 1477 1.94
2001 1532 0.2 1336 1.73
2002 1269 0.16 1158 1.44
2003 1204 0.15 949 1.18
2004 828 0.1 858 1.04
2005 642 0.1 746 0.9
2006 572 0.1 666 0.75
2007 510 0.1 552 0.66
2008 540 0.1 530 0.62
2009 350 0.04 413 0.48
2010 318 0.04 359 0.41
2011 322 0.04 374 0.43
2012 265 0.03 296 0.34
2013 260 0.02 294 0.29
2014 187 0.02 227 0.2
2015 178 0.02 168 0.19
2016 138 0.02 153 0.15
2017 109 0.01 112 0.12
2018 96 0.01 77 0.1
Table 1. 
Prevalence and case detection in Vietnam (1983–2018).
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programme activities, such as service coverage, community awareness and the 
reporting system as well as sensitivity and specificity of diagnosis, the new case 
detection rate may not represent the true incidence and the degree of transmission 
of infection in the community.
3.2.3 Grade 2 disability proportion among new cases
Leprosy usually affects the skin and peripheral nerves. Visible disability, 
expressed as grade 2 disabilities, may be noted as the results of involvement damage 
of certain peripheral nerves [6, 7]. The proportion of grade 2 disabilities among 
new cases from 1983 to 2018 fluctuated a lot depending on the trend in case detec-
tion (see Figure 3). The highest rate was 40.82% in 1983 then decreased to 17.86% 
in 1993 (Table 2). The main cause may be related to shortening of timely diagnosis 
and treatment of cases, before nerve damage has occurred. Ensuring good treat-
ment compliance of patients also led to reduce the visible disability rate. This decline 
reflected the efficacy of leprosy control activities. The grade 2 disability proportion 
between 1994 and 1997 increased related to the intensive case-finding efforts that 
were carried out in this period. The projects including LECs, mini-LECs and SAPEL 
have detected a large number of backlog cases, most of whom could suffer severe 
deformities and disfigurements as a result of delayed diagnosis. Additionally, some 
of old patients re-registered as new cases especially those with disabilities that also 
contributed to increasing the grade 2 disability proportion among new cases. On 
the other side, the high stigma and low awareness about the disease in the society 
Figure 3. 
Proportion of grade 2 disability among new cases.
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Year Female Children under 15 years old MB cases
Number Proportion (%) Number Proportion (%) Number Proportion (%)
1983 612 30.28 169 8.59 811 40.10
1984 622 29.50 83 3.95 651 31.13
1985 504 24.40 141 7.84 804 39.10
1986 646 28.20 185 8.07 802 35.20
1987 642 29.40 157 7.21 1009 46.24
1988 509 27.60 141 7.63 738 39.60
1989 466 22.50 120 5.79 932 45.56
1990 463 23.20 130 6.52 798 39.40
1991 494 19.80 120 4.96 1075 43.40
1992 739 23.50 241 7.67 1413 45.50
1993 1114 35.00 231 7.25 1496 47.20
1994 872 27.50 151 4.76 2062 65.20
1995 926 35.70 222 9.57 1632 62.68
1996 1017 35.20 211 7.32 1807 63.70
1997 1011 36.00 159 6.66 1687 59.11
1998 803 37.10 162 6.49 1189 54.67
1999 676 37.70 124 6.91 1071 61.27
2000 571 38.70 105 7.11 905 62.00
2001 497 37.00 77 6.00 822 61.74
2002 437 37.74 65 5.61 715 62.17
2003 339 35.72 52 5.48 616 65.27
2004 322 37.53 47 5.48 570 66.59
2005 269 36.06 39 5.30 492 66.71
2006 245 36.79 35 5.26 443 66.80
2007 178 32.25 25 4.53 377 68.30
2008 202 38.11 18 3.40 378 71.32
2009 144 34.87 12 2.91 295 71.43
2010 98 27.30 14 3.90 259 72.14
2011 121 32.35 11 2.94 269 71.93
2012 105 35.47 10 3.38 191 64.53
2013 82 31.54 14 5.38 180 69.23
2014 66 35.29 7 3.74 153 81.82
2015 53 29.78 5 2.81 143 80.34
2016 39 28.26 4 2.90 115 83.33
2017 38 34.86 2 1.83 91 83.49
2018 24 25.00 0 0 89 92.71
Table 3. 
Proportions of female and children in MB patients among newly detected cases (1983–2018).
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have contributed to the delay in case detection that affected high grade 2 disability 
proportion. Fortunately, the rate decreased again and reached a level of 18.75% in 
2018 (Table 2). It requires that the healthcare system conduct retraining courses on 
leprosy at provincial, district and communal levels to sustain the effectiveness of the 
network of leprosy control programme for self-reporting and early treatment.
3.2.4 Female and children among new cases
The age-old stigma associated with the disease remains at least hundreds of 
years ago in Vietnam. The impact of stigmata attached to leprosy had effect not 
only on male but also on female and children [7]. Because of the fear of infecting 
the family members and being divorced, leprosy women were forced to be infertil-
ized and kept themselves aloof. In the past, the children who were born by parental 
leprosy were not allowed to attend or study with other “normal” children. Table 3 
shows that the distribution of sex and age leprosy patients among new cases was 
not stable. The proportion of female leprosy detected from 1983 to 2018 was around 
19.8–38% (Figure 4). This is convenient with other previous studies in some coun-
tries in the region such as Thailand, India and Myanmar [1, 2, 8–12].
Here the reported rate of children among new case detection decreased from 
169 in 1983 to under 10 cases since 2014 (Table 3). From 9.57% in 2000, there is 
no case observed in 2018 (Figure 4). This is a good signal and could be related to 
success in completing the subnational target at the end of the year 2000 in Vietnam. 
Some tests have been conducted to make prognosis in high-risk children group, 
such as gelatin particle agglutination test (GPAT). This measurement tool helped 
dermatologists to easily assess the transmission of the disease in the community. 
Tran Hau Khang et al. reported that children with GPAT positive at high titer of 
more than 1:64 and whose mother/father is a leprosy patient can be considered as 
the highest risk group developing the disease [13]. As a result, GPAT has proven its 
important role in early detection of leprosy in children. This could partially explain 
why the decrease of transmission of the disease led to the reduction in the propor-
tion of children among new cases.
Figure 4. 
Proportion of female and children among new cases.
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3.2.5 Multibacillary (MB) among new cases
The proportion of MB leprosy among new cases is an important indicator of the 
magnitude of a potential source of transmission and risk for complications includ-
ing reactions and neuritis that could lead to disabilities when not treated adequately. 
In Vietnam, there was the gradual elevation of MB patient rate among newly 
detected cases from 40.1% in 1983 to 47.2% in 1993. However, from 1994 onwards, 
the proportion increased significantly. More than 90% (92.71% in 2018) of new 
case detection were MB patients (Table 3). This could be explained by some factor, 
such as change in the criteria for classification and in the clinical presentations to 
some extent. Further studies in various countries in the long term are necessary to 
determine the relation between the operational and the epidemiological factors that 
are contributing to the increase in MB proportion.
4. Special leprosy projects
In order to enhance knowledge about leprosy which increases misconceptions 
about the disease’s transmission and treatment and to widen case-finding activi-
ties in certain areas, several special projects were carried out, such as SAPEL, 
LECs, mini-LECs and health educational campaigns. A total of 32 activities were 
implemented from 1991 to 1997 covering over 3 million inhabitants. It comprised 
8 LEC projects (1,100,200 populations), 6 SAPEL activities (872,000 individuals) 
and 18 other activities (1,030,000 people). The number of new cases detected was 
reported corresponding to these projects: 603, 154 and 663 cases [3, 7]. The total 
number of newly detected cases in 7 years (1991–1997) was 1420 related to these 
activities, corresponding to 7% out of total new cases in this period (20,282 cases). 
This reflected the effectiveness of the network of leprosy control programme. 
Besides that, the support of the Pacific Leprosy Foundation (PLF) as a partner 
member and the coordination meetings about leprosy activities that were held 
with government and local nongovernmental organizations (NGOs) assisted the 
strengthening of the national leprosy programmes in Vietnam. This ensured pro-
gramme sustainability by promoting integration within the general health system 
and also emphasized the need for building and maintaining effective partnerships 
to improve quality leprosy services and reduce further the disease burden due to 
leprosy.
5. Effectiveness of MDT in management of leprosy
Leprosy is a long-lasting infection caused by bacteria that can be eliminated 
by antibiotics. Early diagnosis and treatment of cases can prevent or minimize 
the onset of further disabilities related to complications, including reactions and 
neuritis [5, 6, 14–17]. MDT implementation began in 1985 in the Western Pacific 
Region. It reached 10% coverage in 1988. By 1994, almost 100% MDT coverage 
was reached [1, 2, 9, 14]. Development and implementation of MDT was the most 
important achievement in the history of leprosy control in which the introduction 
of a single-dose treatment regimen for single lesion and 1 year duration for MB 
leprosy has contributed a great benefit to leprosy patients by shortening of the 
required duration of MDT. One of the most essential components of the leprosy 
programme is also ensuring that all new patients who start MDT complete the full 
course of treatment within the prescribed period of time. A completed treatment 
patient means that a PB leprosy patient completes 6 monthly doses of PB-MDT 
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within 9 months and a MB leprosy patient completes 12 monthly doses of MB-MDT 
within 18 months [1, 2, 5, 6, 9, 14]. Vietnam was one of many countries selected as a 
centre to perform the clinical trial of treatment of leprosy with ofloxacin containing 
combined drug regimens [5]. Both PB and MB patients undergo six new multidrug 
regimens containing ofloxacin in comparison with the standard WHO/MDT. The 
efficacy, tolerance and adverse side effects were considered.
The patients were diagnosed and classified based on bacteriological and clinical 
manifestations. Both MB and PB patients were randomly allocated to six regimens 
from A to F. All were examined and followed by the health worker. Individuals 
were seen daily in the first month and monthly during 5 consecutive months for 
PB and 23 consecutive months for MB. At the end of treatment, they were assessed 
once every 6 months for clinical change or any symptom of relapse for at least 
10 years.
The results of this previous study showed that all patients treated with ofloxa-
cin-containing regimens have reached moderate to marked clinical and bacterial 
improvement. However, relapse rate was very high among patients treated with 
regimen combining ofloxacin and rifampicin daily for 1 month [5, 6]. Several 


























Number of patients who completed MDT (1995–2018).
Current Topics in Neglected Tropical Diseases
102
3.2.5 Multibacillary (MB) among new cases
The proportion of MB leprosy among new cases is an important indicator of the 
magnitude of a potential source of transmission and risk for complications includ-
ing reactions and neuritis that could lead to disabilities when not treated adequately. 
In Vietnam, there was the gradual elevation of MB patient rate among newly 
detected cases from 40.1% in 1983 to 47.2% in 1993. However, from 1994 onwards, 
the proportion increased significantly. More than 90% (92.71% in 2018) of new 
case detection were MB patients (Table 3). This could be explained by some factor, 
such as change in the criteria for classification and in the clinical presentations to 
some extent. Further studies in various countries in the long term are necessary to 
determine the relation between the operational and the epidemiological factors that 
are contributing to the increase in MB proportion.
4. Special leprosy projects
In order to enhance knowledge about leprosy which increases misconceptions 
about the disease’s transmission and treatment and to widen case-finding activi-
ties in certain areas, several special projects were carried out, such as SAPEL, 
LECs, mini-LECs and health educational campaigns. A total of 32 activities were 
implemented from 1991 to 1997 covering over 3 million inhabitants. It comprised 
8 LEC projects (1,100,200 populations), 6 SAPEL activities (872,000 individuals) 
and 18 other activities (1,030,000 people). The number of new cases detected was 
reported corresponding to these projects: 603, 154 and 663 cases [3, 7]. The total 
number of newly detected cases in 7 years (1991–1997) was 1420 related to these 
activities, corresponding to 7% out of total new cases in this period (20,282 cases). 
This reflected the effectiveness of the network of leprosy control programme. 
Besides that, the support of the Pacific Leprosy Foundation (PLF) as a partner 
member and the coordination meetings about leprosy activities that were held 
with government and local nongovernmental organizations (NGOs) assisted the 
strengthening of the national leprosy programmes in Vietnam. This ensured pro-
gramme sustainability by promoting integration within the general health system 
and also emphasized the need for building and maintaining effective partnerships 
to improve quality leprosy services and reduce further the disease burden due to 
leprosy.
5. Effectiveness of MDT in management of leprosy
Leprosy is a long-lasting infection caused by bacteria that can be eliminated 
by antibiotics. Early diagnosis and treatment of cases can prevent or minimize 
the onset of further disabilities related to complications, including reactions and 
neuritis [5, 6, 14–17]. MDT implementation began in 1985 in the Western Pacific 
Region. It reached 10% coverage in 1988. By 1994, almost 100% MDT coverage 
was reached [1, 2, 9, 14]. Development and implementation of MDT was the most 
important achievement in the history of leprosy control in which the introduction 
of a single-dose treatment regimen for single lesion and 1 year duration for MB 
leprosy has contributed a great benefit to leprosy patients by shortening of the 
required duration of MDT. One of the most essential components of the leprosy 
programme is also ensuring that all new patients who start MDT complete the full 
course of treatment within the prescribed period of time. A completed treatment 
patient means that a PB leprosy patient completes 6 monthly doses of PB-MDT 
103
Epidemiology of Leprosy in Vietnam and the Effectiveness of Multidrug Therapy (MDT)…
DOI: http://dx.doi.org/10.5772/intechopen.86971
within 9 months and a MB leprosy patient completes 12 monthly doses of MB-MDT 
within 18 months [1, 2, 5, 6, 9, 14]. Vietnam was one of many countries selected as a 
centre to perform the clinical trial of treatment of leprosy with ofloxacin containing 
combined drug regimens [5]. Both PB and MB patients undergo six new multidrug 
regimens containing ofloxacin in comparison with the standard WHO/MDT. The 
efficacy, tolerance and adverse side effects were considered.
The patients were diagnosed and classified based on bacteriological and clinical 
manifestations. Both MB and PB patients were randomly allocated to six regimens 
from A to F. All were examined and followed by the health worker. Individuals 
were seen daily in the first month and monthly during 5 consecutive months for 
PB and 23 consecutive months for MB. At the end of treatment, they were assessed 
once every 6 months for clinical change or any symptom of relapse for at least 
10 years.
The results of this previous study showed that all patients treated with ofloxa-
cin-containing regimens have reached moderate to marked clinical and bacterial 
improvement. However, relapse rate was very high among patients treated with 
regimen combining ofloxacin and rifampicin daily for 1 month [5, 6]. Several 


























Number of patients who completed MDT (1995–2018).
Current Topics in Neglected Tropical Diseases
104
adverse side effects were observed, including itch, erythema and vomit, all of which 
resolved quickly within 2–3 days. Only 1.7% developed erythroderma and required 
hospitalization [5, 6, 15–17]. With these results, ofloxacin has proven to be a power-
ful bactericidal drug against M. leprae. The introduction of MDT therapy contain-
ing Ofloxacin reduced the prevalence rate down to under 0.5% since 1998.
High rate of MB leprosy treatment completion was reported. Nearly 24,000 
patients implemented MDT with the completion rate of 100% from 2013 to 2018 
(112/112 detected cases treated with MDT in 2017, 77/77 in 2018) (see Tables 1 
and 4). It coincided with a continuous decline in the prevalence rate (see Figures 2 
and 5). These results represent the effectiveness of expending efforts of healthcare 
system form national to grassroot levels. With the financial aid of the government, 
NGOs and WHO, leprosy patients are treated free of charge with MDT at their own 
home and can pursue a job suitable to their health. There is lack of data of relapse 
case during the conduct of MDT therapy from 2000 until now and therefore, the 
effectiveness of MDT in the management of leprosy in Vietnam over the recent 
18 years could not exactly be concluded.
6. Conclusions
With the introduction of MDT in 1983 and the efficacy of leprosy programme 
activities, the epidemiology of leprosy in Vietnam has dramatically improved. 
Leprosy is becoming a part of skin neglected tropical diseases (NTDs), a diverse 
group of communicable diseases that prevail in tropical and subtropical countries, 
particularly in the easternmost country, Vietnam. At present, leprosy is one of 20 
diseases formally recognized as NTDs worldwide. However, three out of five main 
strategies given to combat NTDs are particularly for leprosy. This means that even 
though leprosy is considered to be eliminated, the health system including the 
Ministry of Health and the leading institute, NHDV, in Vietnam are still focusing on 
sustaining quality leprosy services. Nowadays, majority of the patients are now able 
Figure 5. 
Number of patients who completed MDT (1995–2018).
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to live normal lives in the community without being stigmatized and discriminated. 
MDT is still the cornerstone of the leprosy control programme in which the timely 
and regular supply of MDT and proper MDT drug management is very important 
in attaining the goal of sustaining quality leprosy services and further reducing 
the leprosy burden. Since 1995, the WHO has supplied MDT free of cost to leprosy 
patients in all endemic countries. Currently, with the efforts of leprosy network 
activities, all patients are receiving MDT free from local health facilities.
To maintain these great results, Vietnam set up the Vietnamese criteria for 
elimination of leprosy at subnational levels including province and district grade 
since 1997. From three criteria at the beginning, the Ministry of Health decided 
to set up to five criteria in 2002 [7], such as ensuring that the prevalent propor-
tion in 3 consecutive years is below 0.2 cases per 10,000 people, that the newly 
detected case rate is under 1 per 100,000 populations and also that the grade 
2 disability proportion among new cases is below 15% at the time of examina-
tion. The supply criteria were being added to ensure elevating the capacity of 
health staff worker. There was about 20% of total commune officers, who were 
randomly checked, who could correctly answer all the content of elimination of 
leprosy programme. In the future, all activities of the leprosy control programme 
need to be sustained at all levels, from the nation to the grassroot. With the 
introduction of the newly detected species of Mycobacterium, Mycobacterium 
lepromatosis, in both of MB and PB patients in Mexico in 2008, early detection 
of Mycobacterium which induces leprosy could be a challenge [18, 19]. Further 
serological tools and other tests on leprosy need to be developed in health ser-
vice to identify, sequence and detect genes responsible for drug resistance of 
Mycobacteria [20, 21]. In recent years, a few studies in development to investigate 
the feasibility of a uniform multidrug therapy (U-MDT) regimen for PB and MB 
patients, with a fixed duration of 6 months, were recommended at the WHO’s 
Technical Advisory Committee meeting in 2002 [22]. China, India, Bangladesh 
and Brazil were the first four countries performing U-MDT regimen [23–26]. The 
results showed that there was no statistical difference between the group that 
received WHO-MDT and those who received U-MDT and also in MB and or PB 
patients on the frequency of the first reaction occurrence, the mean reduction 
of BI and the recurrent rates [24–27]. However, in a controlled clinical study in 
India, from 2003 to 2005, it was observed that for MB patients, U-MDT regimen 
is not as effective as WHO-MDT with a 12-month duration [23]. Some difficulties 
related to the disease complexity, clinical trial development and in reproducing 
the in vitro findings in clinical practice are the obstacles to make the U-MDT 
regimen accessible to most patients. To this date, there is nothing in short period 
of time to replace MDT [28]. Recently, the recommendation of the WHO about 
the implementation of U-MDT among central strategies for leprosy control in 
the quadrennium 2017/2020 was published [29, 30]. In Vietnam, there was no 
controlled clinical study, comparing the efficacy of U-MDT and WHO-MDT for 
PB and MB patients. This advocates the need for new studies to access the effec-
tiveness of U-MDT or new therapeutical regimens in the treatment and manage-
ment of leprosy in the long term in Vietnam. Thenceforth, all endemic areas have 
the uniform regimen in the treatment and management of leprosy to sustain the 
disease in skin NTDs in the long run.
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Leprosy is becoming a part of skin neglected tropical diseases (NTDs), a diverse 
group of communicable diseases that prevail in tropical and subtropical countries, 
particularly in the easternmost country, Vietnam. At present, leprosy is one of 20 
diseases formally recognized as NTDs worldwide. However, three out of five main 
strategies given to combat NTDs are particularly for leprosy. This means that even 
though leprosy is considered to be eliminated, the health system including the 
Ministry of Health and the leading institute, NHDV, in Vietnam are still focusing on 
sustaining quality leprosy services. Nowadays, majority of the patients are now able 
Figure 5. 
Number of patients who completed MDT (1995–2018).
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to live normal lives in the community without being stigmatized and discriminated. 
MDT is still the cornerstone of the leprosy control programme in which the timely 
and regular supply of MDT and proper MDT drug management is very important 
in attaining the goal of sustaining quality leprosy services and further reducing 
the leprosy burden. Since 1995, the WHO has supplied MDT free of cost to leprosy 
patients in all endemic countries. Currently, with the efforts of leprosy network 
activities, all patients are receiving MDT free from local health facilities.
To maintain these great results, Vietnam set up the Vietnamese criteria for 
elimination of leprosy at subnational levels including province and district grade 
since 1997. From three criteria at the beginning, the Ministry of Health decided 
to set up to five criteria in 2002 [7], such as ensuring that the prevalent propor-
tion in 3 consecutive years is below 0.2 cases per 10,000 people, that the newly 
detected case rate is under 1 per 100,000 populations and also that the grade 
2 disability proportion among new cases is below 15% at the time of examina-
tion. The supply criteria were being added to ensure elevating the capacity of 
health staff worker. There was about 20% of total commune officers, who were 
randomly checked, who could correctly answer all the content of elimination of 
leprosy programme. In the future, all activities of the leprosy control programme 
need to be sustained at all levels, from the nation to the grassroot. With the 
introduction of the newly detected species of Mycobacterium, Mycobacterium 
lepromatosis, in both of MB and PB patients in Mexico in 2008, early detection 
of Mycobacterium which induces leprosy could be a challenge [18, 19]. Further 
serological tools and other tests on leprosy need to be developed in health ser-
vice to identify, sequence and detect genes responsible for drug resistance of 
Mycobacteria [20, 21]. In recent years, a few studies in development to investigate 
the feasibility of a uniform multidrug therapy (U-MDT) regimen for PB and MB 
patients, with a fixed duration of 6 months, were recommended at the WHO’s 
Technical Advisory Committee meeting in 2002 [22]. China, India, Bangladesh 
and Brazil were the first four countries performing U-MDT regimen [23–26]. The 
results showed that there was no statistical difference between the group that 
received WHO-MDT and those who received U-MDT and also in MB and or PB 
patients on the frequency of the first reaction occurrence, the mean reduction 
of BI and the recurrent rates [24–27]. However, in a controlled clinical study in 
India, from 2003 to 2005, it was observed that for MB patients, U-MDT regimen 
is not as effective as WHO-MDT with a 12-month duration [23]. Some difficulties 
related to the disease complexity, clinical trial development and in reproducing 
the in vitro findings in clinical practice are the obstacles to make the U-MDT 
regimen accessible to most patients. To this date, there is nothing in short period 
of time to replace MDT [28]. Recently, the recommendation of the WHO about 
the implementation of U-MDT among central strategies for leprosy control in 
the quadrennium 2017/2020 was published [29, 30]. In Vietnam, there was no 
controlled clinical study, comparing the efficacy of U-MDT and WHO-MDT for 
PB and MB patients. This advocates the need for new studies to access the effec-
tiveness of U-MDT or new therapeutical regimens in the treatment and manage-
ment of leprosy in the long term in Vietnam. Thenceforth, all endemic areas have 
the uniform regimen in the treatment and management of leprosy to sustain the 
disease in skin NTDs in the long run.
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Abstract
Reconstructive surgery (RCS) has made a significant improvement in deformi-
ties and disabilities management among leprosy patients. However, it seems that 
due to existing misconceptions that is hereditary and not curable regarding leprosy 
still lead to concealing the disease, therefore the patients hesitate and unenthu-
siastic to avail these facilities. This study was carried out in Sonepur district of 
Odisha with 60 RCS has undertaken leprosy patients. Out of 71 operative patients 
during 2000–2012, only 60 patients were alive and interviewed, in this study 
entire universe was used without any sampling. A semi-structured questionnaire 
was administered to assess their understanding, better quality of life (QOL) after 
reconstructive surgery. Nearly, 98.6% could meet their expectations to some extent, 
another 1.6% failed to get their expectations. Among all the RCS patients only 
33.3% changed their profession to avoid further risk in their life after surgery. This 
study concludes that Reconstructive surgery plays a vital role to bring for leprosy 
patients into their normal life and lead their life in this open society of today. The 
result implies a motivational message for the deformed leprosy patients to come 
forward and depicts to encourage the surgeons to counsel the patients towards 
reconstructive surgery, which will reduce stigma in due course.
Keywords: leprosy, stigma, RCS, QOL, knowledge, acceptance
1. Introduction
Leprosy is a chronic infectious disease caused by Mycobacterium leprae (M. leprae). 
It is a micro-organism which has a predilection for soft tissues of a human organism 
like skin and nerve. Now leprosy is known as a common cause of non-traumatic 
peripheral neuropathy worldwide [1]. This Mycobacterium leprae, the causative agent 
of leprosy, was first discovered by Hansen in 1873. Therefore leprosy is also known 
as Hansen’s disease and considering it the first bacterium to be identified as causing 
disease in human [2].
The transmission of Mycobacterium leprae always occurs through upper airways 
and manifested as skin lesions with reducing sensation including nodule, pigmenta-
tion, and patches on some portion of the body. These lesions can affect any part 
of the body as a nasal bridge and oral cavity [3]. The above said causative agent of 
leprosy, Mycobacterium bacillus, is associated with a prolonged incubation period 
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of leprosy, was first discovered by Hansen in 1873. Therefore leprosy is also known 
as Hansen’s disease and considering it the first bacterium to be identified as causing 
disease in human [2].
The transmission of Mycobacterium leprae always occurs through upper airways 
and manifested as skin lesions with reducing sensation including nodule, pigmenta-
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of the body as a nasal bridge and oral cavity [3]. The above said causative agent of 
leprosy, Mycobacterium bacillus, is associated with a prolonged incubation period 
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between initial infection and development of skin reactions. The incubation period 
of leprosy is 5–10 years but it hardly takes 20 years to have appeared as skin patches, 
deformities, and disabilities [4].
The extent of social stigma aggravates due to the blind believe or the misconcep-
tion that leprosy is not curable and is hereditary. The crippled limbs (finger and 
feet) add fuel to fire of social stigma.
Reconstructive surgery to correct deformities in leprosy has made dramatic and 
revolutionary changes in the lives of affected patients [5, 6]. Nevertheless, leprosy 
patients are still hesitating to avail these benefits of reconstructive surgery due to 
many reasons [7]. The existing reasons associated with leprosy lead to take delay 
treatment and concealment of disease in society.
Since history, the misconceptions about leprosy being a hereditary disease, lead 
to increase the level of stigma related to death and mutilation due to its existing 
attributed causes like deformity and disability. This misconception also leads to 
prejudice, discrimination and social exclusion which are resulting in infliction of 
congenital suffering on leprosy patients, which can have serious repercussions in 
their personal and professional lives [8].
Government integrated Reconstructive surgery unit in the health care system 
to reduce stigma, which caused due to misconceptions, and to eliminate leprosy 
burden in different states of our country with the help of PPP (Public-private 
partnership) program including Government and non-government organizations 
Contemporary to Govt. The non-government organization has put more efforts. 
NGOs had handled 1076 surgery cases whereas Government hospitals had done 921. 
Maharastra has performed a better result in comparison to other states with 495 
RCS by both Government and NGO. The recorded data on Reconstructive surgery 
has been given below (Table 1).
Table 1 shows that among 35 states all across India, Maharastra has performed 
well at both Government and NGO level, i.e., 39 and 456. Next to Andhra Pradesh 
NGO has performed 487 RCS. In Madhya Pradesh, the government has done 122, 
whereas 91 was performed by NGO. Similarly, Odisha has performed very nicely 
in Government level, i.e., 248 RCS in 2013–2014 and Chhattisgarh has performed 
as well in same Government level with 234 RCS than 5 in NGO. In NGO level the 
performance of RCS is far better than Government. In Uttar Pradesh, 235 RCS has 
carried out in NGO and 33 in Govt level. But some states have not performed sat-
isfactorily in both. Thus, it gives an idea of RCS (1786) has been well performed 
in NGO level.
1.1 State
The present research has been conducted in Odisha, consists of 30 districts. 
Among these districts, seven designated surgical units have been inaugurated in 
few districts for leprosy RCS. These districts are Berhampur, Dhenkanal, Koraput, 
Sonepur, and Cuttack, etc. In Odisha 10 government institution and 5 NGOs have 
been recognized for performing RCS. In Odisha, the number of Reconstructive 
Surgery performed by the Government is 262 in 2012–2013, 248 in 2013–2014 and 
307 in 2014–2015 (end of March) whereas NGO has not performed any RCS.
Figure 1 the NGO-LEPRA Institutional Based Rehabilitation (IBR) is working 
tirelessly on post rehabilitation of RCS patients and provides free footwear and skill 
development training. The health staffs of this IBR have taken endeavour to aware 
the people about the system for early diagnosis and available Government facilities 
for leper patients.
In Odisha many studies have been conducted on leprosy, its stigma and how 
does it affect man and women, its community perception and knowledge about its 
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Sl. no State Inst. recognized for RCS RCS performed
Govt. NGO Govt. NGO
1 Andhra Pradesh 1 9 0 487
2 Arunachal Pradesh 0 0 0 0
3 Assam 1 1 0 16
4 Bihar 2 2 21 64
5 Chhattisgarh 1 2 234 5
6 Goa 1 0 0 0
7 Gujrat 3 0 136 0
8 Haryana 1 0 0 0
9 Himachal Pradesh 0 0 0 0
10 Jharkhand 2 3 10 47
11 Jammu & Kashmir 0 0 0 0
12 Karnataka 5 4 34 106
13 Kerala 0 2 0 0
14 Madhya Pradesh 2 1 122 91
15 Maharastra 9 8 39 456
16 Manipur 1 0 0 0
17 Meghalaya 0 0 0 0
18 Mizoram 0 0 0 0
19 Nagaland 0 0 0 0
20 Odisha 10 5 248 0
21 Punjab 0 0 0 0
22 Rajasthan 1 0 2 0
23 Sikkim 1 0 1 0
24 Tamilnadu 2 8 1 106
25 Tripura 0 0 0 0
26 Uttar Pradesh 3 2 33 235
27 Uttarakhand 1 0 15 0
28 West Bengal 9 2 18 90
29 A&N Island 0 0 0 0
30 Chandigarh 1 0 0 0
31 D&N Haveli 0 0 0 0
32 Daman and Diu 0 0 0 0
33 Delhi 2 2 5 83
34 Lakshadweep 0 0 0 0
35 Pondicherry 1 0 2 0
Total 60 51 921 1786
No. of RCS performed in different states of India 2013–2014 (NLEP progress report on 2013–2014, dt.26/8/2015) [9].
Table 1. 
Institutes and No. of RCS cases operated state wise.
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between initial infection and development of skin reactions. The incubation period 
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tion that leprosy is not curable and is hereditary. The crippled limbs (finger and 
feet) add fuel to fire of social stigma.
Reconstructive surgery to correct deformities in leprosy has made dramatic and 
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many reasons [7]. The existing reasons associated with leprosy lead to take delay 
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Since history, the misconceptions about leprosy being a hereditary disease, lead 
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to reduce stigma, which caused due to misconceptions, and to eliminate leprosy 
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in NGO level.
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The present research has been conducted in Odisha, consists of 30 districts. 
Among these districts, seven designated surgical units have been inaugurated in 
few districts for leprosy RCS. These districts are Berhampur, Dhenkanal, Koraput, 
Sonepur, and Cuttack, etc. In Odisha 10 government institution and 5 NGOs have 
been recognized for performing RCS. In Odisha, the number of Reconstructive 
Surgery performed by the Government is 262 in 2012–2013, 248 in 2013–2014 and 
307 in 2014–2015 (end of March) whereas NGO has not performed any RCS.
Figure 1 the NGO-LEPRA Institutional Based Rehabilitation (IBR) is working 
tirelessly on post rehabilitation of RCS patients and provides free footwear and skill 
development training. The health staffs of this IBR have taken endeavour to aware 
the people about the system for early diagnosis and available Government facilities 
for leper patients.
In Odisha many studies have been conducted on leprosy, its stigma and how 
does it affect man and women, its community perception and knowledge about its 
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Sl. no State Inst. recognized for RCS RCS performed
Govt. NGO Govt. NGO
1 Andhra Pradesh 1 9 0 487
2 Arunachal Pradesh 0 0 0 0
3 Assam 1 1 0 16
4 Bihar 2 2 21 64
5 Chhattisgarh 1 2 234 5
6 Goa 1 0 0 0
7 Gujrat 3 0 136 0
8 Haryana 1 0 0 0
9 Himachal Pradesh 0 0 0 0
10 Jharkhand 2 3 10 47
11 Jammu & Kashmir 0 0 0 0
12 Karnataka 5 4 34 106
13 Kerala 0 2 0 0
14 Madhya Pradesh 2 1 122 91
15 Maharastra 9 8 39 456
16 Manipur 1 0 0 0
17 Meghalaya 0 0 0 0
18 Mizoram 0 0 0 0
19 Nagaland 0 0 0 0
20 Odisha 10 5 248 0
21 Punjab 0 0 0 0
22 Rajasthan 1 0 2 0
23 Sikkim 1 0 1 0
24 Tamilnadu 2 8 1 106
25 Tripura 0 0 0 0
26 Uttar Pradesh 3 2 33 235
27 Uttarakhand 1 0 15 0
28 West Bengal 9 2 18 90
29 A&N Island 0 0 0 0
30 Chandigarh 1 0 0 0
31 D&N Haveli 0 0 0 0
32 Daman and Diu 0 0 0 0
33 Delhi 2 2 5 83
34 Lakshadweep 0 0 0 0
35 Pondicherry 1 0 2 0
Total 60 51 921 1786
No. of RCS performed in different states of India 2013–2014 (NLEP progress report on 2013–2014, dt.26/8/2015) [9].
Table 1. 
Institutes and No. of RCS cases operated state wise.
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treatment, etc. But no literature is available on patients’ perception after surgery. 
So the intention of this work is to explore the patients’ perception regarding post 
RCS and its consequences. This study is conducted in Sonepur district of Odisha; 
the LEPRA society office at Sonepur has a rehabilitation center for leprosy patients. 
They did help me in getting the old patients contacts.
The aim of this study is to assess the patients’ socio-psychological condition and 
their acceptance in society after reconstructive surgery.
Figure 2 depicts about the lepers of Kustha Ashram in Sonepur district, Odisha. 
It has been established in the year 2001 by the Government to facilitate the isolated 
deformed and disability lepers from society. Government supports the patients to 
rehabilitate them by supplying footwear, cloth, food along with pay pension, widow 
pension and compensation for surgery who have undergone for RCS.
2. Methodology
The study area was selected according to the highest prevalence and annual case 
detection rate of leprosy in Odisha. In the year 2009–2010, the highest ANCDR 
was 41.7% of Sonepur district in comparison to another endemic zone of Odisha. 
During this study, the record of surgery patients reported that 71 had undergone for 
surgery of six different blocks of Sonepur district. Out of these RCS patients list, 
only 60 RCS patients were alive and included in this study, which is the universe 
Figure 1. 
An IBR of lepers at Sonepur.
Figure 2. 
Lepers at Kustha ashram.
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sample of this study area. In this work above age 60+ and below 15 year leprosy 
patients, non-RCS patients in leprosy were excluded. This study was conducted in 
three phases like pilot study, main field work-1, and main fieldwork-2.
In Pilot study, which was conducted for 4 weeks to interact with patients, health 
staffs like MO, DLO and Paramedical health staffs who were working in leprosy. A 
semi-structured questionnaire was developed and examined various tools for the 
assessment of RCS patients. In the first phase of the main fieldwork, data pertaining 
to the demographic profile of the patients and their household and the quality of 
life were gathered from reconstructive surgery leprosy patients.
In the second phase of the main fieldwork, data pertaining to social and psy-
chological consequences were gathered from leprosy patients and interaction with 
their caregivers and family members is carried out. Then a number of case studies 
with leprosy patients, two rounds of focus group discussion (FGD) with different 
stakeholders such as, patients, family members, and health staff were collected 
from all six blocks of Sonepur district which were hectic.
Limitation of this study was following the subject participants at their place 
of residence or was a daunting task as they were dispersed in the wide area of six 
blocks. To some extent, it became a limitation due to inadequate time and inconve-
nient traveling to communicate the patients, their respective family members and 
the varied socio-cultural set-ups where they are living.
3. Result
3.1 Patients selection
All the Reconstructive surgery patients of Sonepur district were selected for the 
purpose of this study. It was reported that 71 patients had surgery but only 60 could 
be interviewed and others were migrated/died. All the patients were dispersed in six 
blocks of this above-said district.
Table 2 represents the effect of RCS among the undergone surgery patients. 
Deformities were observed in both hand and feet of the registered RCS patients. 
Before surgery, 48.3% had deformities in their hands and needed full assistance but 
after surgery, only 18.3% required help from others. Out of 60 RCS patients, 54% 
had hand deformities but some extent they could manage their work. In the third 
parameter, after surgery, 96.6% did not need the assistance of anyone. Similarly, in 
feet deformities only 10% required full assistance after surgery and 93.3% need no 
assistance. This above table reveals that RCS enables a patient to perform all activi-
ties of hand and feet independently.
Current Topics in Neglected Tropical Diseases
112
treatment, etc. But no literature is available on patients’ perception after surgery. 
So the intention of this work is to explore the patients’ perception regarding post 
RCS and its consequences. This study is conducted in Sonepur district of Odisha; 
the LEPRA society office at Sonepur has a rehabilitation center for leprosy patients. 
They did help me in getting the old patients contacts.
The aim of this study is to assess the patients’ socio-psychological condition and 
their acceptance in society after reconstructive surgery.
Figure 2 depicts about the lepers of Kustha Ashram in Sonepur district, Odisha. 
It has been established in the year 2001 by the Government to facilitate the isolated 
deformed and disability lepers from society. Government supports the patients to 
rehabilitate them by supplying footwear, cloth, food along with pay pension, widow 
pension and compensation for surgery who have undergone for RCS.
2. Methodology
The study area was selected according to the highest prevalence and annual case 
detection rate of leprosy in Odisha. In the year 2009–2010, the highest ANCDR 
was 41.7% of Sonepur district in comparison to another endemic zone of Odisha. 
During this study, the record of surgery patients reported that 71 had undergone for 
surgery of six different blocks of Sonepur district. Out of these RCS patients list, 
only 60 RCS patients were alive and included in this study, which is the universe 
Figure 1. 
An IBR of lepers at Sonepur.
Figure 2. 
Lepers at Kustha ashram.
113
Impact of Reconstructive Surgery (RCS) among Leprosy Patients: A Social Appraisal
DOI: http://dx.doi.org/10.5772/intechopen.86973
sample of this study area. In this work above age 60+ and below 15 year leprosy 
patients, non-RCS patients in leprosy were excluded. This study was conducted in 
three phases like pilot study, main field work-1, and main fieldwork-2.
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staffs like MO, DLO and Paramedical health staffs who were working in leprosy. A 
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chological consequences were gathered from leprosy patients and interaction with 
their caregivers and family members is carried out. Then a number of case studies 
with leprosy patients, two rounds of focus group discussion (FGD) with different 
stakeholders such as, patients, family members, and health staff were collected 
from all six blocks of Sonepur district which were hectic.
Limitation of this study was following the subject participants at their place 
of residence or was a daunting task as they were dispersed in the wide area of six 
blocks. To some extent, it became a limitation due to inadequate time and inconve-
nient traveling to communicate the patients, their respective family members and 
the varied socio-cultural set-ups where they are living.
3. Result
3.1 Patients selection
All the Reconstructive surgery patients of Sonepur district were selected for the 
purpose of this study. It was reported that 71 patients had surgery but only 60 could 
be interviewed and others were migrated/died. All the patients were dispersed in six 
blocks of this above-said district.
Table 2 represents the effect of RCS among the undergone surgery patients. 
Deformities were observed in both hand and feet of the registered RCS patients. 
Before surgery, 48.3% had deformities in their hands and needed full assistance but 
after surgery, only 18.3% required help from others. Out of 60 RCS patients, 54% 
had hand deformities but some extent they could manage their work. In the third 
parameter, after surgery, 96.6% did not need the assistance of anyone. Similarly, in 
feet deformities only 10% required full assistance after surgery and 93.3% need no 
assistance. This above table reveals that RCS enables a patient to perform all activi-
ties of hand and feet independently.
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Table 3 elaborates on the satisfaction of the patients with society as a whole 
pre RCS. It gives data about the satisfaction level obtained from family members, 
friends, relatives, society and their over-all life.
In the case of the family, none of the patients are very satisfied with the accep-
tance of their family members. Out of 60 patients, 54, i.e., 90%, were partially 
satisfied with the behavior and acceptance of their family members in pre RCS. Six 
patients, i.e., 10%, were dissatisfied with their family members pre RCS.
In the case of friends only one, i.e., 1.6% patient found to be very satisfied 
with the acceptance of his friend before RCS. Forty-nine patients, i.e., 81.6% were 
partially satisfied by the acceptance of friends. Ten patients, i.e., 16.6% were fully 
dissatisfied by the behavior of their friends pre RCS.
Only one patient (1.6%) is fully satisfied with the acceptance of relatives before 
RCS. Eighty percent, i.e., 48 patients out of 60 were partially satisfied with the 
relatives before RCS, 11 patients, i.e., 18.3% were fully dissatisfied with the behavior 
of the relatives with them pre RCS.
If we take society as a whole, only one patient, i.e., 1.6% was fully satisfied with 
the society pre RCS stage. Forty-two patients, i.e., 70% were partially satisfied 
with the society before RCS. Seventeen patients, i.e., 28.3% were fully dissatisfied 
with the society before RCS.
The disease is such that no one can be satisfied with overall life. Only one 
patient, i.e., 1.6% was in spite of the disease fully satisfied with his overall life. 
Sixteen patients, i.e., 26.6% are partially satisfied with overall life. Forty-three 
patients, i.e., 71.6% are fully dissatisfied with their overall life.







1 How satisfied are you with your 
acceptance by family
0 (0) 54 (90) 6 (10)
2 How satisfied are you with your 
acceptance by friends
1 (1.60) 49(81.60) 10 (16.6)
3 How satisfied are you with your 
acceptance by relatives
1 (1.60) 48 (80) 11 (18.3)
4 How satisfied are you with your 
acceptance by society
1 (1.60) 42 (70) 17 (28.3)
5 How satisfied about your overall life 1 (1.60) 16 (26.6) 43 (71.6)
Table 3. 
Quality of social relation and support of pre RCS patients.
Deformities occurred body organ Parameters Before (%) After (%)
Hand Full assistance 29 (48.3) 11 (18.3)
Some assistance 54 (90) 18 (30)
No assistance 20 (33.3) 58 (96.6)
Feet Full assistance 12 (20) 06 (10)
Some assistance 19 (31.6) 04 (6.6)
No assistance 54 (90) 56 (93.3)
Table 2. 
Quality of life of pre and post RCS patients.
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Table 4 presents the result of Post RCS acceptance and support. Almost 86% 
of patients are very satisfied with the acceptance of their family, friend, relatives, 
and society. But 47 (78.3%) patients showed their satisfaction on overall life. 
After surgery among all the criteria of acceptance, 20% replied they are partially 
satisfied upon their life which is greater than other cases. In other cases, only 
11–13% of patients answered they feel less satisfied. A very negligible percentage 
of patients have been counted in the dissatisfy column. Thus, Table 4 shows bet-
ter result and improvement in the patient’s life after reconstructive surgery when 
compared to Table 3.
Table 5 and Figure 3 depict that after surgery among the 60 reconstructive 
surgery patients only 20 (33.3%) patients had changed their profession as they 
still had little loss of sensation in hand and feet and so they preferred a profes-
sion which needed less movement and it was flexible for them to adopt. After 
surgery patients were suggested to take rest for 6 months and go to work only 
after complete healing. So only 40 patients could prefer their same old profes-
sion presently people believe that absence of deformity is the only concern of 
society for an individual to lead his/her life as a normal being. Many research 
work on leprosy stated that deformity is creating a social stigma against this 
disease in society. So after surgery, it is proved that “no deformity is equal to 
no stigma.” RCS has given a great effort to reduce the pressure of social stigma 
from society.
3.2 Economic status
Figure 4 describes the economic status of the patients after and before the 
RCS. Before RCS 35% of patients’ income was below Rs. 1000 but however, in 
post RCS it is found that only 21.6% of patients income was below Rs. 1000. 
Similarly, the income of 60% was between Rs. 1000 and 5000 in Pre RCS but it 
increased to 66.6% in post RCS. 8.3% of patients’ had earned Rs. 6000–10,000 
which was only 5% in patients before surgery. In post RCS only 3.3% patient 
could get above Rs. 10,000 but in Pre-surgery, no one was capable to earn this 
much amount. So it is concluded that RCS has helped the patients to earn more 
than what they earned before RCS and the economic status of the patients has 
improved to a great level. The highest number of patients are earning a minimum 
amount between Rs. 1000 and 5000 because most of the patients belong to the 
farming profession.







1 How satisfied are you with your 
acceptance by family
51 (85) 8 (13.30) 1 (1.60)
2 How satisfied are you with your 
acceptance by friends
52 (86.60) 6 (10) 2 (3.30)
3 How satisfied are you with your 
acceptance by relatives
52 (86.60) 6 (10) 2 (3.30)
4 How satisfied are you with your 
acceptance by society
51 (85) 7 (11.60) 2 (3.30)
5 How satisfied about your overall life 47 (78.30) 12 (20) 1 (1.60)
Table 4. 
Impact of RCS on social relationship and support of post RCS patients.
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Table 4 presents the result of Post RCS acceptance and support. Almost 86% 
of patients are very satisfied with the acceptance of their family, friend, relatives, 
and society. But 47 (78.3%) patients showed their satisfaction on overall life. 
After surgery among all the criteria of acceptance, 20% replied they are partially 
satisfied upon their life which is greater than other cases. In other cases, only 
11–13% of patients answered they feel less satisfied. A very negligible percentage 
of patients have been counted in the dissatisfy column. Thus, Table 4 shows bet-
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Serial number Change in occupation Number of patients (%)
1 Farming 6 (10)
2 Business 3 (5)
3 Job 4 (6.6)
4 Others 7 (11.7)
Total 20 (33.3)
Table 5. 
Incidence of RCS patients changing profession.
4. Discussion
The purpose of the study is to assess the quality of life for those who had under-
gone RCS with leprosy. The overall result shows that after reconstructive surgery 
performance of patients have improved due to better mobility of limbs. 96.6% 
reported that they do not need others to support to meet their expectations. This 
result is comparable with the similar study of John in which he explained more 
than 50% patients said that after correction of deformities they could meet their 
Figure 3. 
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expectations [10], subjectively assessed, 85% and above were satisfied with their 
social acceptance with respect to family, relatives, and peers, 13% were partially 
satisfied and 2% were dissatisfied. These results were corroborating with that of 
Ebenezer et al.’s study [11]. Similarly, Virmond and Palande stated that RCS has 
undergone patients’ income and acceptance which was reduced to a great extent 
before disease, again regained. Therefore, they opined that early correction of 
disabilities prevents dehabilitation [12]. When it was discussed in regard to depres-
sion and anxiety of leprosy patients, a psychological study of Ramanathan et al. 
explained that 25 randomly selected patients undergoing corrective surgical proce-
dure for their disabilities and deformities, high anxiety and depression levels were 
found preoperatively and in contrast to the result of the present study only 40% 
could meet their expectations [13]. After interaction with all the RCS patients, it 
was observed that they followed the doctor’s advice for 6 months complete rest and 
avoided to lift heavy materials. This had helped them for complete recovery and no 
complications for which the satisfaction level is high 85%. If we discuss about the 
gender difference in the impact of leprosy; women with leprosy are more vulnerable 
than men in respect to all aspects like relationship, acceptance and workability. This 
study observed that 6.6% women were separated, rejected and avoided by their 
family and community members. These similar findings were observed in Mull 
et al. study which was conducted in Karachi. They reported that the proportion of 
diagnosed male with leprosy were high than female. They observed that women 
were not forewarned about MDT regimens and it might have been due to practice 
of purdah and lack of female health worker [14]. In addition, Naik et al. explained 
that women faced more domestic violence and deprived from personal contacts 
with others [15]. Similarly, Carol et al. and Janna et al. reported that women are 
more vulnerable because they were derived from personal contact with their family 
as well as community. Even they observed that women were more sufferers from 
rejection and isolation [16, 17]. Besides, according to psychological domain, Oliveira 
and Romanelli reported that female leprosy patients tend to neglected themselves, 
that the fear of abandonment, stigma and they are concerned about their appear-
ance [18]. In addition Mankar et al. measured the QOL for the sexes and found it 
relatively higher impact of leprosy on women than the control leprosy patients [19]. 
Thus deformity and disabilities among patients made them to deprive from work 
activities. Another study of Natasja et al. explained that comparison of SLASA scale 
assessment on limitation of activities of the patients after 1 year it revealed that 
those had reconstructive surgery showed a significant improvement in their activi-
ties but there was no significant change found among them who declined RCS. Thus, 
concluded that reconstructive surgery has a beneficial effect on the functioning of 
limbs [20]. This present study result showed that due to the avoidance of further 
difficulties in their life only 33% changed their profession. It was earlier stated by 
Dharmendra that, “the beggar problem is a difficult one in India as the money and 
institutions needed for them are not available” [21]. Thus, it has been reported that 
in many studies: begging is the ideal profession of leprosy patients. One of these 
papers of Harvinder and Brakel, they specified that isolation and prohibition of the 
patients make them incapable to do any profession for their livelihood. Therefore, 
they choose to beg as their profession and stick to it till the end of their life [22]. If 
we consider the income of surgery patients before RCS they faced problem due to 
their deformities and lost strength to continue their work. Thus their socioeconomic 
status is categorized as per SES scale of Kuppuswamy into five groups. Sixty percent 
were earning Rs. 1000–5000 and no one was getting 10,000. After surgery 3.3% are 
earning more than 10,000 and <5 people were in <1000 and rest was in the bracket 
of Rs. 6000–10,000 with SES scale. This suggests that RCS brought an economic 
upliftment, which gave them social status and security. ($ = 70.30/− and £ = 90.39).
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they choose to beg as their profession and stick to it till the end of their life [22]. If 
we consider the income of surgery patients before RCS they faced problem due to 
their deformities and lost strength to continue their work. Thus their socioeconomic 
status is categorized as per SES scale of Kuppuswamy into five groups. Sixty percent 
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5. Conclusion
Reconstructive surgery (RCS) had revealed the visible impact among the leprosy 
patients. This study concludes that patients who had undergone RCS have improved 
quality of life when compare to their past experience before RCS and with those 
who are still concealing the deformities and disabilities without availing the RCS 
facilities due to social stigma. It may be noted that in case of leprosy the self-stigma 
dominates among all leprosy patients. This needs a proper counseling at family 
level to understand the disease, its curability nature and that is not a hereditary 
by nature. This study reports that post RCS acceptance by society and the level of 
quality of overall life has improved to 78.3% from 1.6% in pre-surgery. Similarly, the 
performance of limbs in post RCS is very satisfactory, i.e., 96.6% in hand and 93.3% 
in foot mobility.
The findings of this present work will hopefully could motivate the hidden 
and concealed cases to come forward and avail the free surgery RCS in designated 
centers. In turn, the surgeons would also be encouraged for their great effort which 
could reduce social stigma among these leprosy patients. It will also help to dispel 
the misconception about disease and create awareness about diagnosis and treat-
ment. Thus, RCS reduces the social stigma in a significant way.
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Abstract
The worldwide prevalence of the neglected tropical diseases (NTD) shows the 
diseases are affecting more than 1 billion. The burden of the Neglected tropical 
diseases cost to developing, the burden of the diseases cost to developing economies 
billions of dollars every year. The genomic research in the last decades providing a 
full sequence (some currently in the sequencing pipeline) of genomes of many of the 
organisms including those which are responsible of neglected tropical diseases, may 
help in the management of such diseases. With the human genome being sequenced, 
the understanding of the genomic interaction between human and NTD pathogen 
enable scientists to develop new strategies to prevent and treat these devastating 
diseases. In this context of genomic era, African scientists may interestingly play 
an insider role in order to be part of the history of the elimination of these diseases. 
However, a critical mass of African scientists in genomic area constitutes the first 
step toward this long way in struggle against NTD. Although the challenge is enor-
mous, it is very important to recognize that some African countries and institutions 
are fully committed to develop and strengthen African leadership in genomic area, 
while some are conspicuously absent from this debate. Joining African competences 
and leadership through collaborative activities and moving forward remains the next 
challenge to really impact the control and elimination of the NTD.
Keywords: NTD, genomic, scientists, elimination, Africa
1. Introduction
The neglected tropical diseases (NTDs) are known as a group of bacterial, 
parasitic, viral, and fungal infections strongly associated with poverty with an 
increase overlapping in tropical areas. They occurred particularly in areas affected 
by socioeconomic progress and unfortunately combined with other factors such 
as limited access to safe water and sanitation, chronic hunger, and also in areas 
where vector-transmitted diseases are more frequent. According to the World Bank 
Study, Sub-Saharan Africa population represents the major focus for the NTDs [1] 
and as mentioned from the 2010 Global Burden of Disease Study, NTDs accounted 
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for more than 26 million [2]. Most of the NTDs are well known as ancient diseases 
resulting in humanity concerns for centuries [3]. From the 2020 Roadmap, 20 
NTDs were identified as following: Buruli ulcer, Chagas disease, cysticercosis/
taeniasis, dengue fever, dracunculiasis (guinea worm disease), echinococcosis, 
food-borne trematodiasis, human African trypanosomiasis (HAT) (sleeping sick-
ness), leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis (river blindness), 
rabies, schistosomiasis, soil-transmitted helminthiasis (ascariasis, hookworm, and 
trichuriasis), trachoma, and yaws [4]. The World Health Organization classified 
the NTDs into two mains groups: in one hand the preventive chemotherapy and 
transmission control (PCT) NTDs including prominently lymphatic filariasis, 
onchocerciasis, schistosomiasis, and soil-transmitted helminthiasis while the inno-
vative and intensified disease management (IDM) on the other hand is constitute 
with Buruli ulcer, Chagas disease, human African trypanosomiasis, and leishmani-
asis disease that are currently lack suitable tools for large scale use [5]. NTDs remain 
as a public health problem for poor populations living in tropical environments and 
difficult-to-access areas with more than 40% of impacted people living in the WHO 
African Region. The challenge is as much as important to justify the development of 
a specific program at WHO AFRO which mission is to provide technical orientation, 
support and guidance to Member States in the WHO African region. The develop-
ment of genomic represents an opportunity that can contribute to the accelerated 
prevention, control, elimination, and eradication of NTDs and neglected zoonoses.
2. Geographical distribution and global burden of the NTDs
The concept, the burden, and the geographical repartition of the NTDs 
(Figure 1) justify the need of a global advocacy including the health policy-makers 
and ultimately the opportunity for tackling the NTDs with the same urgency and 
the commitment as for HIV/AIDS, tuberculosis, and malaria [6].
As previously well described by Hotez [6–8], the NTDs are characterized by the 
following important elements:
• Described as the most common infections of people living in sub-Saharan 
Africa, Asia, and Latin America and the Caribbean where the poverty is known 
as the component.
• NTDs affect about 1.4 billion people who live below the World Bank poverty 
figure of US$1.25 per day.
• Unfortunately, the NTDs result in chronic infections lasting years or even 
decades resulting in a great impact on the affected people family revenue.
• The chronicity of The NTDs affect child growth and intellectual and cognitive 
developments, impair pregnancy outcomes, and decrease worker productivity 
and then the billions of affected people cannot escape poverty.
• Among the consequence, the NTDs also cause blindness and disfigurement 
that are psychologically devastating and result in social stigma.
• This high level of morbidity, economic impairment, and stigma does not 
necessarily translate into large numbers of deaths; overall, the NTDs cause 
high-morbidity but low-mortality conditions.
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Regarding the chronicity of the disease but also as diseases afflicting humankind 
for centuries, NTDs are considered as “non-emerging” disease in contrast to emerg-
ing infections such as HIV/AIDS, SARS, and avian influenza.
Moreover, based on the previous studies, it is well documented that there is a 
geographic overlap among seven of the NTDs (ascariasis, trichuriasis, hookworm 
infection, schistosomiasis, LF, onchocerciasis, and trachoma). This is especially 
observed in sub-Saharan Africa where those NTDs present a very high prevalence. 
However, the overlapping of the NTDs in this part of the world allow to target 
these conditions simultaneously by combining the drugs in an integrated concept 
so named “rapid-impact package” [7, 9], as the drugs can be easily and quickly 
deployed by a contingent of community drug distributors. The rapid-impact pack-
age strategy if well implemented should ultimately contribute to the interruption of 
the diseases transmission such LF, onchocerciasis, and trachoma [9].
3. Impact of NTDs on public health
Although the NTDs are known to severely impact everyone, the diseases affect 
women and girls disproportionately for the following reasons:
Biological and physiological factors of women and girls lead to increased vulner-
ability of this specific category to particular pathologies—for example, female 
genital schistosomiasis and severe helminth-related anemia in pregnant women.
Socio-cultural factors are suspected in increasing risk to NTDs. A specific notified 
example is the water-based domestic activities carried out in two-third Sub-Saharan 
Africa by women or girls which increases risk of diseases such as schistosomiasis, 
whereas child-care and caregiving increases risk of trachoma and blindness. In fact, 
research suggested that women account for 80% of disability-adjusted life years 
linked to trachoma-related blindness.
NTDs that cause disfigurement and disability (such as lymphatic filariasis) can 
have a disproportionately negative impact on employability and marriageability 
Figure 1. 
Global intensity map of EReNTD regions of endemicity. Data are from the World Health Organization (2013).
Current Topics in Neglected Tropical Diseases
124
for more than 26 million [2]. Most of the NTDs are well known as ancient diseases 
resulting in humanity concerns for centuries [3]. From the 2020 Roadmap, 20 
NTDs were identified as following: Buruli ulcer, Chagas disease, cysticercosis/
taeniasis, dengue fever, dracunculiasis (guinea worm disease), echinococcosis, 
food-borne trematodiasis, human African trypanosomiasis (HAT) (sleeping sick-
ness), leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis (river blindness), 
rabies, schistosomiasis, soil-transmitted helminthiasis (ascariasis, hookworm, and 
trichuriasis), trachoma, and yaws [4]. The World Health Organization classified 
the NTDs into two mains groups: in one hand the preventive chemotherapy and 
transmission control (PCT) NTDs including prominently lymphatic filariasis, 
onchocerciasis, schistosomiasis, and soil-transmitted helminthiasis while the inno-
vative and intensified disease management (IDM) on the other hand is constitute 
with Buruli ulcer, Chagas disease, human African trypanosomiasis, and leishmani-
asis disease that are currently lack suitable tools for large scale use [5]. NTDs remain 
as a public health problem for poor populations living in tropical environments and 
difficult-to-access areas with more than 40% of impacted people living in the WHO 
African Region. The challenge is as much as important to justify the development of 
a specific program at WHO AFRO which mission is to provide technical orientation, 
support and guidance to Member States in the WHO African region. The develop-
ment of genomic represents an opportunity that can contribute to the accelerated 
prevention, control, elimination, and eradication of NTDs and neglected zoonoses.
2. Geographical distribution and global burden of the NTDs
The concept, the burden, and the geographical repartition of the NTDs 
(Figure 1) justify the need of a global advocacy including the health policy-makers 
and ultimately the opportunity for tackling the NTDs with the same urgency and 
the commitment as for HIV/AIDS, tuberculosis, and malaria [6].
As previously well described by Hotez [6–8], the NTDs are characterized by the 
following important elements:
• Described as the most common infections of people living in sub-Saharan 
Africa, Asia, and Latin America and the Caribbean where the poverty is known 
as the component.
• NTDs affect about 1.4 billion people who live below the World Bank poverty 
figure of US$1.25 per day.
• Unfortunately, the NTDs result in chronic infections lasting years or even 
decades resulting in a great impact on the affected people family revenue.
• The chronicity of The NTDs affect child growth and intellectual and cognitive 
developments, impair pregnancy outcomes, and decrease worker productivity 
and then the billions of affected people cannot escape poverty.
• Among the consequence, the NTDs also cause blindness and disfigurement 
that are psychologically devastating and result in social stigma.
• This high level of morbidity, economic impairment, and stigma does not 
necessarily translate into large numbers of deaths; overall, the NTDs cause 
high-morbidity but low-mortality conditions.
125
Neglected Tropical Diseases Pathogen and Human Genetic Interaction in the Genomic Era…
DOI: http://dx.doi.org/10.5772/intechopen.89982
Regarding the chronicity of the disease but also as diseases afflicting humankind 
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Figure 1. 
Global intensity map of EReNTD regions of endemicity. Data are from the World Health Organization (2013).
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of affected women, making them dependent on family members and potentially 
leading to stigmatization and social exclusion.
Indirect impact of NTDs can also disproportionately affect women and girls as 
caregivers, having to give up their jobs or drop out of school in order to take care of 
a sick family member (Figure 2).
4.  Global mobilization and role of scientific commitment against 
neglected tropical disease
The worldwide burden of NTDs lead to a global mobilization with a develop-
ment of a strategic work plan 2014–2020, which has been developed with the 
following objectives: scale up access to NTD-related interventions; enhance 
planning for results, resource mobilization, and financial sustainability of national 
NTD programs; strengthen advocacy, coordination, and national ownership; and 
enhance monitoring, evaluation, surveillance, and research [10] (WHO, 2012): 
Roadmap: accelerating work to overcome the global impact of neglected tropical 
diseases.
The 2020 roadmap against NTD recommend further research including the 
need for newer and safer drugs, vector control, personal hygiene, and the develop-
ment of vaccines. In the implementation of the roadmap, there are several initiative 
including control programs or research initiatives bringing their resources and 
competences. Then, a more macro approach may be necessary to promote greater 
effectiveness in addressing the underlining social, human health, zoonotic, and 
environmental challenges to prevent morbidity, and mortality from these diseases. 
One such approach that is growing worldwide in recognition is the “One Health” 
initiative, a commitment of interdisciplinary and multistakeholder involved locally, 
nationally, and globally in areas of human and animal health, agriculture, and the 
environment [1–15]. However, these one health approaches should be sensitive 
Figure 2. 
A woman washing dishes in a canal. Image credit Anouk Gouvras.
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to resource-poor settings and should leverage partners and broader global public 
health networks as it is represented in Figure 3.
Although there are many NGOs and partners committed in NTDs control, sci-
entific commitment is quite negligible in designing strategies and implementation. 
However, very few of them are from Africa where most of the NTD are present. 
Although African scientist’s mobilization and commitment are well practical in 
some of the NTD control, very few inputs is observed in the genetic and genomic 
area. Indeed, the control and the elimination of certain NTD will be rapidly and 
successfully carried out with the contribution of the understanding of human and 
pathogen genomic interaction. Interestingly genomic constitute the new insight 
generating from genetic studies that can provide explanations and may even allow 
predictions to be made, in the context of a range of biological problems includ-
ing the field of inherited human disorders. The development of the genetic in the 
last decade leads ineluctably to the “genomic” era. Then, importantly, with the 
improvement of sequencing technologies and the enormous reduction in the cost 
of sequencing, biologists are facing with a “data avalanche.” The development of 
the next generation whole exome or genome sequencing may bring to the scientific 
community large possibility of tools to elucidate genetic perturbation occurring in 
many diseases including the neglected tropical diseases. Consequently, genomic 
data analysis may also be useful for the dissection of the genetic mechanisms 
underlying complex polygenic diseases or in understanding how some modi-
fiers genes can influence the age of onset or clinical severity of a given disease 
Figure 3. 
Proposed United Nations “One Health” framework. FAO, Food and Agriculture Organization; OIE, World 
Organization for Animal Health; TDR, WHO Special Programme for Research and Training in Tropical 
Diseases; UNDP, United Nations Development Programme; UNEP, United Nations Environment Programme; 
UNFPA, United Nations Population Fund; UNICEP, United Nations Children's Fund; WHO, World Health 
Organization; WMO, World Meteorological Organization.
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entity. Interestingly, while we are acquiring new research capabilities, we are also 
encountering new problems with the analysis of genomic data such as genomic data 
presentation, format, sharing, and reanalysis.
5.  Programs and strategies ongoing in the field of genomic supporting 
the eradication of neglected tropical disease
The number of emerging infectious diseases is increasing annually despite the 
numerous of effort going on. In parallel to the wide incidence of the infectious 
disease including neglected tropical disease, characterizing novel or re-emerging 
infections is aided by the availability of pathogen genomes. This also helps to 
develop new approaches. Indeed, recently an in silico approach for discovering 
new filarial drug targets was developed in which comparative sequence analysis 
and functional genomics data from the related model nematode Caenorhabditis 
elegans are combined into subtractive filters that can be used to identify poten-
tially essential nematode genes and generate a pool of pre-validated candidate 
targets [15–17]. Different techniques such as the RNA interference (RNAi) 
experiments and other functional studies serve as potential genomic tools to 
examine gene function from NTDs pathogen. Interestingly, sequencing of patho-
gen genomes, can contribute to describing nearly every aspect of transmission 
dynamics when some of the following information, date, location, clinical mani-
festation, or others data regarding the samples origin are including. The analyses 
of these data can positively affect the clinical management of the disease or the 
public health practice such as policies for surveillance, prevention, and treatment. 
The combination of genomic and epidemiological data represents consequently a 
perfect tool to address answers to epidemiological questions and reduce incidence 
and prevalence. How can genomic approaches support neglected tropical disease 
eradication particularly by analogy with how conservation genomics is supporting 
efforts to prevent extinctions. They are genomic approaches of capacity building 
programs in Africa as described through the next paragraphs that are contributing 
to reach this goal demonstrating the opportunity behind this cutting-edge method 
for African scientists.
6. Genomic training programs in Africa
Genomics remain one excellent component in the long way of NTD control and 
elimination. In order to tackle neglected tropical disease and move forward with 
elimination steps, the development of competent resources constitute one of the 
important challenge particularly in Sub-Saharan Africa, where the NTD present 
the highest prevalence. There are few institute in Africa taking the opportunity 
of genomic era that are focused and committed to the development of scientists 
with excellent competence and capacity in genomic. The global effort required to 
apply genomic science and associated technologies to improve the understanding 
of health and disease in diverse populations is undeniable todays. In fact, identify 
individuals and populations who are at risk for developing specific diseases such as 
NTDs, and to better understand underlying genetic and environmental contribu-
tions to risk could greatly contribute in finding sustainable responses. And the 
large diversity of African continent that constitute genetic complexity represents 
an enormous opportunity to utilize such approaches to benefit African populations 
and to inform global health.
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The most involved institution in the training of human resources in genomic 
are Pan African based in South Africa and Nord Africa. Few are developing in west 
Africa mainly in Nigeria, Ghana and recently introduced in Mali.
6.1 H3Africa
The Human Heredity and Health in Africa (H3Africa) constitute one of the larg-
est consortium with the objectives to facilitate fundamental research into diseases 
on the African continent, while also developing infrastructure, resources, training, 
and ethical guidelines to support a sustainable African research enterprise. By his 
constitution, H3Africa is led by African scientists, for the African people. Today, 
H3Africa initiative consists of 48 African projects that include different data set 
from population-based genomic studies of common, non-communicable disorders 
such as heart and renal disease to communicable diseases such as tuberculosis. 
Those studies are designed by African scientists with the objective to identify 
hereditary and environmental contributions to health and disease. While H3Africa 
is working mainly in developing African scientist’s capacity, the consortium is also 
committed to support many crucial capacity building elements, such as ethical, 
legal, and social implications research; training and capacity building for bioinfor-
matics; capacity for biobanking; and coordination and networking.
As a continental consortium, today H3Africa constitutes as one of the most 
important supporting institutions to African researchers and also contributing to 
the establishment of effective collaborations among African researchers. Through 
these different collaborations, the consortium is able to generate specific and 
large data set in relation to the global health. The consortium is supporting dif-
ferent initiative in Africa such the West African Center of Excellence for Global 
Health Bioinformatics Research Training in Mali, the Eastern Africa Network for 
Bioinformatics Training (EANBIT), the Collaborative African Genomics Network” 
(CAfGEN) and the Integrated approach to the identification of genetic determi-
nants of susceptibility to trypanosomiasis (TrypanoGEN) in Uganda.
H3Africa is also collaborating with the African Center of Excellence for 
Genomics of Infectious Diseases (ACEGID) at Redeemer’s University in partnership 
with academic, clinical, and research institutions in Nigeria, Sierra-Leone, and 
Senegal to develop African research capacity in genomics by building a critical mass 
of well-trained scientists.
In order to boost the genomic concept and interest African scientists to this revo-
lutionary scientific area, a group of stakeholders from the H3BiotNet (Pan African 
Bioinformatics Network for H3Africa) and the African Society of Human Genetic 
launched in 2016 in Dakar in Senegal, the African Genomic Medicine Training 
initiative called AGMT.
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The African Genomic Medicine Training Initiative (AGMT) was initiated by a 
Working Group made up of volunteers from across the globe with a clear vision to 
“increased effectiveness of Health Care in Africa through the application of Genomic 
Medicine”. This initiative includes several mission:
 Design and develop Genomic Medicine training for African-based healthcare 
professionals.
 Develop competency-based Genomic Medicine curriculum for healthcare work-
ers in Africa.
 Develop and implement flagship training courses based on the collaboratively 
developed curricula.
 The first iteration was run in 2017 with 19 classrooms in 11 countries, 1 online 
class, and 225 students registered.
 The second iteration is running from March to July 2019 as a professional 
development course.
The purpose of this Professional Development Course is to provide genomics 
and genetics education to nurses based in Africa emphasizing the practical applica-
tion of content into learners’ current settings and roles. In addition to contributing 
increasing knowledge in the genetics of African health issues, this second iteration of 
the AGMT initiative aim to develop skills in Genetic counseling, Community engage-
ment/Ethical conduct in research, and patient care and development of health 
promotion material. Therefore, this course seeks to support improved Genetics & 
Genomics knowledge, attitudes and skills for genomic medicine in Africa.
6.2 Genomics Africa
Genomic Africa is a training program organized by the Kwazulu-Natal Research 
Innovation and Sequencing Platform (KRISP) with the aim of “Bringing genomic 
technologies to Africa to fight our great challenges: loss of biodiversity, famine, migration 
and diseases.”
As a Flagship program of the South African Medical Research Council 
(SAMRC), KRIS develops collaboration with DIPLOMICS ASSOCIATED 
LABORATORIES which is a South African Research Infrastructure Roadmap 
(SARIR) program of the Department of Science and Technology (DST). To reach 
his mention, different training programs are developed and run each year at KRISP 
Genomics Africa targeting several diseases including tropical neglected disease as 
well as the development of new technologies to help in Africa including Microbiome 
and Metagenomics Sequencing with Illumina and Nanopore.
There are others genomic training initiatives developed and running in 
Africa, and even not targeting specifically neglected tropical disease are greatly 
contributing to human resources strengthening. By helping strengthen human 
capacity in genomic area, they may help answering how African scientists are 
prepared to tackle the NTDs in the context of genomic era.
6.3 DELGEME
The Developing Excellence in Leadership and Genetics Training for Malaria 
Elimination in sub-Saharan Africa (DELGEME) is a new training programme 
sponsored by the Wellcome Trust Developing Excellence in Leadership, 
Training and Science Africa (DELTAS Africa) initiative in partnership with 
the Department of International Development (DFID) and the Alliance for 
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Accelerating Excellence in Science in Africa (AESA). Led by the University of 
Science Techniques and Technologies of Bamako Mali (USTTB), this genetic 
and genomic training program is partnering with the Medical Research 
Council (MRC) Unit in The Gambia, The United States Army Medical Research 
Directorate (USAMRD-K)/KEMRI Kenya, The Noguchi Memorial Institute 
for Medical Research (NMIMR)-Navrongo Health Research Centre, Ghana, 
The National Institute of Medical Research (NIMR) Tanzania, Université 
des Sciences de la Santé of Libreville, Gabon, Benhard-Nocht Institute for 
Tropical Medicine (BNITM) Germany/Kumasi Centre for Collaborative 
Research (KCCR) Ghana, and the University of Oxford/Wellcome Trust Sanger 
Institute UK. In collaboration with MalariaGEN (www.malariagen.net) and the 
Plasmodium Diversity Network, The DELGEME program aims to enrich the 
pool of African Scientists working in African institutions with relevant exper-
tise to leverage big genetics and genomics data in the drive for malaria elimina-
tion in sub-Saharan Africa.
In order to reach this objective DELGEME aim to:
To train, retain, and develop Graduates, Doctoral, and Post-doctoral fellows on 
genomics and bioinformatics across malaria endemic countries.
To develop programs to enhance the understanding and dissemination of genetic 
data relevant to malaria interventions and eradication program.
Short-term training will be delivered for various trainees including public health 
officers on genetics, clinical studies, ethics, grant writing, grant management, 
leadership development, etc.
Formal long-term curricula (big data science, biostatistics, health informatics, 
genomics, cell biology, molecular biology, and bioinformatics) will be designed 
and implemented with contribution and oversight from a wide range of local and 
International Faculty and relevant advisory boards.
6.4 Others genomic training institutions/programs in Africa
Interestingly from last year, genomic education is progressively taking off 
in Africa. Indeed, many genomic training programs at the countries or regional 
level are entering in operational phase. Many of them are mainly supported by 
H3ABioNet which organizes a variety of high quality courses and training events 
covering various aspects of bioinformatics from general introductory topics to more 
specialized ones such Next Generation Sequencing and Genome Wide Association 
Studies analyses. Indeed, H3ABioNet is comprised of 28 Nodes distributed among 
17 countries, 16 of which are African.
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7. Conclusions
Genomic is a rapidly evolving medical field relying on technological advances 
and with a direct effect on disease treatment, control, and elimination including 
such neglected tropical disease. Nevertheless, in Africa, the introduction, the devel-
opment, and the application of genomic are variously appreciated. Interestingly, 
there are institutions greatly introduced in genomic era and they are working to 
spread the knowledge to the rest of the African continent as pioneers with support 
from some North European and American institutions. Hence, even there is still 
limit critical mass of African scientists well trained in this new scientific domain to 
contribute to the diseases control and elimination in general and neglected tropi-
cal disease in particular, there is room of hope since there is positive signal within 
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Leishmaniasis is the third most important vector-borne disease after malaria 
and lymphatic filariasis. It is common disease in all over the world. The vector for 
leishmaniasis is Phlebotomus and there have found around 20 different types of this 
vector. There are different clinical forms under the name of leishmaniasis such as 
kala-azar, dum-dum fever, white leprosy, espundia, pian bois, chiclero’s ulcer, uta. 
Environmental factors leading to climate changes and global warming are major 
risk factors for the spreading of the disease. Leishmania spp. to prevent the spread 
of the definitive host and intermediate hosts is difficult compared to Plasmodium 
spp. Therefore; leishmaniasis disease will retain its importance for many years.
Keywords: leishmaniasis, neglected tropical diseases, vector-borne disease, 
epidemiology, ecology
1. Introduction
This fact is mainly due to the presence of many different species of leishmania, 
its vectors and hosts in different parts of the world. More than 20 pathologic species 
of leishmania and over 30 species of Phlebotomus—the vector- are known worldwide 
(Figure 1, Table 1).
On the other hand, deterioration of the eco-systems by human beings also 
contribute to the spread of the disease in the world.
Leishmaniasis has four clinical forms. These are cutaneous leishmaniasis (CL, 
local—LCL or diffuse—DCL), mucocutaneous leishmaniasis (MCL), visceral 
leishmaniasis (VL), post-kala-azar dermal leishmaniasis (PKDL), (Table 1).
Figure 1. 
Taxonomy of leishmania family [1].
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In this section we aimed to reveal the epidemiologic analysis of different types of 
leishmaniasis in all over the world in every aspect.
2. Geographic distribution and incidence
Leishmaniasis, as being one of the world’s most neglected diseases, affects 
mainly the poor, developing countries; 350 million people are thought to be at risk 
of contracting leishmaniasis. It is estimated that approximately 12 million men are 
ill and 2 million new cases occur annually [1, 2].
With new epidemics occurring in endemic areas and the spread of leishmani-
asis to previously free areas because of migration, tourism, and military activities. 
Leishmaniasis is a disease of the poor, occurring mostly in remote rural villages with 
poor housing and little or no access to modern health-care facilities. In endemic 
areas, diagnosis of any form of leishmaniasis puts a huge financial strain on an 
already meagre financial resource at both the individual and community levels [3].
Visceral leishmaniasis: approximately 90% of new cases occur in the world’s 
cases of India, Bangladesh, Nepal, Ethiopia, Sudan and Brazil are seen. The annual 
number of cases worldwide has been estimated to be visceral leishmaniasis, 
between 200,000 and 400,000. The two important causative agents of visceral 
leishmaniasis (VL), namely Leishmania (L) donovani and L. infantum, cause signifi-
cant health problems [1, 4].
Visceral leishmaniasis (VL), also known as “kala azar,” is caused by parasites of 
the L. donovani complex in some parts of the world. The L. donovani complex can be 
found throughout Asia, North Africa, Latin America and Southern Europe, affect-
ing mostly vulnerable and uncared populations. As being the most severe form, VL 
is almost always fatal if left untreated. It is characterized by undulating fever, loss 
Subgenus L. (Leishmania) L. (Leishmania) L. (Viannia) L. (Viannia)
Old World L. donovani L. major




New World L. infantum L. infantum L. braziliensis L. braziliensis
L. mexicana L. guyanensis L. panamensis
L. pifanoia L. panamensis
L. venezuelensis L. shawi
L. garnhamia L. naïffi




Principal tropism Viscerotropic Dermotropic Dermotropic Mucotropic
aSpecies status is under discussion.
bTaxonomic position is under discussion.
Table 1. 
Leishmania found in humans [1].
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of weight, splenomegaly, hepatomegaly and/or lymphadenopathies and anemia 
L. infantum, the other causative agent of VL, is found in Southern Europe, North 
Africa and West and Central Asia [1, 5].
Post-kala-azar dermal leishmaniasis (PKDL) is another clinical composition of 
kala azar and it is seen in all areas endemic for L. donovani. It especially comments 
in East Africa and on the Indian subcontinent with a prevalence of 50 and 10%, 
respectively [1, 6].
Cutaneous leishmaniasis: approximately 90% of the world’s cases of 
Afghanistan, Pakistan, Sudan, Syria, Saudi Arabia, Algeria, Iran, Iraq, is seen in 
Brazil and Peru. The annual number of cases worldwide has been estimated to be 
visceral leishmaniasis, cutaneous leishmaniasis: between 700,000 and 1.2 million 
[1]. Old World species: L. major, L. infantum, and L. tropica, New World species, 
such as, L. amazonensis, L. chagasi, L. mexicana, L. viannia (V) naiffi, L. (V.)  
braziliensis, and L. (V.) guyanensis [6, 7]. Antroponotic cutaneous leishmaniasis 
(ACL) is caused by most Leishmania species, occur in most subtropical and tropical 
regions (for example, L. major from Africa and Asia, and L. mexicana from Central 
and South America), and by many species in the subgenus Viannia, which are 
limited to Latin America (for example, L. (V) brasiliensis) [6].
Old World cutaneous leishmaniasis caused by L. tropica (seen particularly in 
the Mediterranean Basin, the Middle East, Pakistan and India) and L. infantum, 
(found sporadically in the Middle East, South Russia, and rural regions of Africa). 
New World cutaneous leishmaniasis, caused by L. brazilensis and L. mexicana is 
seen in Mexica and South America. Leishmaniasis exists on every continent except 
Australia, the Pacific Islands and Antarctica. The parasites that cause leishmaniasis 
are found in 98 countries around the world [7].
L. tropica, L. major, L. aethiopica and L. infantum causes Old World cutaneous leish-
maniasis. Leishmania tropica is mainly seen in urban areas and causes ACL. Related 
vectors are Phlebotomus sergenti and Phlebotomus papatasii. Lesions are generally dry 
and remain without ulceration. During the course lesions change to papules [1, 8].
L. tropica is found in urban areas. It causes ACL via the vectors Phlebotomus 
sergenti and Phlebotomus papatasii. The lesions are dry and stay for a long period of 
time without ulceration. Thereafter, painless lesions as papules, tubercles or nodules 
subside without scarring in 9–12 months [8].
L. major infections generally cause wet lesions in habitants of rural areas. 
Incubation period is less than 4 months. Lesions are usually seen on the legs. They 
start as acute papillary infection in the bite area and advances into pustular ulcers 
in 1–3 weeks. The infection is categorized as “zoonotic cutaneous leishmaniasis 
(ZCL)” due to the transmission to rodents, dogs via Phlebotomus papatasi [9].
L. infantum often causes small (0.5–1 cm), solitary ulcers on the face [10].
L. aetropica lesions are seen in the mouth and nose with local or wide spread 
dermal involvement. Lesions rarely become ulcerated. Healing may take 1–3 years 
or more [11].
L. braziliensis, L. mexicana, L. amazoensis, L. guyanensis, L. panamensis and L. 
peruviana cause New World cutaneous leishmaniasis [8, 12].
The disease caused by L. braziliensis is named “espundia.” The infection leads 
to metastatic lesions, damages and deformation of the cartilage and soft tissues by 
affecting buccal and nasal mucosa [13].
L. mexicana causes usually solitary, painless lesions in the pinna. It leads to 
chronic lesions in the pinna called “chiclero’s ulcer” [14].
L. guyanensis infection is consisted of flat ulcerative plaques with leakage in 
whole body. The lesion is called “pianbois” in Uruguay and Venezuella [15].
L. amazonensis causes solitary or multiple lesions with rarely spontaneous remis-
sion. It is rare in humans [8].
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L. peruviana infection causes solitary or multiple painless dermal lesions they 
usually subsided spontaneously in 4–5 months. This infection is called uta [16].
Lesions of L. panamensis are ulcers without spontaneous improvement the 
reservoirs are dogs and monkeys [12].
L. venezuelensis generally causes solitary painless nodular lesion. [12, 17].
L. garnhami usually causes solitary or multiple lesions and may spontaneously be 
healed in 6 months [12].
The Eastern Hemisphere (Old World): leishmaniasis is found in some parts of 
Asia, the Middle East, Africa (especially in the tropical region and North Africa), 
and Southern Europe.
The Western Hemisphere (New World), leishmaniasis is found in some parts of 
Mexico, Central America, and South America. It is not found in Chile or Uruguay.
Leishmaniasis is seen in most tropical and subtropical regions with climate, 
mainly in South and Central America, Africa, Asia, and Southern Europe. The 
leishmaniasis is considered as one of the neglected tropical diseases (NTD) 
(Figures 2 and 3) [18].
Figure 3. 
World CL distribution in the last 10 years [19].
Figure 2. 
World VL distribution in the last 10 years [19].
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3. Epidemiology of leishmaniasis according to vector
a. Phlebotomus spp. (sandfly). (Old World).
b. Lutzomyia spp. (New World).
Humidity and moisture, whether from rainfall or in the soil, have often been 
identified as important for the sandfly, with humidity influencing breeding and 
resting [6].
Sandflies belonging to either Phlebotomus spp. (Old World) or Lutzomyia spp. 
(New World) are the primary vectors; domestic dogs, rodents, sloths, and opos-
sums are amongst a long list of mammals that are either incriminated or suspected 
reservoir hosts [1, 21, 22]. Most of its foci in the Old World have a Mediterranean 
climate and sand fly vectors, usually Phlebotomus (Larroussius) species, Phlebotomus 
species (P. papatasi, P. sergenti, Phlebotomus alexandri, P. tobbi, Phlebotomus syriacus, 
Phlebotomus neglectus, Phlebotomus perfiliewi, Phlebotomus galilaeus, Phlebotomus 
transcaucasicus, and Phlebotomus halepensis) two Sergentomyia species (Sergentomyia 
theodori and Sergentomyia dentata), (Phlebotomus ariasi and Phlebotomus perniciosus, 
Phlebotomus longicuspis) can diapauses for human visceral leishmaniasis [21–24].
In contrast to malaria, there is little evidence for the effect of vector control in 
leishmaniasis because terrestrial habitat of Phlebotomus is mostly unknown.
4. Host
4.1 Human
Leishmania species are transmitted to human via vectors, blood transfusion, 
organ transplantation or vertically via transplacental route. Other factors that cause 
the transmission of the disease are contact with contaminated materials or needle 
stick injuries in the labs [25–27].
Leishmania-infected humans especially in poor socioeconomic conditions play 
a pivotal role as a reservoir in transmission of the agent to vectors or to other hosts. 
In another words, one can say that human beings contribute the disease transmis-
sion by themselves [26, 27]. Poor living conditions in adobe, wooden houses, barns 
create a tendency towards an increase of vectors [27–29].
In all three clinical types of Leishmania spp., antimonials (sodium stibogluconate 
[SSG]), miltefosin (MIL), amfoterisin B (AmB) veparomomisin (PMM)) are being 
used [30]. Children and people with immune suppression, HIV infection or malig-
nant diseases cause rapid spread of leishmaniasis. Apart from these, undiagnosed or 
untreated infected people create an important risk factor. Especially drug resistance 
and high expense of the medication cause insufficient treatment [27–29]. The first 
drug resistance was reported in VL treatment against SSG and against MIL, in India 
and Nepal, respectively [31–33]. Later, resistance against MIL was also reported in 
one patient with HIV and another two patients with Indian origin [34, 35].
Verma et al. showed that the effectiveness of PMM was decreased by 6 times for 
the promastigote forms of L. donavani [36]. Invasion of macrophages by PMM-R 
parasites led to increased nitric oxide (NO), whereas the levels of reactive oxygen 
species (ROS) remained unchanged. This finding shows resistance of Leishmania 
spp. against PMM [36]. Similarly, Deep et al., reported high recurrence rates in 
patients with VL and PKDL when treated with MIL [37].
In conclusion, due to immune problems of the patient, co-existence of other dis-
eases, inappropriate use of the drugs during the medical treatment of leishmaniasis, 
“drug resistance” may occur via gene over-expression, deletion, single nucleotide 
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L. peruviana infection causes solitary or multiple painless dermal lesions they 
usually subsided spontaneously in 4–5 months. This infection is called uta [16].
Lesions of L. panamensis are ulcers without spontaneous improvement the 
reservoirs are dogs and monkeys [12].
L. venezuelensis generally causes solitary painless nodular lesion. [12, 17].
L. garnhami usually causes solitary or multiple lesions and may spontaneously be 
healed in 6 months [12].
The Eastern Hemisphere (Old World): leishmaniasis is found in some parts of 
Asia, the Middle East, Africa (especially in the tropical region and North Africa), 
and Southern Europe.
The Western Hemisphere (New World), leishmaniasis is found in some parts of 
Mexico, Central America, and South America. It is not found in Chile or Uruguay.
Leishmaniasis is seen in most tropical and subtropical regions with climate, 
mainly in South and Central America, Africa, Asia, and Southern Europe. The 
leishmaniasis is considered as one of the neglected tropical diseases (NTD) 
(Figures 2 and 3) [18].
Figure 3. 
World CL distribution in the last 10 years [19].
Figure 2. 
World VL distribution in the last 10 years [19].
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3. Epidemiology of leishmaniasis according to vector
a. Phlebotomus spp. (sandfly). (Old World).
b. Lutzomyia spp. (New World).
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In all three clinical types of Leishmania spp., antimonials (sodium stibogluconate 
[SSG]), miltefosin (MIL), amfoterisin B (AmB) veparomomisin (PMM)) are being 
used [30]. Children and people with immune suppression, HIV infection or malig-
nant diseases cause rapid spread of leishmaniasis. Apart from these, undiagnosed or 
untreated infected people create an important risk factor. Especially drug resistance 
and high expense of the medication cause insufficient treatment [27–29]. The first 
drug resistance was reported in VL treatment against SSG and against MIL, in India 
and Nepal, respectively [31–33]. Later, resistance against MIL was also reported in 
one patient with HIV and another two patients with Indian origin [34, 35].
Verma et al. showed that the effectiveness of PMM was decreased by 6 times for 
the promastigote forms of L. donavani [36]. Invasion of macrophages by PMM-R 
parasites led to increased nitric oxide (NO), whereas the levels of reactive oxygen 
species (ROS) remained unchanged. This finding shows resistance of Leishmania 
spp. against PMM [36]. Similarly, Deep et al., reported high recurrence rates in 
patients with VL and PKDL when treated with MIL [37].
In conclusion, due to immune problems of the patient, co-existence of other dis-
eases, inappropriate use of the drugs during the medical treatment of leishmaniasis, 
“drug resistance” may occur via gene over-expression, deletion, single nucleotide 
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polymorphisms generating stop codons or amplification of sets of genes [38–40]. 
This very important for epidemiological standpoint and thus proper use of drugs 
when needed should be stressed, and also new drug formulations and/or vaccine 
should be investigated.
Technological advances let the people travel all over the world. This may cause 
vectored spread or spread directly by infected people [41].
4.2 Dogs
Dogs are very important in terms of the epidemiology of leishmaniasis. All 
forms of leishmaniasis namely cutaneous, mucocutaneous and visceral types may 
be found in dogs. Since the infected dogs are important reservoir of the disease, 
their controls and treatments are mandatory for the disease control. Dogs as pets 
are being controlled by vets however stray or wild dogs, fox species like Lycalopex 
vetulus [42], Cerdocyonthous [43] may cause outbreaks. Dogs are natural hosts 
for L. infantum, L. chagasi, L. tropica and L. peruviana as well as being infected 
by them. Especially they are endemic in dogs in Mediterranean region, Asia and 
Latin America. Leishmania infantum is the causative agent of visceral leishmani-
asis and it is prevalent especially in Mediterranean region. Vectors for this type are 
Phlebotomus ariasi, P. major, P. perniciosus, P. longicuspis, P. chiensis, P. mongolensis, 
P. papatasi [44, 45]. In the same region, the causative agent of zoonotic cutaneous 
leishmaniasis is L. tropica and the vectors are P. perfilievi, P. papatasi and P. sergenti 
[1, 46]. In South America, the causative agent of canine cutaneous leishmaniasis is 
L. chagasi and the vectors are Lu. longipalpalis, Lu. evansi, Lu. gomezi [1].
4.3 Rodents
Comparing to dogs, eradication of the infectious agent of leishmaniasis from the 
rodents is more difficult and even sometimes impossible.
Different rodents such as Didelphis albiventris (opossum), Mus musculus (domes-
tic mouse), Microtus socialis, Rattusrattus (black rat), Cercomys cunicularius (wild 
rat), Mesocricetus auratus (Syrian hamsters) in America, Africa and Asia lead to 
spread of leishmaniasis [47–51].
Phlebotomus papatasi, vector of L. tropica, transmitted cutaneous leishmani-
asis to small rodents such as Psammomys obesus (Israel), Meriones crassus (Israel), 
Meriones libycus (Iran), Rhombomys opimus (Iran), Rhombomys opimus (Iran), 
Meriones sacramenti (Egypt) [9].
Rattus rattus and Rattus norvegicus have been found naturally infected with L. 
infantum in the Mediterranean and in Next Orient endemic areas (Table 2) [49, 52, 53].
5. Transmission cycle
There are two different types of transmission;
1. In many geographic areas, infected people are not needed to sustain the 
transmission cycle of the parasite in nature; transmission cycle continue 
via the infected animals (rodents or dogs, felines). Leishmania infection in 
reservoir animals are specifically named; if it is in dogs, it is named as canine 
leishmaniasis whereas in cats, it is called feline leishmaniasis dogs species of 
Leishmania species in the reservoir in animals, canine leishmaniasis, which is 
in feline called leishmaniasis. L. infantum is the most common and important 
cause of canine leishmaniasis worldwide. The zoonotic transmission of L. 
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infantum, from canine to humans, is not only in the Mediterranean region 
where it may have originated, but also it may be found in many of the drier 
regions of Latin America. Leishmania species reported from dogs include 
L. mexicana, L. donovani, and L. braziliensis. These Leishmania species are 
occasionally reported from the cats. Cats are at risk of infection especially in 
areas where these parasites are endemic [6, 54, 55].
2. In some parts of the world, infected people are needed to sustain the cycle; this 
kind of transmission (human—Phlebotomus—human) is called anthroponotic 
transmission.
Full knowledge on these two transmission cycles is very important in effective 
prevention of leishmaniasis [54, 55].
6. Effect of deteriorated eco-system on spread of leishmaniasis
Unlike other parasites, it is extremely difficult to eradicate whole kinds of spe-
cies of Leishmania in nature. This is contrary to some other parasites. As example 
Plasmodium vivax is specific to human, thus it can be eradicated by vector control. 
However, this is not the case for Leishmania spp. [54, 55].
There are many check points to establish the control of the disease. Firstly, all 
patients with leishmaniasis should be properly treated. Leishmania transmission is 
dependent on the togetherness of contaminated sandflies with the reservoir hosts, 
and humans. Additionally, climatic and environment factors are important, too.
As the development of chemical insecticides use such as dichlorodiphenyltri-
chloroethane (DDT) against mosquito was a key component of the eradication, 
similarly they were proposed to have an effect on the sandflies, vectors of visceral 
leishmaniasis [56–58]. Since DDT use is found to be harmful to the environment 
and people, its use is prohibited by the World Health Organization [59]. At the 
moment there isn’t any strategy to control Phlebotomine by using insecticides by 
governments [60, 61]. Preliminary experiments for developing a vaccine against 
Leishmania spp. was reported [62]. However, the vaccine did not appear to protect 
against visceral leishmaniasis [63]. fucose-mannose ligand from an extract of 
L. donovani has been used in conjunction with a saponin adjuvant in attempts to 
vaccine [64]. Further studies are needed to develop an effective vaccine against 
leishmaniasis.
7. Summary
Leishmaniasis is still an important parasite disease in all over the world. The 
reasons are presence of many different species of Leishmania, and their ability 
to survive in many different organisms, such as vectors, dogs, rodents, humans. 
Leishmania spp. may cause different clinical scenarios by affecting different tissues 
and organs. As eukaryotic cells, Leishmania spp. can survive in the immune system 
of the most advanced organism, human. Presence of amastigote forms even in the 
hosts’ defensive cells shows the strength of the parasite.
Leishmaniasis is an important public health problem. Thus, relevant public 
health policies such as education of the people especially in endemic areas, multi-
disciplinary approach, diagnosis, treatment will be helpful in the elimination of the 
disease. Additionally, further epidemiological studies as well as vaccination studies 
will continue to strive for eradication.
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L. mexicana, L. donovani, and L. braziliensis. These Leishmania species are 
occasionally reported from the cats. Cats are at risk of infection especially in 
areas where these parasites are endemic [6, 54, 55].
2. In some parts of the world, infected people are needed to sustain the cycle; this 
kind of transmission (human—Phlebotomus—human) is called anthroponotic 
transmission.
Full knowledge on these two transmission cycles is very important in effective 
prevention of leishmaniasis [54, 55].
6. Effect of deteriorated eco-system on spread of leishmaniasis
Unlike other parasites, it is extremely difficult to eradicate whole kinds of spe-
cies of Leishmania in nature. This is contrary to some other parasites. As example 
Plasmodium vivax is specific to human, thus it can be eradicated by vector control. 
However, this is not the case for Leishmania spp. [54, 55].
There are many check points to establish the control of the disease. Firstly, all 
patients with leishmaniasis should be properly treated. Leishmania transmission is 
dependent on the togetherness of contaminated sandflies with the reservoir hosts, 
and humans. Additionally, climatic and environment factors are important, too.
As the development of chemical insecticides use such as dichlorodiphenyltri-
chloroethane (DDT) against mosquito was a key component of the eradication, 
similarly they were proposed to have an effect on the sandflies, vectors of visceral 
leishmaniasis [56–58]. Since DDT use is found to be harmful to the environment 
and people, its use is prohibited by the World Health Organization [59]. At the 
moment there isn’t any strategy to control Phlebotomine by using insecticides by 
governments [60, 61]. Preliminary experiments for developing a vaccine against 
Leishmania spp. was reported [62]. However, the vaccine did not appear to protect 
against visceral leishmaniasis [63]. fucose-mannose ligand from an extract of 
L. donovani has been used in conjunction with a saponin adjuvant in attempts to 
vaccine [64]. Further studies are needed to develop an effective vaccine against 
leishmaniasis.
7. Summary
Leishmaniasis is still an important parasite disease in all over the world. The 
reasons are presence of many different species of Leishmania, and their ability 
to survive in many different organisms, such as vectors, dogs, rodents, humans. 
Leishmania spp. may cause different clinical scenarios by affecting different tissues 
and organs. As eukaryotic cells, Leishmania spp. can survive in the immune system 
of the most advanced organism, human. Presence of amastigote forms even in the 
hosts’ defensive cells shows the strength of the parasite.
Leishmaniasis is an important public health problem. Thus, relevant public 
health policies such as education of the people especially in endemic areas, multi-
disciplinary approach, diagnosis, treatment will be helpful in the elimination of the 
disease. Additionally, further epidemiological studies as well as vaccination studies 
will continue to strive for eradication.
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